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Background: Autism spectrum disorder (ASD) is a heritable, heterogeneous 
neurodevelopmental disorder affecting social communication and motor stereotypies.  
Comorbid mental and physical conditions, perinatal risk factors, genetic risk factors, and 
early developmental trajectories of communication, social, and motor abilities are 
important sources of phenotypic and etiologic heterogeneity of ASD and other 
neurodevelopmental disorders.  Methods: Data from the National Comorbidity Survey 
Adolescent Supplement (NCS-A) were used to characterize mental and physical 
comorbidity and parent report of perinatal risk factors among ASD and learning disorder 
(LD) in a nationally representative sample of US adolescents.  Two enriched risk infant 
cohorts, the Early Autism Risk Longitudinal Investigation (EARLI) and the Infant Brain 
Imaging Study (IBIS) were used to identify common ASD-related genetic variation 
associated with differential trajectories of cognitive and motor development. Results: In 
the NCS-A, both ASD and LD adolescents were more likely to have gastrointestinal 
problems, epilepsy/seizures, and attention-deficit/hyperactivity disorder (ADHD), while 
ASD, but not LD, had increased risk for allergies, acne, heart problems, and sleep 
disturbances.  Prenatal exposure to alcohol, maternal urinary tract infections, slow 
heartbeat, and respiratory distress at birth were associated with both ASD and LD.  
Persistent proteinuria and neonatal complications were associated with ASD but not LD.  
In the EARLI/IBIS combined cohort, three latent classes were identified and labeled 
“normative”, “intermediate”, and “declining” based on longitudinal patterns of the 
Mullen Scales of Early Learning. ASD polygenic risk score was marginally associated 
with the “declining” class when compared to the “normative” class and was significantly 
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associated with ASD diagnosis.  Testing SNPs in ASD candidate genes revealed 
associations of suggestive significance (p < 1x10
-3
) at chr3:2928197 in CNTN4 and 
rs10265509 in CNTNAP2 on chromosome 7, comparing the “intermediate” to the 
“normative” class.  Conclusions: ASD and LD appear to share many comorbid 
conditions and pre-/perinatal risk factors.   Gastrointestinal problems, epilepsy/seizures, 
ADHD, and insults during the pre-/perinatal period may be associated with 
neurodevelopment broadly.  These findings may have important implications for clinical 
evaluation of adolescents with neurodevelopmental disorders. Genes coding for proteins 
involved in cell-cell interactions and neuronal migration in the developing nervous 
system may be specifically related to early cognitive developmental trajectory. 
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1.1.  Overview 
Autism spectrum disorder (ASD) is an early onset neurodevelopmental disorder 
(NDD) characterized by social and communication deficits and restrictive and repetitive 
interests or behaviors and results in varying degrees of lifelong functional impairment 
(American Psychiatric Association, 2013).  ASD is a phenotypically heterogeneous 
disorder, presenting with varying degree of severity, symptomatology, onset trajectory, 
and comorbidity profiles. ASD is also etiologically heterogeneous, with strong evidence 
that both genetic and environmental risk factors each play a significant role, either 
independently or interactively (Gaugler et al., 2014; Hallmayer et al., 2011; Sandin et al., 
2014). It is likely that multiple combinations of risk factors, genetic and environmental, 
contribute to ASD susceptibility.  Additionally, both genetic and environmental risk 
factors associated with ASD may contribute to neurodevelopment broadly (Pettersson, 
Anckarsäter, Gillberg, & Lichtenstein, 2013; Schieve, Clayton, Durkin, Wingate, & 
Drews-Botsch, 2015).  Here, we examined patterns of physical and mental comorbidity 
and perinatal environmental risk factors for specificity to ASD among a population-based 
sample of US adolescents.  We then examined the relationship between ASD genetic risk 
variants and early cognitive developmental trajectory among infants enrolled in an 








The current chapter (Chapter 1) introduces the motivation and goals of this 
dissertation and provides a review of the existing literature.   We begin with a brief 
history of Autism as a diagnostic entity and then describe the current diagnostic criteria 
and procedures.  Then, we will describe the current burden and demographic correlates of 
ASD.  Next, we will describe clinical correlates of ASD, including both physical and 
mental comorbidity, as well as its relationship to other neurodevelopmental disorders.  
This will be followed by what is known on the etiology of ASD, consisting of a review of 
evidence for both genetic and environmental risk factors.  Methodological challenges to 
studying ASD epidemiologically will then be discussed.  This will be followed by a 
review of ASD onset heterogeneity, and arguments for both combining across and 
splitting within diagnostic boundaries in etiologic research.  Finally, we state the specific 
aims of this work.   
Chapter 2 presents an analysis of prevalence and risk for various physical and mental 
health problems among adolescents with ASD and learning disorder (LD) from the 
National Comorbidity Survey Adolescent supplement (NCS-A).  Chapter 3 presents a 
similar analysis of prevalence and risk for ASD and LD in the presence of various pre- 
and perinatal risk factors in the NCS-A.  Chapter 4 presents an association analysis 
between purported ASD-related genetic variants associated with latent trajectories of 
early cognitive and motor development among infant siblings of children with ASD in 
the Early Longitudinal Risk Investigation (EARLI) and the Infant Brian Imaging Study 
(IBIS).  Chapter 5 concludes this dissertation with a review of findings from the three 
manuscripts, intentions for future research, and public health significance of this work.  
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1.3. Background on autism spectrum disorder 
The term “autism” was originally coined in 1908 by Swiss psychiatrist Eugen 
Bleuler, and was used it to describe severely withdrawn schizophrenic patients who had 
difficulty engaging with the outside world (Crespi, 2010).  However, in the 1940’s the 
term was redefined by Leo Kanner and Hans Asperger, who independently began to 
describe children with social difficulties, sensitivity to various stimuli, and general 
difficulty adapting to change in daily routines, with varying degrees of linguistic 
problems.  Over the next sixty years, the name and diagnostic criteria would continue to 
change over time.  From 1994 to 2013, the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) defined ASD as  a group of three separate disorders that included 
autistic disorder, Asperger’s syndrome, and pervasive developmental disorder – not 
otherwise specified (PDD-NOS) (American Psychiatric Association, 2000). These criteria 
were in effect at the time of data collection for the NCS-A survey and were used for final 
evaluation of infants in the IBIS cohort.  Therefore this dissertation will report on ASD as 
defined by DSM-IV.  However, in 2013, the DSM-5 was published and made some 
changes to the way we currently diagnose ASD.  It was re-conceptualized into one 
disorder that may vary in severity on a spectrum.  The diagnostic criteria are presence of 
A) deficits in social communication and social interaction in multiple contexts and B) 
restricted repetitive behaviors, interests, or activities. Examples of social and 
communication deficits include failure to initiate or respond to social interactions, 
difficulty making eye contact or understanding use of gestures, or absence of interest in 
peers.  Examples of restricted repetitive behaviors include repetitive movements or 
speech, inflexibility with change in routine, intense fixation on interests, and increased or 
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decreased sensitivity to sensory input.   Symptoms from both domains must be present 
with onset in early development and cause significant impairment in functioning 
(American Psychiatric Association, 2013).  The purpose for diagnostic changes was to 
enable earlier diagnosis and to streamline diagnoses across clinical settings. Changes 
made from DSM-IV are relatively minor and should result in similar prevalence estimates 
and minimal change in diagnostic status (Huerta, Bishop, Duncan, Hus, & Lord, 2012; 
Maenner et al., 2014).   
While some known genetic syndromes carry increased likelihood of presenting ASD 
related symptoms (Miller et al., 2010), there are no known biomarkers specifically for 
ASD (G. M. Anderson, 2015).  Therefore, diagnosis must be made by direct 
observational assessment by a clinician.  Clinicians will often use the Autism Diagnostic 
Observation Scale (ADOS) (Lord et al., 1989) and Autism Diagnostic Interview- revised 
(ADI-R) (Lord, Rutter, & Le Couteur, 1994) to aid in diagnosis and assessment of 
individuals with ASD.  The ADOS is used to assess social and communication behaviors 
related to autism symptoms by direct interaction with the subject.  The ADI-R is a 
structured interview conducted with parents or caregivers of a child referred for ASD 
evaluation.  The ADI-R evaluates language and communication skills, reciprocal social 
interactions, and restricted and repetitive behaviors/interests.  The best way to obtain an 
accurate ASD diagnosis is through evaluation by experienced clinicians aided by 
diagnostic instruments such as the ADOS and ADI-R (Lord et al., 2006).  
 
1.4.  Descriptive epidemiology and public heath burden of autism spectrum disorder   
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According the Centers for Disease Control, the incidence of ASD is increasing over 
time (Boyle et al., 2011).  US estimates from educational and health records indicated 
that 1 in 68 eight-year-old children met criteria for ASD in 2012 (Christensen et al., 
2016) and 2010 (CDC, 2014), compared to 1 in 88 in 2008 (CDC, 2012) and 1 in 110 in 
2006 (CDC, 2009).  The most recent national estimates indicate significant differences in 
distribution by gender, race/ethnicity, and region (Christensen et al., 2016).  Prevalence 
among boys was nearly 4.5 times greater than girls (23.6 compared to 5.3 per 1,000 
eight-year-olds).  Prevalence of identified ASD was significantly higher among non-
Hispanic white children compared to Hispanic and non-Hispanic black children.  The 
authors suggest this disparity is likely due to lack of treatment and service availability 
among Hispanic and black populations rather than a lower actual prevalence. The data 
also indicated that Hispanic children were more likely to be identified later than non-
Hispanic white and non-Hispanic black children.  There were also regional disparities in 
ASD prevalence, ranging from 8.2 to 24.6 per 1,000 eight-year-old children.  Regions 
where research sites had access to both school and health records had significantly higher 
prevalence of identified ASD than sites where only health records were reviewed.  This 
suggests the educational system plays a significant role in evaluating and providing 
services to affected children.   
ASD adds significant financial burden to affected families and communities.  The 
estimated cost of supporting an individual with ASD over the lifespan is $2.4 million US 
with co-occurring intellectual disability (ID) and $1.4 million US for ASD without ID 
(Buescher, Cidav, Knapp, & Mandell, 2014).  During childhood, the majority of cost is 
attributed to special education needs and parental lost wages.  In adulthood, the majority 
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of cost is attributed to residential and assisted living needs and lost personal wages 
(Buescher et al., 2014).  Having a child with ASD limits earning potential and incurs 
extra costs, the combination of which creates a substantial financial burden to families 
(Cidav, Marcus, & Mandell, 2012).   Primary caregivers of children with ASD are likely 
to earn substantially less (Cidav et al., 2012), experience instability in employment, and 
are less likely to partake in leisure activities (Hodgetts, McConnell, Zwaigenbaum, & 
Nicholas, 2014).  In addition, family members of affected children are more likely to 
experience divorce, higher levels of distress, lower well-being, and higher rates of mental 
and physical health problems than family members of typically developing children and 
children with other developmental disorders (Karst & Van Hecke, 2012; Keenan, 
Newman, Gray, & Rinehart, 2016). 
Adults with ASD experience decreased earning potential and increased living and 
medical costs (Buescher et al., 2014) and are more likely to be unemployed, 
underemployed, or employed at jobs not well suited to their abilities, resulting in low 
employment retainment and financial insecurity (Roux et al., 2013; Shattuck et al., 2012).  
Even high functioning ASD adults, despite capacity and willingness to work, face 
challenges in the workplace related to lack of understanding, and lack of support 
(Baldwin, Costley, & Warren, 2014).  Additionally, adults with ASD are less likely to 
live independently (K. A. Anderson, Shattuck, Cooper, Roux, & Wagner, 2014), 
experience more social isolation, higher rates of mental and physical comorbidity, and 
will have decreased life expectancy compared to adults without ASD (Perkins & 





1.5.  Clinical correlates of autism spectrum disorder 
1.5.1. Overview of autism spectrum disorder comorbidity  
Children with ASD are more likely to experience an array of comorbid physical and 
mental health problems compared to typically developing children (Gurney, McPheeters, 
& Davis, 2006; Schieve et al., 2012).  A school-based study found that over 70% of 
children identified with ASD had at least one comorbid condition (Memari, Ziaee, 
Mirfazeli, & Kordi, 2012).  Cost of medical treatment for ASD-affected individuals 
significantly increases when they reach adulthood (Buescher et al., 2014).  This section 
will provide background on the prevalence and shared risk factor s of other 
neurodevelopmental disorders that frequently co-occur with ASD, focusing on 
intellectual disability, learning disorder, and attention deficit hyperactivity disorder.  
Then evidence for the burden of various physical and mental health conditions among 
those with ASD will be reviewed. 
 
1.5.2. Comorbid neurodevelopmental disorders 
Neurodevelopmental disorders (NDDs) are a group of disorders characterized by 
impairments in cognition, communication, learning, motor skills, and/or daily functioning 
that typically emerge before adolescence and persist throughout the lifespan (American 
Psychiatric Association, 2013).  ASD, intellectual disability (ID), attention deficit 
hyperactivity disorder (ADHD), and learning disorder (LD) are categorized as NDDs in 
the DSM5.  NDDs often co-occur with one another, and current research suggests 
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potential commonality in both genetic and environmental risk factors (Lichtenstein, 
Carlstrom, Rastam, Gillberg, & Anckarsater, 2010; Pettersson et al., 2013; Schieve et al., 
2015).   
ID is characterized by limitations in both intellectual capacity (learning, 
reasoning, and problem solving) and adaptive functioning (conceptual, social and 
practical skills).  IQ scores below 70 on standardized testing instruments generally 
indicate an ID.  The overall prevalence of ID is between approximately 1-2% (Bhasin, 
Brocksen, Avchen, & Van Naarden Braun, 2006; Bourke, de Klerk, Smith, & Leonard, 
2016; Boyle et al., 2011) while the prevalence of ID among those with ASD is estimated 
to be between 30% and 60% (CDC, 2007, 2014).  There are many causes of ID, including 
genetic syndromes, environmental exposures, and brain injury, but the limited intellectual 
and adaptive functioning may result from common risk factors that also cause ASD or 
from symptoms of ASD itself (Hu, Chahrour, & Walsh, 2014). 
LD is characterized by impairments in understanding, remembering, and 
processing new information.  While these difficulties are likely present in early 
developmental years, LD is typically not recognized and diagnosed until a child enters 
school, where they tend to have difficulty in listening/paying attention, speaking, reading, 
writing, and/or math.  Children with LD perform lower than expected on one or more of 
these areas of learning, but unlike ID, have IQ scores within the normal range (American 
Psychiatric Association, 2013).  The prevalence of LD in the general population is 
approximately 10% (Altarac & Saroha, 2007).  LD in the context of ASD is far less 
studied in comparison to comorbid ID, but prevalence estimates of LD among ASD from 
a national parent-report survey is estimated to be nearly 80% (Schieve et al., 2012).   
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Children with chronic health conditions are more likely to be affected by LD than healthy 
peers (Schulte, 2015). Several comorbid conditions (Schieve et al., 2012) and risk factors 
(Schieve et al., 2016) for ASD have also been reported in LD.   
ADHD is a common NDD that affects approximately 3.4% of children and 
adolescents worldwide (Polanczyk, Salum, Sugaya, Caye, & Rohde, 2015) and is 
characterized by persistent problems with inattention, hyperactivity, and impulsivity that 
affect daily functioning.  Symptoms are often identified in the school setting, but persist 
throughout adulthood(American Psychiatric Association, 2013).  Although a concurrent 
diagnosis of ADHD and ASD was not possible under DSM guidelines until the recent 
release of DSM5, clinicians and parents have long noticed ADHD traits in children with 
ASD (Matson, Rieske, & Williams, 2013).  Prevalence estimates of ADHD among ASD 
range from 40 to 50% in both clinically referred and population samples (Gurney et al., 
2006; Matson et al., 2013; Schieve et al., 2012).  Similar to ID and LD, ADHD has been 
linked to several comorbid physical conditions (allergy, asthma, epilepsy, sleep 
disturbances), perinatal, and genetic risk factors that we also see in ASD (Matson & 
Goldin, 2013; Nikolac Perkovic et al., 2014; Rommelse, Franke, Geurts, Hartman, & 
Buitelaar, 2010). 
 
1.5.3. Comorbid physical conditions 
Individuals with ASD reportedly experience chronic physical health conditions at 
a higher rate compared to their typically developing peers (Gurney et al., 2006; Schieve 
et al., 2012).  The most studied comorbid physical conditions are epilepsy, 
gastrointestinal disorders, sleep disturbances, and allergic/autoimmune conditions; but 
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these studies tend to examine one comorbid condition at a time from clinically 
ascertained samples (Matson & Goldin, 2013).  The reported prevalence of any GI 
disorder, including diarrhea, constipation, and abdominal pain, in ASD ranges from 9% 
to 90%, depending on the study design (Coury et al., 2012) and an estimated 4.5 times 
greater odds of having a GI disorder compared non ASD individuals(McElhanon, 
McCracken, Karpen, & Sharp, 2014).  Approximately 50 to 80% of children with ASD 
are reported to have marked sleep disturbances compared to 9 to 50% of typically 
developing children.  This is an increased rate in comparison to other developmental 
disorders (Reynolds & Malow, 2011) and is correlated with more cognitive and adaptive 
behavioral problems in among ASD children (Taylor, Schreck, & Mulick, 2012).  The 
large range of prevalence estimates of epilepsy (5 to 46%)  likely results from differences 
in sample characteristics (Spence & Schneider, 2009; Tuchman & Rapin, 2002) as others 
have shown that epilepsy is associated with both comorbid ID and gender, where the 
male to female ratio of affectedness narrows from 3.5:1 to 2:1 when restricting to those 
with comorbid epilepsy (Amiet et al., 2008).  Allergy and other diseases involving mast 
cell activation are reported at higher frequency in ASD cases compared to controls and is 
thought to possibly create an inflammatory response that releases neurotoxic molecules 
(Angelidou et al., 2011; Theoharides, 2013). 
 Children with comorbid conditions tend to have higher ASD symptom severity 
than those without comorbid conditions (Memari et al., 2012).  Proper identification of 
comorbid physical conditions may lead to treatment that can substantially improve 
quality of life and behavioral symptoms as well as potentially inform etiologically 
meaningful subtypes of ASD (Bauman, 2010).  A recent analysis of electronic health 
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records studied patterns of comorbid medical conditions over time suggests that these 
comorbidities cluster distinctly and may indicate distinct etiologies (Doshi-Velez, Ge, & 
Kohane, 2014).   
 
1.5.4. Comorbid mental disorders 
 
A greater number of studies have examined psychiatric, or mental, comorbidity of 
ASD compared to physical comorbidity, with a greater proportion of studies examining 
more than one mental health disorder simultaneously; however, the vast majority of these 
studies are on ADHD, anxiety, and general psychopathology (Magiati et al., 2016; 
Matson & Goldin, 2013; Vasa & Mazurek, 2015).  Limited research exists on the full 
range of mental health problems, including depression, bipolar disorder, eating disorders, 
and psychosis (Matson & Goldin, 2013).  A sample of clinically referred adults found 
that those with ASD had nearly twice as many psychiatric problems, including major 
depressive disorder, and multiple anxiety disorders, compared clinically referred adults 
without ASD.   Additionally, ASD adults experienced higher levels of functional 
impairment and a greater need for therapeutic and pharmacologic treatment (Joshi et al., 
2013).   Parents of children with ASD who participated in the National Survey of 
Children’s Health reported high rates of anxiety and depression in their children 
(McPheeters, Davis, Navarre, & Scott, 2011), but we do not currently have population-
based estimates of mental disorders in children or adolescents with ASD that were 
obtained from direct assessment of the affected individual.    
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1.6.  Etiology of autism spectrum disorder 
1.6.1. Overview of etiology 
While the exact cause of ASD is unknown, research suggests that both genetic 
and environmental factors play a role in ASD etiology.  Here, we will review the current 
state of the literature describing evidence supporting a polygenic nature of ASD risk.   
First we will discuss family-based heritability studies, then evidence for the contribution 
of common variants, followed by rare genetic variants, including inherited and de novo 
point mutations and structural variants.  We will then discuss epigenetic changes that may 
provide a mechanism for gene-by-environment interaction effects that contribute to ASD 
risk.  Finally, we review evidence supporting a hypothesis for early-life (preconception 
through perinatal periods) non-genetic (environmental) risk factors contributing to ASD 
risk, as previous work on neuroanatomic and serologic studies have suggested that ASD 
pathophysiology begins in utero, thus, the pre-/perinatal period as a critical window for 
exposure to potential etiologic risk factors (Bailey et al., 1998; Bauman & Kemper, 2005; 
Newschaffer, Fallin, & Lee, 2002; Rodier, 2002; Rodier, Ingram, Tisdale, Nelson, & 
Romano, 1996).    
1.6.2. Genetic risk factors 
Family heritability and relative recurrence risk 
While early twin studies reported genetic liability of estimates at approximately 
90%, recent family study research suggests that approximately half of the phenotypic 
liability for ASD can be explained by genetic factors (Gaugler et al., 2014).  A 
comparison of dizygotic and monozygotic twins found an ASD probandwise concordance 
rate of .77 for monozygotic .31 for dizygotic twins, suggesting a genetic heritability 
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component of 38% for ASD (Hallmayer et al., 2011).  Among families from a 
population-based cohort from Swedish national register data, relative recurrence risk was 
estimated at 153 for monozygotic twins, 8.2 for dizygotic twins, 10.3 for full siblings, 
and 2.0 for cousins (Sandin et al., 2014).    The same study estimated the overall 
heritability for ASD to be approximately 50% (Sandin et al., 2014).   An enriched risk 
cohort of infant siblings of children with ASD found that nearly 19% of siblings were 
diagnosed with ASD by 3 years of age, suggesting a nearly 20 fold risk compared to the 
general population (Ozonoff et al., 2011).  More recently, a population-based twin sample 
from the UK estimated heritability of ASD and ASD-related traits to be between 56 and 
95%, with higher estimates for stricter diagnostic criteria (Colvert et al., 2015).      
 
Common genetic variation 
Recent molecular genetic studies have suggested that the majority of genetic 
liability for ASD is the results of many common variants acting additively.  Studies 
examining additive genetic effects have estimated that up to 50% of phenotypic liability 
in ASD is due to common genetic variation , while rare de novo variants, while they 
contribute substantially to individual liability, account for only about  2.6% of overall 
liability variance in the population (Gaugler et al., 2014; Klei et al., 2012; S. H. Lee et al., 
2013).   
However, genome-wide association (GWA) studies aiming to identify locus 
specific common variants have had limited success.  Six GWA studies have been 
published to date, where only a few SNPs from these studies have reached genome-wide 
significance and none have been replicated in independent samples (Anney et al., 2012; 
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Anney et al., 2010; Hussman et al., 2011; Ma et al., 2009; Salyakina et al., 2010; Wang et 
al., 2009; Weiss, Arking, Daly, & Chakravarti, 2009).  A potential reason for this is lack 
of sufficient statistical power due to small effect sizes expected from individual SNPs 
(Anney et al., 2012).  Thus, larger mega-analyses are currently underway to increase 
statistical power through larger sample size ("Psychiatric Genomics Consortium,"). 
Nonetheless, combining these GWA results with other genomic data has aided in 
identification potential candidates pathways and networks for ASD susceptibility;  
Poelmans et al. were able to identify enrichment of three signaling networks implicating 
steroidogenesis, neurite outgrowth, and synaptic function, which are all functionally 
integrated by A-kinase anchor proteins (AKAPs)  (Poelmans, Franke, Pauls, Glennon, & 
Buitelaar, 2013).  The authors of this study suggest plausibility for AKAPs as a potential 
target for developing new treatments for ASD. 
 
Rare genetic variation 
Copy number variants (CNVs) are a type of genomic structural variation greater 
than 1kb in length, where segments of the genome are either duplicated (greater than two 
copies) or deleted (less than two copies).  While smalls structural variation is common in 
the general population, larger CNVs encompassing several genes are individually rare at 
the locus-specific level.  Genome-wide interrogation of CNVs has revealed that ASD 
cases have more rare CNVs than controls (Griswold et al., 2012; Pinto et al., 2010; 
Sanders et al., 2015).  CNVs at specific regions, such as 16p11.2, have provided the most 
promising locus-specific genomic associations to date (Weiss et al., 2008).  However, 
such locus-specific associations are typically not specific to ASD, often carrying risk for 
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additional neuropsychiatric conditions, such as ID, schizophrenia and bipolar disorder 
(Malhotra & Sebat, 2012).  Moreover, while effect sizes are large, prevalence, even 
among ASD cases is low (Gaugler et al., 2014; Malhotra & Sebat, 2012).  Additionally, 
ASD is associated with increased burden of de novo CNVs, rare inherited CNVs, and rare 
CNVs intersecting genes, particularly ASD candidate genes (Levy et al., 2011; Pinto et 
al., 2010; Sanders et al., 2011).  Enrichment analysis of rare CNVs has implicated 
disruption of functional gene sets involved in cell proliferation, projection, and motility, 
and GTPase/Ras signaling (Pinto et al., 2010).        
Single nucleotide variants (SNVs) are ultra-rare variants identified by DNA 
sequencing techniques.  Next generation sequencing (NGS) methods have been used in 
more recent publications to assess this type of rare variation.  Two whole-exome 
sequencing (WES) studies show that de novo SNVs, while extremely rare in the general 
population, are over represented among ASD probands in more than 40 genes (De Rubeis 
et al., 2014; Iossifov et al., 2014).  Additionally, whole-genome sequencing (WGS) 
efforts found considerable heterogeneity in de novo and rare inherited mutations, even 
within families, with nearly 70% of affected sibling pairs harboring discordant mutations 
in ASD candidate genes (Yuen et al., 2015).   
 
Epigenetic variation 
Epigenetic changes are chemical modifications to the genome that control gene 
expression.  DNA methylation, the most widely studied type of epigenetic change, is 
where there is an addition of a methyl group to the 5’ position of cytosine.  Generally, 
hypermethylation resulting in decreased gene expression and hypomethylation results in 
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increased gene expression.  DNA methylation is tissue specific, may change over time, 
and can be modified by environmental exposures (Keil & Lein, 2016; Tordjman et al., 
2014).  Methylation marks are heritable and can be reversed over the lifespan (Waterland 
& Michels, 2007).  DNA methylation and ASD have been associated, mainly in studies 
where DNA methylation has been isolated from brain and peripheral blood tissues. 
However, to date sample sizes have remained small (all studies < 100 samples) and thus 
additional studies are needed to understand the role of DNA methylation in 
ASD. Genome-wide approaches in brain tissue have implicated various genes, such as 
TSAPN32/C11orf21, ZFP57, PRRT1, and SDHAP3 (Ladd-Acosta et al., 2014; Nardone et 
al., 2014), while candidate gene approaches have found associations with the 
MeCP2, OXTR, EN-2, and SHANK3 (Gregory et al., 2009; James, Shpyleva, Melnyk, 
Pavliv, & Pogribny, 2013; Nagarajan, Hogart, Gwye, Martin, & LaSalle, 2006; Zhu et al., 
2014).   Genome-wide methylation studies using peripheral blood have also implicated 
various genes such as NFYC, PTPRCAP, and MBD4 (Gregory et al., 2009; Nguyen, 
Rauch, Pfeifer, & Hu, 2010; Wong et al., 2014).  
    
1.6.3. Environmental (non-genetic) risk factors 
Parental age 
Many studies, including meta-analyses, have linked advanced parental age to 
ASD in offspring (Gardener, Spiegelman, & Buka, 2009; Hultman, Sandin, Levine, 
Lichtenstein, & Reichenberg, 2011; Hultman, Sparen, & Cnattingius, 2002; Lampi et al., 
2013; Parner et al., 2012).  This has led to hypotheses about increasing risk for de novo 
mutations in gametes, epigenetic changes associated with aging, or suboptimal in utero 
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environment for the fetus through increased risk for obstetric complications and toxicant 
exposure (Hultman et al., 2011; Parner et al., 2012).  However, since maternal and 
paternal ages are often highly correlated, it remains unclear whether it is advanced 
maternal and paternal contributes to ASD risk independently or jointly.  A large 
population cohort study from five countries with over 30,000 ASD cases revealed that 
advancing maternal and paternal age were both independently associated with ASD risk 
(Sandin et al., 2016).  However, they also found that low maternal age (< 20 years) was 
also associated with ASD in the child, and that joint effects were present for 
maternal/paternal pairs with increased difference in age (Sandin et al., 2016).   
 
Prenatal, perinatal, and neonatal risk factors 
Maternal infection 
Animal studies have suggested that maternal immune activation during pregnancy 
affects neurodevelopment in the fetus (Patterson, 2011; Shi, Fatemi, Sidwell, & 
Patterson, 2003; Smith, Li, Garbett, Mirnics, & Patterson, 2007).  As a result, maternal 
infection has been studied in several epidemiologic samples, with inconsistent findings 
(Brown, Jones, MacKewn, & Plank, 2008; Guinchat et al., 2012; Mamidala et al., 2013; 
Meldrum et al., 2013; Ornoy, Weinstein-Fudim, & Ergaz, 2015; Visser et al., 2013; 
Zerbo, Iosif, et al., 2013).  Results from a large Danish population-based cohort suggest 
that common, mild infections and brief febrile episodes did not incur higher risk for ASD 
in offspring, but that influenza, prolonged febrile episodes and antibiotic use resulted in a 
two- to threefold risk (Atladottir, Henriksen, Schendel, & Parner, 2012).  Similar findings 
were reported using California health record data, where any infection during pregnancy 
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was not associated with ASD, but severe infections and multiple infections were 
associated with ASD in the offspring (Zerbo, Qian, et al., 2013). 
Smoking and alcohol use during pregnancy 
Many population-based studies have investigated exposure to maternal smoking 
during pregnancy, with mixed results. Some studies reported positive associations with 
ASD diagnoses or traits (Hultman et al., 2002; Hvidtjorn et al., 2011; Indredavik, 
Brubakk, Romundstad, & Vik, 2007; Larsson, Weiss, Janson, Sundell, & Bornehag, 
2009; Ronald, Happe, Dworzynski, Bolton, & Plomin, 2010; Tran et al., 2013; Visser et 
al., 2013), while others report null or trending toward negative associations (Bilder, 
Pinborough-Zimmerman, Miller, & McMahon, 2009; Burstyn, Sithole, & Zwaigenbaum, 
2010; Kalkbrenner et al., 2012; B. K. Lee et al., 2012; Maimburg & Vaeth, 2006).  Lyall 
et al. suggests interpreting reported associations with caution, and urge further, more 
rigorous investigation in this hypothesized risk for ASD (Lyall, Schmidt, & Hertz-
Picciotto, 2014).   Results from a large population cohort study suggest that smoking may 
be a confounding factor associated with ASD through other risk factors correlated with 
other demographic factors (B. K. Lee et al., 2012). 
Far less work has been done in the epidemiologic investigation into alcohol 
consumption during pregnancy and ASD in offspring.  Some have reported no 
association between alcohol and ASD (Eliasen et al., 2010; Lyall et al., 2014) while 
others have reported an inverse relationship between alcohol use during pregnancy and 
ASD risk (Visser et al., 2013).  A review of existing literature on prenatal toxicant 
exposures concludes that evidence to date does not suggest an association between 
maternal smoking and alcohol use during pregnancy and ASD, but that future studies 
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should investigate the potential for this relationship more rigorously, with better exposure 
assessment (Lyall et al., 2014).  
 
Obstetric complications 
Results from studies reporting associations between preeclampsia and related 
conditions (hypertension, swelling, proteinuria, etc.) have been largely inconclusive.  A 
meta-analysis of over fifty prenatal risk factors found that maternal obstetric 
complications, including preeclampsia, proteinuria, swelling, and hypertension, showed 
the strongest association with ASD (Gardener et al., 2009).  In 2012, a review of prenatal 
risk factors suggested further investigation into preeclampsia in the role of ASD risk 
(Guinchat et al., 2012). In a large population cohort in Western Australia, no association 
was found between any maternal conditions and ASD, but there was weak association for 
ASD with comorbid ID (Langridge et al., 2013).  However, maternal high blood pressure 
was associated with ASD in a large Finnish population cohort (Polo-Kantola et al., 2014).  
Others have found that preeclampsia and swelling are associated with increased ASD 
severity scores measuring both communication and restricted repetitive behaviors 
(Wallace, Anderson, & Dubrow, 2008).  A more recent study implicates preeclampsia as 
a risk factor for both ASD and developmental delay more broadly (Walker et al., 2015). 
Mechanisms by which preeclampsia and related symptoms might affect fetal 
neurodevelopment include: enhanced inflammation, vascular damage, insulin resistance 
in the mother as well as decreased placental perfusion and blood and oxygen to the fetus.  
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Gestational diabetes increases risk for a mother to develop preeclampsia and related 
symptoms and has been reportedly associated with ASD diagnosis and related cognitive 
and adaptive behavior traits in offspring (Gardener et al., 2009; Krakowiak et al., 2012). 
However, a subsequent review of prenatal risk factors cautions against over interpretation 
of these findings and suggests further investigation is necessary into the potential link 
between gestational diabetes and ASD (Guinchat et al., 2012). 
Birth outcomes, perinatal and neonatal conditions 
A meta-analysis including neonatal factors found nearly twenty specific perinatal 
and neonatal complications, including fetal distress, birth injury/trauma, maternal 
hemorrhage, low birth weight, small for gestational age,  and neonatal anemia, were 
associated with ASD (Gardener, Spiegelman, & Buka, 2011).  Many studies have found 
that low birth weight and being small for gestational age is associated with ASD, 
however it does not seem to be specific in association as it is also linked to various other 
developmental disabilities, including ID and LD (Lampi et al., 2012) (Maimburg & 
Vaeth, 2006; Mamidala et al., 2013; Schieve et al., 2010; Schieve et al., 2015; Schieve et 
al., 2016; Tamaru et al., 2011).    For example, Schieve et al. found similar population 
attributable fractions of low birth weight and preterm birth, ranging from 10-20%, for 
ASD, ID, and LD (Schieve et al., 2016).   On the other hand, examining a full range of 
birth weights and developmental disabilities, others have found that birth weight was not 
associated with ASD, but was associated with various developmental delays and learning 
disability (Boulet, Schieve, & Boyle, 2011).   
Many perinatal and neonatal conditions, such as hypoxia, respiratory distress, and 
neonatal jaundice have been linked to ASD risk (Bauer & Kriebel, 2013; Froehlich-
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Santino et al., 2014; Gardener et al., 2009, 2011; Guinchat et al., 2012; Mamidala et al., 
2013).    However, findings for individual risk factors across studies are largely 
inconsistent, possibly due to differences in sample ascertainment and case definition 
(Gardener et al., 2009, 2011).  For example, county-wide study of public records from 
Utah did not find any neonatal factors to be significantly associated with autism (Bilder et 
al., 2009).  Moreover, findings from a population-based matched case-control study of 
autism suggest suboptimal birth conditions often associated with ASD are explained by 
low birth weight and birth defects among cases (Maimburg & Vaeth, 2006).  Further 
work is needed to clarify either individual effects of perinatal risk factors, or understand 
potential common pathways to many of these risk factors that may be mediating the risk 
for ASD. 
 
1.7.  Methodological challenges to studying ASD 
1.7.1. Overview of methodological challenges 
This section will briefly review some of the challenges that accompany studying 
prevalence correlates, and etiology of ASD.  First, we will discuss how low incidence and 
prevalence of ASD affects cross-sectional and prospective study designs.   Specifically, 
we will detail the pros and cons of the two types of studies used in this dissertation:  
nationally representative surveys and enriched-risk prospective cohorts.  Second, we 
discuss issues of heterogeneity (etiologic and phenotypic) and dimensionality (as ASD-
related traits and risk factors that cross diagnostic boundaries).     Specifically, we will 
review examples of both genetic and non-genetic risk factors that show specificity to 
phenotypic subtypes of ASD, as it pertains to comorbidity, or symptomatology.  This will 
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be followed by a review of examples of genetic and non-genetic risk factors that span 
across diagnostic boundaries, either by broader non-clinical ASD traits, or affecting 
multiple neuropsychiatric conditions.   
 
1.7.2. Low incidence and prevalence of ASD 
Cross-sectional designs 
Many cross-sectional study studies ascertain cases through clinics as a convenient 
way to obtain enough cases to make a statistically meaningful comparison to controls.  
Case status is often confirmed by clinical evaluation and phenotypically well-defined; 
that is, we it is we are sure a case is actually affected with ASD and is easy to obtain 
information on comorbid conditions and symptom profiles.  However, clinically 
ascertained samples may lead to biased results, as demographics, risk factors and 
comorbid conditions may be differentially distributed among those currently seeking 
treatment and participating in clinical research compared to those with ASD not visiting 
the particular clinics recruiting for the study.  Therefore, random, representative sampling 
is ideal for determining unbiased prevalence and associations. In this project, we used 
data from the National Comorbidity Survey Adolescent supplement (NCS-A), a 
nationally representative face-to-face survey of prevalence and correlates of DSM-IV 
mental disorders. The NCS-A data are geographically and socio-demographically 
representative of all US adolescents attending school at the time of ascertainment 
(Kessler et al., 2009).  Therefore, we can make unbiased estimates of comorbid 
conditions and risk factors associated with ASD in US adolescents.  However, when a 
disease is relatively rare, such as ASD, the case sample size will be drastically lower than 
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that of non-cases.  Additionally, while the NCS-A was able to obtain in depth phenotypic 
information on a wide range of mental disorders, we rely on parent-reported data for 
ASD, LD, physical comorbidity, and early life risk factors. Here, we sacrifice ASD case 
sample size and in-depth phenotyping for representativeness.   
Prospective designs 
Prospective studies allow us to study the development of disease before symptom 
onset is apparent by ascertaining unaffected individuals and following them over time 
while collecting relevant data on risk factors and markers of disease.  This is beneficial to 
collect time-relevant exposures and assessments. However, when your disease of interest 
is relatively rare, you would have to follow many subjects in order to obtain enough cases 
to draw meaningful conclusions from the study population.  This is often cost prohibitive 
and inefficient when studying rare diseases. High-risk cohort designs, where participants 
are selected based on having higher risk of developing the disease of interested compared 
to the general population, offer an effective alternative to a traditional cohort designs.  
Because siblings of children with ASD are nearly twenty times more likely to develop 
ASD compared to the general population (Ozonoff et al., 2010), ASD high-risk studies 
often recruit baby siblings of children with ASD in order to observe development and 
collect behavioral and biosample data before a diagnosis can be made (Newschaffer et 
al., 2012). In this project, we use two high-risk cohorts, the Early Autism Risk 
Longitudinal Investigation (EARLI) and the Infant Brain Imaging Study (IBIS) that 
collected measures of cognitive and motor development longitudinally from age 6 to 36 
months.  Here, we sacrifice representativeness and sample size for rich phenotypic data 
and enrichment for observing developmental traits associated with ASD. 
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1.7.3. Heterogeneity and dimensionality 
Within-ASD heterogeneity 
ASD is a highly heterogeneous condition, with respect to symptom profile, 
severity, and comorbid conditions.  Several genetic and non-genetic risk factors for ASD 
have shown a differential effect dependent upon ASD subgroups.  For example, maternal 
and paternal age was differentially associated with ASD subtypes, where advanced 
paternal age was associated with more severe autistic disorder, while advanced maternal 
age was associated with less severe subtypes of ASD (Lampi et al., 2013).   An 
examination of rare genic CNVs among ASD cases found that different sets of CNVs 
affected different sub-phenotypes, where CNVs in genes previously implicated in ASD 
and ID were associated with communication and language abilities, while CNVs in 
differentially brain expressed regions were more closely associated with adaptive 
functioning  (Merikangas et al., 2015).  Such findings highlight the importance of 
considering phenotypic heterogeneity in etiologic research of ASD.   
 
Non-specificity across ASD diagnostic boundaries 
As discussed previously, many risk factors (genetic and non-genetic) and 
comorbidities associated with ASD are also associated with other neurodevelopmental 
disorders, suggesting there may be underlying common traits or pathways to disease 
crossing diagnostic boundaries (Schieve et al., 2012).  For example, a study comparing 
birth outcomes between ASD and ID found that preterm birth, low birth weight, small for 
gestational age, and low Apgar scores were associated with both ASD and ID 
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independently (Schieve et al., 2015).  Additionally, several genetic risk factors are non-
specifically associated with ASD.  Rare CNVs associated with ASD often account for 
only a fraction of individual ASD risk, but are also associated other neuropsychiatric 
traits such as schizophrenia and ID (Malhotra & Sebat, 2012).  Additional studies have 
found that ASD-implicated genetic variants are also associated with cognitive and 
subclinical ASD-related traits in the general population (Mannik et al., 2015; Robinson et 



















1.8. Specific Aims 
This research aimed to examine comorbidity, environmental, and genetic risk factors 
associated with ASD in the context of general neurodevelopment.  The specific aims 
were: 
1. To evaluate lifetime presence of physical and mental health conditions associated 
with parent reported ASD and LD in the National Comorbidity Survey 
Adolescent Supplement (NCS-A), a population-based, nationally representative 
sample of US adolescents (Chapter 2). 
2. To estimate prevalence and association of prenatal, perinatal, and neonatal risk 
factors with ASD and LD in a nationally representative, population-based sample 
of US adolescents (NCS-A) (Chapter 3). 
3. To identify common ASD-related genetic variants associated with differential 
trajectories of cognitive and motor development, as measured by the Mullen 
Scales of Early Learning (MSEL), among infant high-risk ASD siblings from the 
Early Autism Risk Longitudinal Investigation (EARLI) and Infant Brain Imaging 
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Objective: Autism spectrum disorder (ASD) and learning disorder (LD) are highly 
comorbid neurodevelopmental disorders (NDDs).  ASD is associated with an array of 
physical and mental conditions in clinically ascertained samples. We report prevalence 
and odds of physical and mental conditions associated with ASD and LD in a nationally 
representative population-based sample of US adolescents.  
Method: Mutually exclusive groups of adolescents with parent survey data from the 
National Comorbidity Survey - Adolescents Supplement (NCS-A) (n=6,296) with ASD 
with or without LD and LD without ASD were compared to those without either ASD or 
LD.  Estimates were weighted to represent the population of US adolescents at the time 
of enrollment. 
Results: Allergies (aOR = 3.48, p = 0.004), acne (aOR = 3.25, p = 0.02), heart problems 
(aOR = 4.08, p = 0.02), and early morning awakening (aOR = 2.44, p = 0.04) were 
specifically associated with ASD.  Gastrointestinal problems (ASD: aOR = 5.60, p = 
0.004; LD: aOR = 1.70, p = 0.03), epilepsy/seizures (ASD: aOR = 9.97, p < 0.001; LD: 
aOR = 2.82, p = 0.001), and ADHD (ASD: aOR = 8.38, p < 0.001; LD: aOR = 6.13, p < 
0.001) were associated with both ASD and LD.   
Conclusion:  Several conditions are specifically associated with ASD.  However, 
gastrointestinal problems, epilepsy/seizures, and ADHD are associated with both ASD 
and LD in our population-based sample, indicating an association with general 
neurodevelopment rather than ASD specifically.  Findings have important implications 






Autism spectrum disorder (ASD) is an early-onset neurodevelopmental disorder 
(NDD) characterized by social and communication deficits and restrictive and repetitive 
behaviors or interests (American Psychiatric Association, 2013). ASD affects 
approximately 1.5% of children in the US, many of whom also suffer from learning 
disorder (LD) (CDC, 2014).  
Previous reports of clinically ascertained samples of youth with ASD have 
suggested higher than expected rates of comorbid physical conditions affecting a variety 
bodily systems, including gastrointestinal, autoimmune/inflammatory disorders, sleep 
disturbances and neurological disorders (Bauman, 2010; Matson & Goldin, 2013). 
Similarly elevated rates of comorbidity with a range of physical conditions and healthcare 
service use have been observed in community-based samples of youth with ASD 
(Gurney, McPheeters, & Davis, 2006; Schieve et al., 2012). ASD has also been 
associated with a variety of mental disorders such as attention deficit/hyperactivity 
disorder (ADHD) (Matson, Rieske, & Williams, 2013; Memari, Ziaee, Mirfazeli, & 
Kordi, 2012), anxiety, and mood disorders (Joshi, Biederman, et al., 2013; Joshi, 
Wozniak, et al., 2013; McPheeters, Davis, Navarre, & Scott, 2011) in clinical and 
community-based samples. Several of these conditions have also been reported at 
increased prevalence for several other neurodevelopmental disorders, such as ADHD and 
intellectual disability (ID) (Schieve et al., 2012).   
Previous work suggests mental and physical conditions may cluster differentially 
among youth with ASD resulting in comorbidity-specific trajectories that may reflect 




been made about the link between ASD and comorbid conditions when studying these 
conditions individually in clinical samples; however, understanding the full range of 
physical conditions associated with ASD in a non-biased population sample could 
improve hypothesis generation regarding underlying pathways to neurodevelopmental 
disorder.  Accurate profiles of comorbid risk can also potentially improve implementation 
of clinical care.   
Most previous research concerning ASD physical and mental comorbidity has 
been conducted in clinically referred samples, which may lead to elevated estimates of 
comorbidity due to differential treatment-seeking among those with comorbid conditions.  
Population-based studies to date have not included direct evaluation of the full range of 
common mental disorders in ASD youth.  Furthermore, there is evidence for increased 
rates of many conditions shared across several neurodevelopmental disorders rather than 
comprising manifestations specifically associated with ASD.(Schieve et al., 2012) 
Specificity of comorbidity of mental and physical conditions with ASD versus broader 
manifestations of neurodevelopmental disorders, such as LD, has not been established. 
 In the current study, we estimate the prevalence and adjusted odds of parent- 
reported physical conditions and directly evaluate mental disorders among mutually 
exclusive groups of youth with ASD (with or without LD) and LD (without ASD) in a 
nationally representative, population-based sample of adolescents.  Additionally, we 









The National Comorbidity Survey Adolescent Supplement (NCS-A) is a 
nationally representative household survey of adolescent mental health in the Unites 
States. Recruitment methods, sampling and weighting strategies have been described in 
detail elsewhere.(Kessler et al., 2009) Adolescents aged 13-17 were recruited via either 
household or school-based sampling schemes.  Professional interviewers administered in-
person, computer-assisted personal interviews in adolescents’ homes between February 
2001 and January 2004. One parent/guardian was asked to complete a self-administered 
questionnaire, the Parent Self-Administered Questionnaire (PSAQ), consisting of 
questions pertaining to the adolescent’s medical and developmental history as well as 
parent and household characteristics.  Informed assent and consent was obtained from 
each participating adolescent and his/her parent or legal guardian. The Harvard Medical 
School and University of Michigan Human Subjects Committees approved all study 
procedures.   
Measures 
Neurodevelopmental Disorders 
Presence of ASD and LD were evaluated by parent response to a single yes/no 
question on in the PSAQ for each condition: “Has [the adolescent] ever had […] 
developmental disorders (such as autism, Asperger’s, or pervasive developmental 
disorder)?” and “Has [the adolescent] ever had […] learning disability?“ A positive 




adolescent has ever received treatment for this problem by a doctor, and whether the 
adolescent has experienced this problem in the past 12 months.   
Comorbid Physical Conditions 
Lifetime presence of chronic physical conditions, including allergies, asthma, 
severe stomach problems, seizures/epilepsy, headache/migraine, acne, skin conditions 
(such as eczema or psoriasis), and heart problems were assessed by parent response to a 
series of yes/no questions about the adolescent’s health.  Enuresis was coded as present if 
the parent reported that the child had ceased bed wetting after age 5.  Sleep problems 
were assessed by adolescent response to a series of three questions in the chronic 
conditions module of the CIDI pertaining to difficulty initiating and maintaining sleep as 
well as frequent early-morning awakening. 
Comorbid Mental Disorders 
Comorbid mental disorders were assessed by direct household interviews with 
adolescents on the World Health Organization Composite International Diagnostic 
Interview (CIDI) 3.0 (Robins et al., 1988), a structured interview for the assessment of 
ICD-10 and DSM-IV criteria for mental disorders.  DSM-IV criteria were applied for 
comprehensive domains of mental disorders including major depressive disorder, bipolar 
I, bipolar II, generalized anxiety disorder, social phobia, separation anxiety disorder, 
panic disorder, post-traumatic stress disorder, anorexia, bulimia, alcohol 
abuse/dependence, drug abuse/dependence, conduct disorder, intermittent explosive 
disorder, and attention deficit hyperactivity disorder.(Merikangas et al., 2010) Diagnoses 
were then grouped by disorder class (mood, anxiety, eating, substance, 




Medication and Services Use 
Adolescents were asked whether they had ever received disorder-specific 
treatment immediately after answering diagnostic questions for each DSM-IV disorder 
category as part of the CIDI.  In a separate interview module focusing on services, all 
respondents were asked whether they ever received service for emotional or behavioral 
problems and the settings in which they had received those services.   Parents were asked 
similar questions pertaining to their child’s healthcare/social services use to those 
administered to the adolescent.   Based on endorsement by either adolescent or parent, 
service use was classified into 5 categories: 1) mental health specialty, 2) general 
medical, 3) complementary and alternative medicine, 4) juvenile justice, and 5) school-
based services.   
 Adolescents were shown a comprehensive list of over 300 brand and generic 
names of pharmacologic medications and were asked to indicate which ones they took on 
a regular basis in the past 12 months.  Responses were recorded and grouped into 6 
categories: anti-depressants, anti-psychotics, anxiolytics, mood stabilizer/anticonvulsants, 
stimulant, and miscellaneous.   
Impairment 
Overall functional impairment was measured by total difficulties score of the Strengths 
and Difficulties Questionnaire (SDQ), which evaluates emotional, attentional, peer 
relationship, and conduct problems in a dimensional manner suitable for population-







Statistical analyses were carried out in R version 3.1.1 (Lumley, 2014; R Core 
Team, 2014). Survey-weighed multiple logistic regression was used to calculate 
associations between parent-reported NDD status - ASD with or without LD (ASD) and 
LD without ASD (LD-only) - and physical condition or mental disorder. All analyses 
adjusted for age, sex, race/ethnicity, and household income of the adolescent and were 
weighted to represent the national population of adolescents attending school at the time 
of study recruitment.  Methods to develop weights are described in detail elsewhere 
(Kessler et al., 2009). Missing data were assumed to be missing completely at random 
and were handled by model-wise deletion.  
 
RESULTS 
The weighted prevalence of parent-reported ASD and LD among adolescents with 
parent report data in the NCS-A was 0.7% (SE: 0.1%) and 14.3% (SE: 0.7%), 
respectively. The prevalence of LD among ASD cases was 70.0% (SE: 8.0%) and 13.7% 
(SE: 0.7%) among non-ASD cases. The prevalence of ASD among LD cases was 3.6% 
(SE: 0.9%), and 0.3% (SE: 0.1%) among non-LD cases.  By statistical comparison group, 
0.7% (SE: 0.1%) had ASD with or without LD while and 13.7% (SE: 0.7%) had LD 
without ASD; 85.6% (SE: 0.7%) had neither ASD nor LD.  
 Table 2.1 shows the comparison of demographic characteristics of the weighted 
sample by ASD and LD status, with statistical comparisons to the unaffected (non-NDD) 
group.  Both NDD-affected groups were predominantly male compared to the non-NDD 
group: ASD: 85.5% v. 48.2%, X
2






29.45, p < 0.001.  The ASD group also differed significantly from the non-NDD group on 
distribution of race/ethnicity (X
2
3=7.32, p < 0.001).  The LD-only group differed 
significantly from the non-NDD group by household income (X
2
3=6.78, p=0.001) and 
parent marital status (X
2
3=3.79, p=0.02). The NDD subgroups did not differ from the 
non-NDD group in mean adolescent age, parent educational status, English spoken in the 
home, geographic region, or urban environment.  Additional comparisons of number of 
siblings and birth order revealed no differences between any NDD group and the non-
NDD group. Gender, age, household income, and parent education were included as 
covariates in subsequent analyses. 
 Table 2.2 presents weighted estimates of prevalence and demographic-adjusted 
odds ratios of comorbid physical conditions among NDD subgroups.  The ASD group 
was more likely to endorse allergies/hay fever (aOR=3.43, 95% CI=1.57-7.48, p=0.004), 
acne (aOR=3.25, 95% CI=1.30-8.13, p=0.02) and heart problems (aOR=4.08, 95% 
CI=1.27-13.13, p=0.02) compared to the non-NDD group, while the LD-only group did 
not differ from the non-NDD group on these conditions.  ASD and LD-only NDD groups 
had higher risk for both severe stomach problems (ASD: aOR= 5.60, 95% CI = 1.86-
16.85, p= 0.004; LD-only: aOR= 1.70, 95% CI = 1.09-2.66, p=0.03) and 
epilepsy/seizures (aOR=9.97, 95% CI=3.24-30.69, p<0.001); LD-only: aOR= 2.82, 95% 
CI = 1.58-5.05, p= 0.001).  The LD-only subgroup showed increased odds for 
headache/migraine (aOR = 1.41, 95% CI = 1.04-1.91, p=0.03), enuresis (aOR = 1.72, 
95% CI = 1.14-2.62, p=0.02), while ASD group was not significantly associated with any 
of these conditions. There were no differences in risk of asthma or skin conditions other 




had higher odds of experiencing frequent early morning awakening (aOR=2.44, 95% 
CI=1.07-5.56, p=0.04) in the past 12 months, while LD-only adolescents had higher odds 
of any sleep problem (aOR = 1.49, 95% CI= 1.17-1.89, p=0.003), and specifically, sleep 
initiation (aOR = 1.47, 95% CI = 1.17-1.89, p=0.003). 
 Table 2.3 presents weighted estimates of prevalence and demographic-adjusted 
odds ratios of comorbid mental disorders by NDD subgroup.  Both the ASD (aOR = 8.38, 
95% CI = 4.15-16.90, p<0.001) and LD (aOR = 6.13, 95% CI = 4.47-8.41, p<0.001) 
affected groups had over six-fold increased odds of meeting ADHD diagnostic criteria. 
The LD-only group showed increased odds of comorbid anxiety disorder (aOR = 1.28, 
95% CI = 1.03-1.59, p=0.03) and conduct/behavioral disorder (aOR = 1.87, 95% CI = 
1.40-2.50, p<0.001). Neither NDD-affected group had significantly higher odds of 
comorbid mood, eating, or substance abuse/dependence disorders compared with the non-
NDD group.   
 Table 2.4 presents weighed estimates of prevalence and demographic-adjusted 
odds of past 12-month medication use and lifetime health and social service use by NDD 
subgroup.  The ASD group had nearly 8.5 times higher odds (aOR = 8.49, 95% CI = 
3.43-21.01, p<0.001) of medication use in the past 12 months while the LD-only group 
had over 3.5 times higher odds (aOR = 3.55, 95% CI = 2.38-5.30, p<0.001) compared to 
the non-NDD group.  Medication subcategory analyses (Table 2.4) revealed that ASD 
status was associated with every subcategory of 12-month medication use and LD status 
was associated with nearly every subcategory (excluding anti-psychotic and anxiolytic). 
Regarding services, the ASD group was more likely to receive mental health specialty, 




group was also more likely to have received these services as well as complementary and 
alternative medicine (CAM) and juvenile justice services.  Both the ASD (aOR = 5.93, 
95% CI = 2.65-13.23, p<0.001) and LD (aOR = 4.16, 95% CI = 3.10-5.59, p<0.001) 
group were significantly more likely to score in the 90
th
 percentile on the difficulties 
composite of the SDQ. 
 
DISCUSSION 
These findings provide estimates of ASD physical and mental comorbidity and 
healthcare service use in a nationally representative sample of US adolescents.  Overall 
prevalence rates of ASD (0.7%) and LD (14.3%) were similar to those found in other 
population-based studies collected during the same time period (CDC, 2007), with the 
majority of ASD adolescents (70%) experiencing concurrent LD (Gurney et al., 2006; 
Schieve et al., 2012).  ASD and LD groups were characterized by different patterns of 
comorbidity, which may have important implications for etiologic inferences and risk 
factor identification.    
The high prevalence of LD among ASD cases calls for identification of comorbid 
conditions specific to ASD. Increased risk for gastrointestinal problems and 
epilepsy/seizures, two physical conditions suspected to be etiologically related to 
ASD,(Amiet et al., 2008; Bauman, 2010; Mayer, Padua, & Tillisch, 2014) were present in 
both the ASD and LD groups. This suggests a potential overarching neurodevelopmental 
component to these conditions that is not specific to ASD alone.  Furthermore, LD in the 
absence of ASD was uniquely associated with several physical and mental conditions, 




providers of specific mental and physical health problems among adolescents with LD. 
Accurate understanding of NDD comorbidity can potentially improve implementation of 
clinical care as well as inform genetic and other etiologic research.  Further prospective 
research is needed to establish temporality and identify potential biological mechanisms 
resulting in cross-domain comorbidity in neurodevelopmental disorders. 
ASD cases were nearly six times more likely and LD-only nearly twice as likely 
to have severe GI problems compared to their non-NDD counterparts. Many previous 
studies have indicated increased rates of GI problems among ASD children, with a recent 
meta-analysis providing consensus, (McElhanon, McCracken, Karpen, & Sharp, 2014) 
but the link is not well understood.(Coury et al., 2012) Furthermore, little is known about 
the prevalence of GI problems specifically among youth with LD alone.  There is 
growing evidence suggesting a link between alterations in the gut microbiome and 
neurodevelopment leading to social, behavioral, and cognitive impairment in ASD 
(Coury et al., 2012; Mayer et al., 2014). These findings suggest that this link may extend 
to other NDDs as well.   
We also found a similar pattern of association between both NDD subgroups and 
risk for epilepsy and seizures.  Previous reports have shown increased prevalence rates of 
seizures in ASD with a range from 5-40%.(Bauman, 2010) A meta-analysis of 23 studies 
suggested that risk is affected by age, gender and cognitive ability, with greater rates of 
epilepsy in ASD girls with intellectual disability (ID)(Amiet et al., 2008). While we do 
not have a measure of ID in the current study, it is interesting to note that we find the 
highest prevalence of epilepsy/seizures in ASD (18.0%) and elevated to a lesser extent, 




associations between these NDDs and both GI problems and seizures are causal or 
comorbid, the association has been consistently found in previous studies, particularly in 
the only prior population based sample of Schieve et al (Schieve et al., 2012), who also 
reported increased risks for seizures and gastrointestinal problems across all 
developmental disabilities examined in the National Health Interview Survey, including 
autism, autism with ID, and LD as well as ADHD. More recently, these associations also 
emerged from the application of an unsupervised clustering statistical approach to 
investigate comorbidity in ASD based on electronic medical records.(Doshi-Velez et al., 
2014) Therefore, these disorders may reflect a broader manifestation of the multi-system 
impact of neurodevelopmental problems or their risk factors.   
ADHD, another NDD, was associated with both ASD and LD.  These findings 
support those of many studies have reported increased ADHD symptoms and diagnoses 
in ASD (Matson et al., 2013; Memari et al., 2012; Schieve et al., 2012) and LD (Pham & 
Riviere, 2015) children.  Further, this association confirms previously reported evidence 
for shared genetic underpinnings across these and other neurodevelopmental disorders 
(Pettersson, Anckarsäter, Gillberg, & Lichtenstein, 2013; Posthuma & Polderman, 2013). 
Several conditions, including early morning awakening, allergy, acne, and heart 
problems, were specifically associated with ASD but not LD. Early morning awakening 
sleep problems (Giannotti, Cortesi, Cerquiglini, Vagnoni, & Valente, 2011) and allergy 
(de Theije et al., 2014; Theoharides, 2013) have both been previously shown to be 
associated with ASD (Bauman, 2010; Gurney et al., 2006; Schieve et al., 2012).  Sleep 
disorders have also been linked to ADHD (Tsai & Huang, 2010) and we find increased 




sleep disruption may be a general problem among youth with NDDs. Amelioration of 
sleep problems could potentially lead to improvements in cognitive and adaptive 
functioning for multiple neurodevelopmental disorders (Taylor, Schreck, & Mulick, 
2012).   
While allergies have previously been associated with neurodevelopment in 
general rather than with ASD specifically, (de Theije et al., 2014; Julvez et al., 2009; 
Meldrum et al., 2012) our results do not indicate a common comorbidity spanning ASD 
and LD.  It is possible that the link between allergy and neurodevelopment does not 
encompass pathways associated with the specific deficits of LD, but perhaps more severe 
cognitive or social/communication deficits.  Adolescents with ASD were also nearly 
three times more likely to have acne.  It has recently been posited that imbalances in the 
human microbiome similar to those associated with ASD and GI problem may also lead 
to acne and various other skin conditions.(Muszer, Noszczynska, Kasperkiewicz, & 
Skurnik, 2015)    
Heart problems were reported in nearly 13% of ASD cases.  Previous research has 
demonstrated autonomic hyper arousal, with elevated basal heart rate and atypical 
reactivity to social tasks among those with ASD.(Kushki, Brian, Dupuis, & Anagnostou, 
2014) Furthermore, some genetic deletion syndromes that frequently present with autistic 
features also present with cardiac defects.(Celestino-Soper et al., 2012; Niklasson, 
Rasmussen, Óskarsdóttir, & Gillberg, 2002) However, we could not examine this further 
because of the lack of information on genetic syndromes in this sample and no subtypes 




By contrast, LD-affected children without comorbid ASD were significantly more 
likely to have comorbid enuresis, sleep problems (primarily initiation), severe 
headaches/migraine, and several mental disorders including anxiety disorders, conduct 
and behavioral disorders compared to non-NDD adolescents. These conditions may be a 
common manifestation of delayed neurodevelopmental maturation that could potentially 
result from common risk factors or consequences of LD. In either case, LD-only 
adolescents clearly carry an increased burden of chronic conditions that is distinct from 
that of adolescents suffering from ASD.  Healthcare providers and educators should be 
aware that LD adolescents are at higher risk for these health problems, which could 
influence implementation and effectiveness of healthcare and school-based interventions.  
 It is possible that differences in sample size/power between NDD subgroups 
could explain why we see some associations in the larger LD-only group, but not the 
ASD subgroups.  However, extending the significance threshold to p < 0.10 in the 
smaller ASD subgroup did not show significant associations, indicating uniqueness for 
the LD-only group.  This may suggest that the LD reported in ASD children may be 
biologically distinct from the LD reported in children without ASD, and that this 
subgroup is at risk for a different, yet still substantial burden of chronic health conditions.  
These findings have particular relevance to the awareness of, and services for adolescents 
with LD. Whereas ASD services are primarily funded through Medicaid or other state 
based funding for youth, either specifically for ASD or through Serious Emotional 
Disorders mandates, resources for the recognition and treatment of LD are primarily in 




conditions, such differential service streams for youth are likely to induce uncoordinated 
and fragmented care for such youth.   
 NDD status and presence of physical conditions were based solely on parent 
report rather than direct parental interview. This may have led to some misclassification 
compared to direct evaluation because of our inability to probe responses.  However, 
previous studies support the validity of parent report of such conditions (Centers for 
Disease Control and Prevention, 2006; Daniels et al., 2012). In addition, statistical 
comparison of ASD and LD comorbidity risk profiles was impeded by the vastly 
different sample sizes between affected groups.  Therefore, we considered overall 
patterns in point estimates and directionality, rather than relying solely upon p-values and 
statistical significance. These disorders are based on DSM-IV diagnostic criteria that do 
not reflect changes implemented in the DSM-5.  However, because the new criteria were 
designed to measure the same psychological phenomena in a dimensional manner, we 
expect that our conclusions are still likely to be relevant (Huerta, Bishop, Duncan, Hus, & 
Lord, 2012).  
These findings are based on a nationally representative sample of adolescents 
ascertained without respect to NDD or comorbidity status, thus limiting potential for 
inflated comorbidity prevalence estimates.  Of note, these are the first prevalence 
estimates of directly assessed mental disorders among ASD and LD in a nationally 
representative sample of U.S. adolescents. While the CIDI has not been validated 
specifically in ASD populations, all ASD participants in the current study had sufficient 
functional status to attend school and to complete the interview process.   Second, 




A provided a rare opportunity for extensive examination of physical-mental comorbidity. 
The extensive information collected from parent questionnaires also permitted evaluation 
of specificity through our inclusion of LD, another NDD highly comorbid with ASD, as a 
comparison group.   
This study utilized nationally representative population-based sample to provide 
estimates of physical and directly assessed mental disorders among adolescents with 
NDDs in the US.  While some conditions appear to be specifically associated with ASD, 
others may reflect broader manifestations of NDDs.  Future research should examine 
these patterns of comorbidity as potential clues to shared etiology.  Furthermore, these 
findings highlight the importance of clinical characterization of the full spectrum of both 
physical and mental disorders that may impact functioning among those with NDDs in 




























American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental 
Disorders (5 ed.). Arlington, VA: American Psychiatric Publishing. 
Amiet, C., Gourfinkel-An, I., Bouzamondo, A., Tordjman, S., Baulac, M., Lechat, P., . . . 
Cohen, D. (2008). Epilepsy in autism is associated with intellectual disability and 
gender: evidence from a meta-analysis. Biological Psychiatry, 64(7), 577-582.  
Bauman, M. L. (2010). Medical comorbidities in autism: challenges to diagnosis and 
treatment. Neurotherapeutics, 7(3), 320-327. doi: 10.1016/j.nurt.2010.06.001 
CDC. (2007). Prevalence of autism spectrum disorders--autism and developmental 
disabilities monitoring network, six sites, United States, 2000. MMWR: 
Surveillance Summaries, 56(1), 1-11.  
CDC. (2014). Prevalence of autism spectrum disorder among children aged 8 years - 
autism and developmental disabilities monitoring network, 11 sites, United States, 
2010. MMWR: Surveillance Summaries, 63(2), 1-21.  
Celestino-Soper, P. B., Skinner, C., Schroer, R., Eng, P., Shenai, J., Nowaczyk, M. M. J., 
. . . Stankiewicz, P. (2012). Deletions in chromosome 6p22.3-p24.3, including 
ATXN1, are associated with developmental delay and autism spectrum disorders. 
Molecular Cytogenetics, 5(1). doi: 10.1186/1755-8166-5-17 
Centers for Disease Control and Prevention. (2006). Mental health in the United States: 
parental report of diagnosed autism in children aged 4-17 years--United States, 
2003-2004. MMWR: Morbidity and Mortality Weekly Report, 55(17), 481-486.  
Coury, D. L., Ashwood, P., Fasano, A., Fuchs, G., Geraghty, M., Kaul, A., . . . Jones, N. 
E. (2012). Gastrointestinal conditions in children with autism spectrum disorder: 
developing a research agenda. Pediatrics, 130 Suppl 2, S160-168. doi: 
10.1542/peds.2012-0900N 
Daniels, A. M., Rosenberg, R. E., Anderson, C., Law, J. K., Marvin, A. R., & Law, P. A. 
(2012). Verification of parent-report of child autism spectrum disorder diagnosis 
to a web-based autism registry. Journal of Autism and Developmental Disorders, 
42(2), 257-265.  
de Theije, C. G., Bavelaar, B. M., Lopes da Silva, S., Korte, S. M., Olivier, B., Garssen, 
J., & Kraneveld, A. D. (2014). Food allergy and food-based therapies in 
neurodevelopmental disorders. Pediatric Allergy and Immunology, 25(3), 218-
226. doi: 10.1111/pai.12149 
Doshi-Velez, F., Ge, Y., & Kohane, I. (2014). Comorbidity clusters in autism spectrum 
disorders: an electronic health record time-series analysis. Pediatrics, 133(1), e54-




Giannotti, F., Cortesi, F., Cerquiglini, A., Vagnoni, C., & Valente, D. (2011). Sleep in 
children with autism with and without autistic regression. Journal of Sleep 
Research, 20(2), 338-347. doi: 10.1111/j.1365-2869.2010.00882.x 
Goodman, R. (1997). The Strengths and Difficulties Questionnaire: a research note. 
Journal of Child Psychology and Psychiatry and Allied Disciplines, 38(5), 581-
586.  
Gurney, J. G., McPheeters, M. L., & Davis, M. M. (2006). Parental report of health 
conditions and health care use among children with and without autism: National 
Survey of Children's Health. Archives of Pediatrics and Adolescent Medicine, 
160(8), 825-830. doi: 10.1001/archpedi.160.8.825 
Huerta, M., Bishop, S. L., Duncan, A., Hus, V., & Lord, C. (2012). Application of DSM-
5 criteria for autism spectrum disorder to three samples of children with DSM-IV 
diagnoses of pervasive developmental disorders. American Journal of Psychiatry, 
169(10), 1056-1064. doi: 10.1176/appi.ajp.2012.12020276 
Joshi, G., Biederman, J., Petty, C., Goldin, R. L., Furtak, S. L., & Wozniak, J. (2013). 
Examining the comorbidity of bipolar disorder and autism spectrum disorders: a 
large controlled analysis of phenotypic and familial correlates in a referred 
population of youth with bipolar I disorder with and without autism spectrum 
disorders. Journal of Clinical Psychiatry, 74(6), 578-586. doi: 
10.4088/JCP.12m07392 
Joshi, G., Wozniak, J., Petty, C., Martelon, M. K., Fried, R., Bolfek, A., . . . Biederman, 
J. (2013). Psychiatric comorbidity and functioning in a clinically referred 
population of adults with autism spectrum disorders: a comparative study. Journal 
of Autism and Developmental Disorders, 43(6), 1314-1325. doi: 10.1007/s10803-
012-1679-5 
Julvez, J., Torrent, M., Guxens, M., Anto, J. M., Guerra, S., & Sunyer, J. (2009). 
Neuropsychologic status at the age 4 years and atopy in a population-based birth 
cohort. Allergy, 64(9), 1279-1285. doi: 10.1111/j.1398-9995.2009.01987.x 
Kessler, R. C., Avenevoli, S., Costello, E. J., Green, J. G., Gruber, M. J., Heeringa, S., . . 
. Zaslavsky, A. M. (2009). Design and field procedures in the US National 
Comorbidity Survey Replication Adolescent Supplement (NCS-A). International 
Journal of Methods in Psychiatric Research, 18(2), 69-83. doi: 10.1002/mpr.279 
Kushki, A., Brian, J., Dupuis, A., & Anagnostou, E. (2014). Functional autonomic 
nervous system profile in children with autism spectrum disorder. Mol Autism, 5, 
39. doi: 10.1186/2040-2392-5-39 




Matson, J. L., & Goldin, R. L. (2013). Comorbidity and autism: Trends, topics and future 
directions. Research in Autism Spectrum Disorders, 7(10), 1228-1233. doi: 
10.1016/j.rasd.2013.07.003 
Matson, J. L., Rieske, R. D., & Williams, L. W. (2013). The relationship between autism 
spectrum disorders and attention-deficit/hyperactivity disorder: an overview. 
Research in Developmental Disabilities, 34(9), 2475-2484. doi: 
10.1016/j.ridd.2013.05.021 
Mayer, E. A., Padua, D., & Tillisch, K. (2014). Altered brain-gut axis in autism: 
Comorbidity or causative mechanisms? Bioessays, 36(10), 933-939. doi: 
10.1002/bies.201400075 
McElhanon, B. O., McCracken, C., Karpen, S., & Sharp, W. G. (2014). Gastrointestinal 
Symptoms in Autism Spectrum Disorder: A Meta-analysis. Pediatrics. doi: 
10.1542/peds.2013-3995 
McPheeters, M. L., Davis, A., Navarre, J. R., 2nd, & Scott, T. A. (2011). Family report of 
ASD concomitant with depression or anxiety among US children. Journal of 
Autism and Developmental Disorders, 41(5), 646-653. doi: 10.1007/s10803-010-
1085-9 
Meldrum, S. J., D'Vaz, N., Dunstan, J. A., Mori, T. A., Hird, K., Simmer, K., & Prescott, 
S. L. (2012). Allergic disease in the first year of life is associated with differences 
in subsequent neurodevelopment and behaviour. Early Human Development, 
88(7), 567-573. doi: 10.1016/j.earlhumdev.2011.12.032 
Memari, A., Ziaee, V., Mirfazeli, F., & Kordi, R. (2012). Investigation of autism 
comorbidities and associations in a school-based community sample. Journal of 
Child and Adolescent Psychiatric Nursing, 25(2), 84-90. doi: 10.1111/j.1744-
6171.2012.00325.x 
Merikangas, K. R., He, J. P., Burstein, M., Swanson, S. A., Avenevoli, S., Cui, L., . . . 
Swendsen, J. (2010). Lifetime prevalence of mental disorders in U.S. adolescents: 
results from the National Comorbidity Survey Replication--Adolescent 
Supplement (NCS-A). Journal of the American Academy of Child and Adolescent 
Psychiatry, 49(10), 980-989. doi: 10.1016/j.jaac.2010.05.017 
Muszer, M., Noszczynska, M., Kasperkiewicz, K., & Skurnik, M. (2015). Human 
Microbiome: When a Friend Becomes an Enemy. Archivum Immunologiae et 
Therapiae Experimentalis, 63(4), 287-298. doi: 10.1007/s00005-015-0332-3 
Niklasson, L., Rasmussen, P., Óskarsdóttir, S., & Gillberg, C. (2002). Chromosome 
22q11 deletion syndrome (CATCH 22): Neuropsychiatric and neuropsychological 
aspects. Developmental Medicine and Child Neurology, 44(1), 44-50.  
Pettersson, E., Anckarsäter, H., Gillberg, C., & Lichtenstein, P. (2013). Different 




Psychology and Psychiatry and Allied Disciplines, 54(12), 1356-1365. doi: 
10.1111/jcpp.12113 
Pham, A. V., & Riviere, A. (2015). Specific Learning Disorders and ADHD: Current 
Issues in Diagnosis Across Clinical and Educational Settings. Curr Psychiatry 
Rep, 17(6), 38. doi: 10.1007/s11920-015-0584-y 
Posthuma, D., & Polderman, T. J. C. (2013). What have we learned from recent twin 
studies about the etiology of neurodevelopmental disorders? Current Opinion in 
Neurology, 26(2), 111-121. doi: 10.1097/WCO.0b013e32835f19c3 
R Core Team. (2014). R: A language adn environment for statistical computing. Vienna, 
Austria: R Foundation Statistical Group. Retrieved from http://www.R-
project.org/ 
Robins, L. N., Wing, J., Wittchen, H. U., Helzer, J. E., Babor, T. F., Burke, J., . . . et al. 
(1988). The Composite International Diagnostic Interview. An epidemiologic 
Instrument suitable for use in conjunction with different diagnostic systems and in 
different cultures. Archives of General Psychiatry, 45(12), 1069-1077.  
Schieve, L. A., Gonzalez, V., Boulet, S. L., Visser, S. N., Rice, C. E., Van Naarden 
Braun, K., & Boyle, C. A. (2012). Concurrent medical conditions and health care 
use and needs among children with learning and behavioral developmental 
disabilities, National Health Interview Survey, 2006-2010. Research in 
Developmental Disabilities, 33(2), 467-476. doi: 10.1016/j.ridd.2011.10.008 
Taylor, M. A., Schreck, K. A., & Mulick, J. A. (2012). Sleep disruption as a correlate to 
cognitive and adaptive behavior problems in autism spectrum disorders. Research 
in Developmental Disabilities, 33(5), 1408-1417. doi: 10.1016/j.ridd.2012.03.013 
Theoharides, T. C. (2013). Is a subtype of autism an allergy of the brain? Clinical 
Therapeutics, 35(5), 584-591. doi: 10.1016/j.clinthera.2013.04.009 
Tsai, M. H., & Huang, Y. S. (2010). Attention-deficit/hyperactivity disorder and sleep 



















Autism Spectrum Disorder  
(N = 51) 
  
Learning Disorder Only 
(N = 879) 
 
None 
(N = 5,366) 
 % (SE) X2, p b   % (SE) X2, p b  % (SE) 
Gender   15.50, <0.001    29.45, <0.001   
     male 85.5 (5.0)    66.7 (3.1)   48.2 (1.3) 
     female 14.5 (5.0)    33.3 (3.1)   51.8 (1.3) 
Age (mean)  -0.34c, 0.74    1.01c, 0.32   
 15.1 (0.33)    15.3 (0.12)   15.2 (0.07) 
Race/Ethnicity  7.32, <0.001    0.41, 0.75   
     Hispanic 3.9 (2.0)          12.9 (1.9)   14.7 (1.5) 
     Black 26.6 (7.4)              16.0 (2.0)   14.4 (1.1) 
     Other 14.4 (2.7)           6.5 (2.7)   4.7 (0.7) 
     White 55.1 (8.1)    64.5 (4.2)   66.1 (1.9) 
Household Income d  1.45, 0.24    6.78, 0.001   
     PIR ≤ 1.5 30.2 (9.9)               19.6 (2.5)   13.2 (1.1) 
     1.5 < PIR ≤ 3 22.0 (8.9)    20.2 (2.7)   19.2 (0.8) 
     3 < PIR ≤ 6 29.7 (8.6)                 24.7 (2.5)   34.1 (1.2) 
     PIR > 6 18.1 (6.4)    35.6 (3.0)   33.6 (1.6) 
Parent Marital Status      1.23, 0.31    3.79, 0.02   
     Married/ cohabiting 45.6 (10.1)                      62.3 (2.3)   69.7 (1.4) 
     Previously married 19.4 (8.5)                 19.3 (2.1)   15.7 (0.7) 
     Never married 8.1 (4.6)    3.9 (1.0)   4.4 (0.6) 
     Unknown 26.8 (9.7)    14.6 (1.9)   10.3 (0.9) 
Parent Education  1.82, 0.16    1.73, 0.18   
     Less than high school 29.0 (10.4)            16.6 (2.2)   11.2 (0.9) 
     High school graduate 20.2 (8.1)            30.6 (2.8)   29.0 (1.2) 
     Some college 11.0 (4.3)              20.7 (2.1)   21.7 (1.0) 
     College graduate 39.8 (9.8)    32.2 (3.8)   38.1 (1.6) 
English spoken at home  0.22, 0.64    3.81, 0.06   
 85.5 (8.9)    86.1 (2.2)   81.3 (0.9) 
Geographic region  0.37, 0.78    1.61, 0.20   
     Northeast 25.9 (8.4)    17.0 (2.2)   18.4 (1.8) 
     Midwest 23.9 (8.5)           21.5 (2.4)   23.5 (2.1) 
     South 30.9 (7.5)           36.1 (3.9)   36.1 (2.6) 
     West 19.2 (9.0)    25.4 (2.4)   22.0 (2.0) 
Urban environment  1.95, 0.15    2.03, 0.14   
     Metropolitan 32.0 (8.9)    41.1 (3.7)   46.7 (2.4) 
     Rural 32.7 (9.4)    44.9 (3.9)   38.7 (3.2) 
     Other 35.4 (9.8)    14.0 (2.8)   14.5 (2.3) 
 
a 
Percentages are weighted to represent the general population of US adolescents  
b





































 All estimates are weighted to represent the general population of US adolescents 
 
b
 aOR = odds ratios calculated from weighed logistic regression models adjusted for gender, age, race/ethnicity and household income, 








(N = 51) 
Learning 
Disorder Only 
(N = 879) 
None 
(N = 5,366) 
 Autism Spectrum Disorder Learning Disorder Only 
 
% (SE) % (SE) % (SE) 






Allergy 58.98 (9.5) 32.8 (3.3) 31.1 (1.1)  
3.43            
(1.57, 7.48) 
0.004 
1.09        (0.78, 
1.51) 
0.63 



































Skin conditions (such as eczema, 
psoriasis) 
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awakening 

















a All estimates are weighted to represent the general population of US adolescents  
b
 aOR = odds ratios calculated from weighed logistic regression models adjusted for gender, age, race/ethnicity and household income, 
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a All estimates are weighted to represent the general population of US adolescents  
b
 aOR = odds ratios calculated from weighed logistic regression models adjusted for gender, age, race/ethnicity and household income, 
compared to the ASD- and LD-unaffected group. 
c
 CAM = complementary and alternative medicine









(N = 879) 
None 
(N = 5,366) 
 Autism Spectrum Disorder  Learning Disorder Only 
 
% (se) % (se) % (se) 






Medications    
 
    
   Any Medication 
29.55 (8.2) 15.9 (2.1) 5.2 (0.5)  
8.49  




   Anti-depressant 
11.85 (6.0) 6.1 (1.5) 3.1 (0.4)  
5.40  




   Anti-psychotic 
4.65 (2.6) 1.1 (0.6) 0.3 (0.1)  
14.15  




   Anxiolytic 
2.41 (1.7) 0.5 (0.3) 0.5 (0.1)  
9.48  




   Mood Stabilizer/Anticonvulsant 
7.25 (4.3) 0.8 (0.4) 0.1 (0.0)  
51.75  




   Stimulant 
15.81 (7.6) 10.1 (1.9) 1.8 (0.3)  
8.05  




   Miscellaneous medications 
13.41 (6.1) 1.3 (0.5) 0.3 (0.1)  
42.19  




Services         
  Mental Health Specialty 







  General Medical  







  CAM c 







  Juvenile Justice 







  School Service 
75.84 (4.9) 48.8 (2.3) 17.3 (0.9)  
14.35 





SDQ Difficulty Composite 












CHAPTER 3:  
POPULATION PREVALENCE AND ASSOCIATION OF EARLY-LIFE RISK 
  









Brooke Sheppard, ScM 
a,b
, Tarannum Lateef, MD 
b,c,d
, Jian-Ping He, MS 
b
, M. Daniele 
Fallin, PhD 
a





Johns Hopkins School of Public Health, Baltimore, MD; 
b 
National Institute 
of Mental Health, Bethesda, MD; 
c 
Pediatric Specialists of Virginia; 
d
 Childrens National 





























Objective: To assess overlap and specificity of pre-, peri-, and neonatal risk factors for 
ASD and LD in a nationally representative, population-based sample of US adolescents.   
Methods: The sample included adolescents aged 13-18 years who participated in the 
National Comorbidity Survey – Adolescent supplement (NCS-A) whose parents 
completed a questionnaire concerning their child’s lifetime health and development 
(N=6,295). ASD, LD and pre/perinatal risk factors were determined by parent report.  
Demographically adjusted odds ratios (aOR) were calculated for ASD (with or without 
LD) and LD (without ASD) compared to typically developing adolescents (no ASD or 
LD).  Estimates for neonatal complications were additionally adjusted for preterm birth. 
Results: Prenatal exposure to alcohol (ASD: aOR=2.43, p=0.017; LD: aOR=1.42, 
p=0.039), maternal urinary tract infections (UTI) (ASD: aOR=4.46, p=0.018; LD: 
aOR=1.67, p=0.036), slow heartbeat (ASD: aOR=6.27, p=0.028; LD: aOR=1.86, 
p=0.031), and respiratory distress (ASD: aOR=5.85, p=0.020; LD: aOR=2.28, p=0.003) 
at birth were associated with both ASD and LD. Persistent proteinuria was the only 
obstetric condition associated with any neurodevelopmental outcome (ASD: aOR=13.13, 
p=0.005). All neonatal complications ascertained in this sample were associated with 
ASD (convulsions: aOR=9.23, p=0.008, jaundice: aOR=3.21, p=0.028, requiring oxygen: 
aOR=2.64, p=0.048, blood transfusion: aOR=7.04, p=0.018), but not LD.   
Conclusion: ASD and LD appear to share many pre- and perinatal risk factors; however, 
certain neonatal complications and persistent proteinuria were specifically associated 
with ASD.  Insults during the pre/perinatal period may adversely affect 




maternal persistent proteinuria during pregnancy and neonatal complications are 
specifically associated with ASD. 
 
INTRODUCTION 
Autism spectrum disorder (ASD) is a neurodevelopmental disorder (NDD) characterized 
by social and communication deficits as well as restrictive and repetitive interests and 
behaviors (American Psychiatric Association, 2013). ASD symptoms appear very early in 
life, typically before 24 months of age, and the diagnosis currently affects up to 1 in 68 
children nation-wide (CDC, 2014).   It has been shown that over 70% of children with 
ASD go on to develop a learning disorder (LD) (Schieve et al., 2012), a childhood-onset 
NDD characterized by persistent difficulty in learning academic skills, such as reading, 
writing, and mathematical reasoning, affecting anywhere from 5-10% of school-age 
children (Altarac & Saroha, 2007). Both ASD and LD result in varying degrees of 
lifelong impairment in social, occupational, and daily functioning (American Psychiatric 
Association, 2013). The causes of these highly comorbid disorders remain unknown, but 
it has been proposed that the joint influence of genetic and environmental factors may 
enhance the risk of a range of neurodevelopmental conditions, including ASD.(Hallmayer 
et al., 2011; Stoltenberg et al., 2010; Tordjman et al., 2014) While progress has been 
made in identifying independent and additive effects of genetic loci associated with ASD 
(Gaugler et al., 2014), there is substantial evidence for the etiologic role of environmental 
risk factors as well.  Pre- and perinatal exposures are of particular interest because of the 
growing evidence for their role in several neuropsychiatric conditions, particularly 




Evidence for a range of pre- and perinatal risk factors for ASD and related 
conditions (Ornoy, Weinstein-Fudim, & Ergaz, 2015; Schieve et al., 2014) as well as 
general neurodevelopmental problems(Tamaru et al., 2011) from community samples 
indicate that the period of environmental risk begins in utero for these early-onset 
conditions.  To date, implicated risk factors include health and lifestyle factors during 
pregnancy (Croen, Grether, Yoshida, Odouli, & Hendrick, 2011; El Marroun, White, van 
der Knaap, et al., 2014; Krakowiak et al., 2012; Polo-Kantola et al., 2014; Visser et al., 
2013; Zerbo, Iosif, et al., 2013; Zerbo, Qian, et al., 2013), obstetric and labor 
complications (Mamidala et al., 2013; Polo-Kantola et al., 2014; Schieve et al., 2014), 
perinatal birth outcomes (Lampi et al., 2012; Schieve et al., 2010; Schieve, Clayton, 
Durkin, Wingate, & Drews-Botsch, 2015; Schieve et al., 2014), and neonatal 
complications (Froehlich-Santino et al., 2014; Mamidala et al., 2013).  However, findings 
are often inconsistent across studies for a given risk factor (Atladottir, Henriksen, 
Schendel, & Parner, 2012; Clements et al., 2014; El Marroun, White, Verhulst, & 
Tiemeier, 2014; El Marroun, White, van der Knaap, et al., 2014; Lee et al., 2012; Lyall, 
Schmidt, & Hertz-Picciotto, 2014).  Moreover, many of these studies have focused on a 
single risk factor, or one particular window of exposure.  
Given the high co-occurrence of ASD with other NDDs, previous studies have 
investigated the potential for shared or specific risk factors, but much of this work has 
focused on the potential link between ASD and intellectual disability (ID) (Langridge et 
al., 2013; Schieve et al., 2015). A recent study evaluating perinatal risk factors for ASD 
and ID found that many risk factors, such as preterm birth and low birth weight, were 




only, while associations were of similar strength for ASD groups, regardless of the 
presence of co-occurring ID (Schieve et al., 2015).  However, little is known about 
specificity of prenatal ASD risk factors in the context of broader NDD phenotypes, 
particularly LD.  
Here, we aim to investigate the specificity and commonality of prenatal, perinatal, 
and neonatal risk factors for ASD and LD using a nationally representative sample of 
adolescents age 13-18 the National Comorbidity Survey Adolescents Supplement (NCS-
A) across a comprehensive range of exposures categories, including maternal 
characteristics during preconception/pregnancy, obstetric complications during 
pregnancy, birth outcomes, and neonatal complications.  We report prevalence of parent-
reported risk factors among adolescents with ASD (with or without co-occurring LD) and 
LD (without co-occurring ASD).  Additionally, we assess demographically adjusted odds 




The National Comorbidity Survey Adolescent Supplement (NCS-A) is a nationally 
representative household survey of adolescent mental health in the Unites States. 
Recruitment methods, sampling and weighting strategies have been described in detail 
elsewhere (Kessler et al., 2009). Adolescents aged 13-17 years were recruited via either 
household or school-based sampling schemes.  Professional interviewers at the Survey 
Research Center at the Institute for Social Research at the University of Michigan 




between February 2001 and January 2004.  While adolescents were being interviewed, 
one parent/guardian was asked to complete a self-administered questionnaire, the Parent 
Self-Administered Questionnaire (PSAQ), consisting of questions pertaining to the 
adolescent’s medical and developmental history as well as parent and household 
characteristics.  Informed assent and consent was obtained from each participating 
adolescent and his/her parent/guardian.  Human Subjects Committees at the Harvard 




Autism spectrum disorder (ASD) and learning disorder (LD) were the primary outcomes 
of interest for this analysis.  Presence of ASD and LD were evaluated by parent response 
to a single yes/no question on in the PSAQ for each condition: “Has [the adolescent] ever 
had […] developmental disorders (such as autism, Asperger’s, or pervasive 
developmental disorder)?” and “Has [the adolescent] ever had […] learning disability?” 
 
Early-Life Risk Factors  
Pre- and perinatal exposures were assessed by parent response to the Birth and Early 
Development section of the PSAQ.  The respondent answered questions regarding the 
biological mother and father’s age at conception, maternal lifestyle behaviors and 
obstetric complications during pregnancy, birth weight, gestational age, and other birth 
and neonatal outcomes.   Advanced maternal and paternal age was defined as ≥ 35 years 




weight was defined as <2500g.  Prenatal smoking, alcohol, non-prescription drugs, and 
caffeine exposure were defined by a response of anything greater than “never” on a 5-
point frequency scale.  Maternal infections (rubella, urinary tract infection (UTI)), 
accident/injury, and obstetric complications (“gestational diabetes”, “hypertension”, 
“persistent proteinuria”, “toxemia” (preeclampsia), “severe nausea and vomiting”, 
“severe anemia”, and “placenta problems”) were defined as a positive response to the 
question: “During her pregnancy with this adolescent, did his/her mother have any of the 
following conditions?”  neonatal complications (“blue at birth” (cyanosis), “slow 
heartbeat”, “did not breathe at first” (respiratory distress), “convulsions”, “jaundice”, 
“required oxygen”, “blood transfusion”) were defined as a positive response to the 
question: “Did he/she have any of the following problems at birth?” 
 
Statistical Analysis 
 Analyses were completed in R version 3.1.1(R Core Team, 2014) using the R 
“Survey” package.(Lumley, 2014)  All reported prevalence estimates and odds ratios 
were weighted to represent the demographic characteristics of US population of 
adolescents attending school at the time of recruitment.  Methods used to develop 
appropriates weights are described elsewhere.(Kessler et al., 2009)  Survey-weighted 
multivariate logistic regression was used to compute odds ratios for ASD (with or 
without LD) and LD (without ASD) risk compared to a reference group of adolescents 
without ASD or LD.  All odds ratios were adjusted for potential socio-demographic 
confounders including adolescent sex, age, and race/ethnicity, and house hold income. 




further adjusted for preterm birth.  Additional sensitivity analyses were completed to 
explore within-ASD risk heterogeneity.  For risk factors that were significantly associated 
with the ASD, the ASD group was partitioned into ASD with LD (ASD + LD) and ASD 
without LD (ASD – LD) and each compared to a non-ASD/non-LD reference group.   
 
RESULTS 
Table 3.1 reports demographic characteristics of the weighted sample by ASD (n = 51) 
and LD (n = 879) status, with statistical comparisons made to the unaffected (non-NDD) 
group (n = 5366).   Both NDD-affected groups were predominantly male compared to the 
non-NDD group: ASD: 85.5% v. 48.2%, X
2
1 = 15.50, p < 0.001; LD-only: 66.7% v. 
48.2%, X
2
1 = 29.45, p < 0.001.  The ASD group also differed significantly from the non-
NDD group on distribution of race/ethnicity (X
2
3=7.32, p < 0.001).  The LD-only group 
differed significantly from the non-NDD group in terms of lower household income 
(X
2
3=6.78, p=0.001) and non-intact parental marital status (X
2
3=3.79, p=0.02). The NDD 
subgroups did not differ from the non-NDD group in mean adolescent age, parent 
educational status, English spoken in the home, geographic region, or urban environment.  
Additional comparisons of number of siblings and birth order revealed no differences 
between any NDD group and the non-NDD group. Sex, age, household income, and 
parent education were included as covariates in subsequent analyses. 
Maternal characteristics during pregnancy as well as advanced paternal age at 
conception are reported in Table 3.2.  Advanced maternal age (≥ 35 years) was associated 
with increased odds for LD (aOR = 1.67, p = 0.027), but not ASD.  Alcohol consumption 




(UTI) (ASD: aOR = 4.46, p = 0.018; LD: aOR = 1.67, p = 0.036) during pregnancy were 
associated with both ASD and LD.  Rubella infection (aOR = 123.57, p<0.001) and 
injury (aOR = 8.01, p = 0.012) during pregnancy were associated with increased ASD 
risk, but not with LD risk.   
Table 3.3 presents prevalence and adjusted odds ratios related to obstetric 
complications.  Persistent proteinuria (aOR = 13.13, p = 0.005) was significantly 
associated with increased ASD risk, but not LD, while severe nausea and vomiting was 
associated with increased risk for LD (aOR = 1.68, p = 0.009), but not ASD.  All other 
pregnancy-related health problems were not associated with ASD or LD. 
Preterm birth was associated with more than 3-fold risk for ASD (aOR = 3.57, p = 
0.018) and more than 2-fold (aOR = 2.33, p = 0.001) risk for LD.  Low birth weight (< 
2500g) was associated with LD (aOR = 2.52, p = 0.004), but not ASD, however this 
association was attenuated after controlling for preterm birth. Table 3.4 presents 
prevalence and adjusted odds ratios related to birth outcomes of the child, additionally 
adjusted for preterm birth.  Slow heartbeat (ASD: aOR = 6.27, p = 0.28; LD: aOR = 1.86, 
p = 0.31) and respiratory distress (ASD: aOR = 5.85, p = 0.020; LD: aOR = 2.28, p = 
0.003) were associated with both ASD and LD, while cyanosis at birth (aOR = 1.90, p = 
0.021) was specifically associated with a nearly 2-fold increase in odds for LD.    
Prevalence and adjusted odds ratios related to neonatal complications are 
presented in Table 3.5. Initially, after controlling for demographics only, blood 
transfusion and requiring oxygen was associated with both ASD and LD, while 
convulsions and jaundice were specifically associated with ASD. However, after 




(aOR = 9.23, p = 0.008), jaundice (aOR = 3.12, p = 0.028), requirement of oxygen (aOR 
= 2.64, p = 0.048), and blood transfusion (aOR = 7.04, p = 0.018) – remained 
significantly associated with ASD, but none remained for LD (Table 3.5). 
Risk factors significantly associated with ASD were assessed for heterogeneity, 
separately comparing ASD with and without concurrent LD to the non-NDD group.  
Prenatal alcohol exposure (aOR = 6.11, p = 0.002) and persistent proteinuria (aOR = 
28.67, p = 0.004) were specifically associated with ASD without LD, but not ASD with 
LD.  Injury during pregnancy (aOR = 12.89, p = 0.004), preterm birth (aOR = 5.43, p = 
0.006), slow heartbeat (aOR = 10.37, p = 0.008), delayed respiration (aOR = 9.92, p = 
0.005), convulsions (aOR = 13.39, p = 0.003), jaundice (aOR = 3.82, p = 0.027), oxygen 
requirement (aOR = 4.05, p = 0.023), and blood transfusion (aOR = 9.50, p = 0.011) 
remained positively associated with ASD with LD, but not ASD without LD.   
 
DISCUSSION 
We used retrospective parent-reported pre- and perinatal data from a nationally 
representative sample of adolescents to identify potential sources of heterogeneity of 
early-life risk factors for NDDs.  Exposure windows spanning pre-conception through the 
neonatal period were assessed.  We found that many of these risk factors were shared 
across NDDs (ASD and LD), but generally showing larger effect sizes in the more severe 
ASD group.  However, persistent proteinuria during pregnancy and neonatal 
complications were associated with ASD, and not LD.  Conversely, advanced maternal 
age, severe nausea and vomiting during pregnancy, and, after controlling for preterm 




ASD specific risk factors   
Rubella infection, accident/injury, and persistent proteinuria during pregnancy were 
exposures among the prenatal exposure window specifically associated with ASD.  
Maternal rubella infection has been linked to ASD previously(Ornoy et al., 2015), 
however due to the very low prevalence of rubella exposure in this sample, the very large 
effect size should be interpreted with caution.  Persistent proteinuria was the only 
obstetric factor related to ASD.  A meta-analysis also suggests that other obstetric health 
concerns such as maternal hypertension, pre-eclampsia, edema, etc. are not associated 
with ASD; however, they also found no evidence for an association between proteinuria 
and ASD, although the authors caution largely inconsistent results from individual studies 
(Gardener, Spiegelman, & Buka, 2009). However, more recently, maternal edema has 
been linked to ASD (Zhang et al., 2010) and social and repetitive behavior domains as 
measured by the ADI-R (Wallace, Anderson, & Dubrow, 2008).  Persistent proteinuria, 
another symptom of pre-eclampsia, has been shown to significantly affect placental 
perfusion, decreased when occurring early in pregnancy and increased perfusion in late 
pregnancy.(Sohlberg et al., 2014) Thus, depending on timing, the link between 
proteinuria and ASD may be a consequence of decreased cerebral blood flow in the fetus.   
It should be noted that we were unable to assessing timing of proteinuria onset.  After 
controlling for preterm birth, requirement of oxygen and blood transfusion remained 
associated with ASD, but not LD.  While it is intriguing that every neonatal complication 
evaluated in this study showed specificity to ASD, it is important to note that these 
neonatal complications could be a result of larger underlying health problems associated 




Nonetheless, identification of ASD-specific-risk factors, whether causes or mediators, 
may elucidate etiologic pathways related to ASD-specific symptoms or traits.  
LD specific risk factors 
Mothers of advanced maternal age (≥ 35 years) at birth had nearly 70% higher odds of 
reporting LD of their adolescent, and no increase in odds of ASD when compared to the 
ASD- and LD-unaffected group.  Interestingly, advanced maternal age is often reported 
as a risk factor for ASD (Gardener et al., 2009; Guinchat et al., 2012; Mamidala et al., 
2013), but our study did not confirm this association.  However, others have found an 
association with advanced maternal age only with ASD cases on the milder end of the 
autism spectrum, including Asperger syndrome and pervasive developmental disorder 
NOS (Lampi et al., 2013), and we did not have the ability to split our ASD group by 
severity. Severe nausea and vomiting was the only obstetric factor that was specifically 
associated with LD.  While nausea and vomiting during pregnancy is a common 
occurrence, the absence of nausea and vomiting during the first trimester has been linked 
to hypothyroidism (Forbes, 2014) during pregnancy and has also been linked ASD in the 
child (Brown, Jones, MacKewn, & Plank, 2008). This specific association to LD (and not 
ASD) could indicate a specific association between the lack of pregnancy sickness and 
ASD.  However, our questionnaire specifically asked about “severe” nausea and 
vomiting, which is highly subjective to participant interpretation.  While low birth weight 
initially showed a significant association with LD, cyanosis was the only birth outcome 
that showed LD-specific associations after controlling for preterm birth.  Low Apgar 
scores (Andrews, Goldberg, Wellen, Pittman, & Struening, 1995) and a combination of 




Syrenicz, 1998).  Further work should explore whether these LD-specific associations 
may indicate a separate etiology for the milder LD phenotype  
Non-specific risk factors   
Alcohol consumption and UTI during pregnancy were associated with both ASD and LD.  
A recent review of the relationship between prenatal toxicant exposure and ASD 
postulates that maternal infection and exposure to toxicants, such as alcohol, causes a 
maternal inflammatory response leading to micronutrient deficiency, thereby disrupting 
fetal brain development (Nuttall, 2015). We did not assess extent of alcohol consumption 
or severity of UTI infection, but both appear to be non-specific insults with potential 
varying degrees of exposure intensity, possibly affecting a continuum of 
neurodevelopmental outcomes by extent of exposure.  Preterm birth was also associated 
with NDDs broadly. After controlling for preterm birth, slow heartbeat, and respiratory 
distress were also broadly associated with both ASD and LD.  These results support 
previous work linking preterm birth (Guinchat et al., 2012; Lampi et al., 2012; Meldrum 
et al., 2013) and low Apgar scores several NDDs, including ASD (Froehlich-Santino et 
al., 2014; Guinchat et al., 2012; Mamidala et al., 2013; Schieve et al., 2015). An 
assessment of perinatal risk factors associated with ASD and ID recently reported a 
stronger association between preterm birth and the more severe ID phenotype in 
comparison to the weaker, but still significant ASD association (Schieve et al., 2015). 
The current findings are in line with this concept, where we see stronger association 
between preterm birth and ASD compared to the lower, yet still significant, LD effect 






While over 6,000 adolescents were included in the current study, the low prevalence of 
ASD resulted in a small ASD-affected NDD subgroup, thereby widening confidence 
intervals associated with those estimates.  However, this results from the nature of using 
nationally representative survey data, and we believe the benefit of a population-based 
sample free of clinical ascertainment bias adds substantial value to literature in the field, 
even with methodological limitations.  Furthermore, prevalence estimates of both ASD 
and LD obtained from the current study are similar to what is expected for the 
participants’ age at the time of recruitment (Altarac & Saroha, 2007; CDC, 2007).  
Because parents were asked to report on pre/perinatal exposures and events of their 
adolescent children, results may be affected by recall bias, where parents of children with 
ASD are may be more likely to remember or over-endorse prenatal and neonatal 
complications.  However, several findings in this study reflect what has been found in 
previous ASD and LD literature, lending some validation to our exposure measures.  
Strengths 
First, we use a nationally representative sample where we do not expect a 
disproportionate amount of severe cases that could result from clinical ascertainment.  
Second, we are able to report comparison with an LD-only affected group to identify 
specificity of ASD-related risk factors from a less sever NDD phenotype.  Previous work 
has focused on differentiating ASD risk factors from those of ID, a more severe NDD 
phenotype.  Third, we assess a wide range of early-life risk factors spanning the entire 
prenatal through neonatal period, which allowed us to assess potential differences in 






This work has both etiologic and clinical relevance.  ASD-specific risk factors 
may be etiologically related in ASD-specific traits, while shared risk factors may be 
etiologically linked to general perturbations in neurodevelopment. We found that insults 
during the pre/perinatal period may adversely affect neurodevelopment broadly.  Future 
research should investigate mechanisms by which prenatal persistent proteinuria and 
neonatal complications are specifically associated with ASD.  Additionally, identified 
early-life risk factors could be analyzed in combination with genetic data to aid in 
completing full picture of NDD etiology.  Given the high comorbidity among NDDs, 
future research should further investigate specificity and overlap concerning not only 
diagnostic criteria, but also individual symptom/trait-related phenomenology of NDDs.  
Clinically, obstetric complications such as proteinuria, birth outcomes, and neonatal 
complications may warrant timely developmental surveillance which could lead to earlier 
intervention, and therefore, better prognosis.   Further work should be done to understand 
where these risk factors lie on the causal pathway.  Perhaps most importantly, some of 
these pre/perinatal exposures are malleable risk factors that could potentially aid in 
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Table 3.1. Demographic characteristics of NCS-A adolescents age 13-18 years by ASD 





Autism Spectrum Disorder  
(N = 51) 
 Learning Disorder Only 
(N = 879) 
 None 
(N = 5,366) 
 % (SE) X2, p  % (SE) X2, p  % (SE) 
Gender   15.50, <0.001   29.45, 
<0.001 
  
     male 85.5 (5.0)   66.7 (3.1)   48.2 (1.3) 
     female 14.5 (5.0)   33.3 (3.1)   51.8 (1.3) 
Age (mean)  -0.34b, 0.74   1.01b, 0.32   
 15.1 (0.33)   15.3 (0.12)   15.2 (0.07) 
Race/Ethnicity  7.32, <0.001   0.41, 0.75   
     Hispanic 3.9 (2.0)         12.9 (1.9)   14.7 (1.5) 
     Black 26.6 (7.4)             16.0 (2.0)   14.4 (1.1) 
     Other 14.4 (2.7)          6.5 (2.7)   4.7 (0.7) 
     White 55.1 (8.1)   64.5 (4.2)   66.1 (1.9) 
Household Income c  1.45, 0.24   6.78, 0.001   
     PIR ≤ 1.5 30.2 (9.9)              19.6 (2.5)   13.2 (1.1) 
     1.5 < PIR ≤ 3 22.0 (8.9)   20.2 (2.7)   19.2 (0.8) 
     3 < PIR ≤ 6 29.7 (8.6)                24.7 (2.5)   34.1 (1.2) 
     PIR > 6 18.1 (6.4)   35.6 (3.0)   33.6 (1.6) 
Parent Marital Status      1.23, 0.31   3.79, 0.02   
     Married/ cohabiting 45.6 (10.1)                    62.3 (2.3)   69.7 (1.4) 
     Previously married 19.4 (8.5)                19.3 (2.1)   15.7 (0.7) 
     Never married 8.1 (4.6)   3.9 (1.0)   4.4 (0.6) 
     Unknown 26.8 (9.7)   14.6 (1.9)   10.3 (0.9) 
Parent Education  1.82, 0.16   1.73, 0.18   
     Less than high school 29.0 (10.4)           16.6 (2.2)   11.2 (0.9) 
     High school graduate 20.2 (8.1)           30.6 (2.8)   29.0 (1.2) 
     Some college 11.0 (4.3)             20.7 (2.1)   21.7 (1.0) 
     College graduate 39.8 (9.8)   32.2 (3.8)   38.1 (1.6) 
English spoken at home  0.22, 0.64   3.81, 0.06   
 85.5 (8.9)   86.1 (2.2)   81.3 (0.9) 
Geographic region  0.37, 0.78   1.61, 0.20   
     Northeast 25.9 (8.4)   17.0 (2.2)   18.4 (1.8) 
     Midwest 23.9 (8.5)          21.5 (2.4)   23.5 (2.1) 
     South 30.9 (7.5)          36.1 (3.9)   36.1 (2.6) 
     West 19.2 (9.0)   25.4 (2.4)   22.0 (2.0) 
Urban environment  1.95, 0.15   2.03, 0.14   
     Metropolitan 32.0 (8.9)   41.1 (3.7)   46.7 (2.4) 
     Rural 32.7 (9.4)   44.9 (3.9)   38.7 (3.2) 
     Other 35.4 (9.8)   14.0 (2.8)   14.5 (2.3) 
 
a 
Percentages are weighted to the general population of US adolescents based on 51 











Table 3.2. Prevalence of reported maternal characteristics during pregnancy and associated odds of reporting ASD and LD in the 
adolescent a 









(N = 879) 
None 
(N = 5,366) 
Autism Spectrum Disorder Learning Disorder Only 
 
















Advanced paternal age 
(≥40) 






















Non-prescription drug 11.6 (7.2) 5.9 (1.1) 3.9 (0.6) 
2.88 



































Percentages and odds ratios are weighted to the general population of US adolescents based on 51 adolescents with parent-reported 
ASD, 879 with LD, and 5,366 without ASD or LD 
b












(N = 51) 
Learning 
Disorder Only 
(N = 879) 
None 
(N = 5,366) 
Autism Spectrum Disorder Learning Disorder Only 
 



































Severe nausea and 
vomiting 

















Percentages and odds ratios are weighted to the general population of US adolescents based on 51 adolescents with parent-reported 
ASD, 879 with LD, and 5,366 without ASD or LD 
b
























Autism Spectrum Disorder Learning Disorder Only 
 







Low birth weight 
 (< 2500g) 







Pre-term birth  
(<37 weeks) c 





































Percentages and odds ratios are weighted to the general population of US adolescents based on 51 adolescents with parent-reported 
ASD, 879 with LD, and 5,366 without ASD or LD 
b
 aOR= adjusted odds ratio; all aORs are adjusted for sex, age, race/ethnicity, household income, and preterm birth 





















(N = 879) 
None 
(N = 5,366) 
Autism Spectrum Disorder Learning Disorder Only 
 





































Percentages and odds ratios are weighted to the general population of US adolescents based on 51 adolescents with parent-reported 
ASD, 879 with LD, and 5,366 without ASD or LD 
b











GENETIC DETERMINANTS OF COGNITIVE DEVELOPMENTAL TRAJECTORIES 























Background: Autism spectrum disorder (ASD) is a heritable, heterogeneous 
neurodevelopmental disorder affecting social communication and motor stereotypies.  
Younger siblings of individuals with ASD are at elevated risk for developing ASD and 
related traits, compared to the general population, and have been an important group for 
examining early signs and symptoms of ASD. Early developmental trajectories of 
communication, social, and motor abilities are a source of phenotypic heterogeneity in 
ASD and may serve as a useful phenotype for genetic analyses. 
Objective:  The aim of this study is to identify common ASD-related genetic variants 
associated with differential trajectories of cognitive and motor development among infant 
high-risk ASD infant siblings. 
Methods: Infant siblings of ASD-affected children were enrolled during pregnancy in the 
Early Longitudinal Autism Investigation (n=231) and just after birth in the Infant Brain 
Imaging Study (n=382).  Latent subgroups of cognitive and motor development were 
estimated based on longitudinal Mullen Scales of Early Learning (MSEL) (at 6, 12, 24, 
and 36 months of age)  using latent class growth analysis (LCGA). A 3-step latent class 
regression method was used to test for association of ASD polygenic risk score (PRS) at 






) and association with each of 
4,257 SNPs within 47 ASD candidate genes among EARLI high-risk siblings for whom 
genotype data were available (n=198).   
Results: Using EARLI and IBIS longitudinal data, three latent classes were identified 









(standardized: OR= 1.66, p = 0.083) when compared to the “normative” class and was 
significantly associated with ASD diagnosis (standardized: OR=1.64, p=0.032, quartiled: 
OR=7.72, p=0.013).  No candidate SNPs reached Bonferroni significance (1.2x10
-5
), but 
chr3:2928197 in CNTN4 and rs10265509 in CNTNAP2 on chromosome 7 reached 
suggestive significance (p < 1x10
-3
) comparing the “intermediate” to the “normative” 
class.   
Conclusion:  Latent class structure was consistent with previous literature. Liberal PRS 
of common genetic variation associated with ASD was marginally associated with 
declining cognitive trajectory and was significantly associated with ASD diagnosis at 36 
months. The candidate genes most strongly associated with class memberships share 
roles in modulating neuronal cell interactions and are associated with a broad range of 
















Autism spectrum disorder (ASD) is a neurodevelopmental disorder defined by 
social and communication deficits as well as restrictive and repetitive interests and 
behaviors (American Psychiatric Association, 2013).  Heritability studies suggest that a 
substantial portion  of phenotypic variance in ASD may be due to genetic factors (Colvert 
et al., 2015; Hallmayer et al., 2011; Sandin et al., 2014), with nearly 50% of this genetic 
risk due to common genetic variation (Gaugler et al., 2014; Klei et al., 2012).  However, 
genome-wide association studies (GWAS) designed to target common polymorphisms 
have identified only a few genome-wide significant risk alleles, most of which fail to 
replicate (Anney et al., 2012; Anney et al., 2010; Curran et al., 2011; Liu & Takumi, 
2014; K. Wang et al., 2009; Weiss, Arking, Daly, & Chakravarti, 2009).  This lack of 
identified common variants could be due to a lack of sufficient statistical power, and thus 
large mega-analyses of GWAS studies are underway ("Psychiatric Genomics 
Consortium,"). However, it could also be that diagnostic phenotypes are not best suited 
for etiologic discovery due to phenotypic heterogeneity within diagnostic boundaries and 
associated traits that cross diagnostic boundaries. Such, muddled phenotypes present a 
challenge in detecting potential genetic associations, particularly in common variant 
studies where effect sizes are likely to be small.   
ASD symptom onset occurs in infancy and progresses through toddlerhood 
(Jones, Gliga, Bedford, Charman, & Johnson, 2014; Ozonoff et al., 2010; Rozga et al., 
2011).  But, symptom onset and course differ across cases, and are major sources of 
phenotypic heterogeneity in ASD.  These differential trajectories begin before diagnosis 




Winter, & Bearman, 2012; Szatmari et al., 2015).  Longitudinal studies assessing 
cognitive and motor deficits have found heterogeneous trajectories of cognitive and 
motor abilities among infants and toddlers at high risk for developing ASD (Estes et al., 
2015; Landa, Gross, Stuart, & Bauman, 2012).  Understanding specific developmental 
pathways associated with ASD may inform our understanding of underlying mechanisms 
involved in ASD etiology.     
Moreover, examining data across a continuous spectrum of ASD-related traits, 
such as cognitive and motor ability, may provide insight for genetic studies of ASD, and 
neurodevelopment generally.  While attempts at splitting an ASD sample by IQ, ASD 
severity, and ASD symptom profiles to account for genetic heterogeneity have not 
yielded better results than using the full ASD sample in simplex family cases(Chaste et 
al., 2014), there is evidence that examining traits across ASD and other disorders may be 
fruitful. ASD genetic risk variants may influence developmental traits on a continuum 
and affect many neurodevelopmental disorders beyond ASD (Coe, Girirajan, & Eichler, 
2012; Lichtenstein, Carlstrom, Rastam, Gillberg, & Anckarsater, 2010), as well as affect 
these traits in neuro-typical individuals (Robinson et al., 2016).  
Younger siblings of children with ASD are nearly 20 times more likely to develop 
ASD compared to the general population (Ozonoff et al., 2011). Therefore, prospective 
cohort studies of infant siblings at high risk for developing ASD allow direct observation 
of patterns of early development from infancy, before a diagnosis is made.  Here, we use 
two high-risk infant studies, the Early Autism Risk Longitudinal Investigation (EARLI) 
and the Infant Brain Imaging Study (IBIS) to characterize very early cognitive and motor 




with differential trajectories.  First, we identify latent subgroups of cognitive and motor 
development as measured longitudinally from six to 36 months of age by the Mullen 
Scales of Early Learning (MSEL) using latent class growth analysis (LCGA). Second, we 
assess association of an ASD polygenic risk score (PRS) with trajectory class.  Third, we 
test for association with specific common variants in ASD candidate genes with 




The EARLI-IBIS combined cohort is a collaborative effort between the Early 
Autism Risk Longitudinal Investigation (EARLI) and the Infant Brain Imaging Study 
(IBIS) designed to study genetic predictors of ASD and ASD-related phenotypes among 
high risk infant siblings of children with ASD.  Recruitment and data collection methods 
are described in detail elsewhere for EARLI (Newschaffer et al., 2012) and IBIS (Estes et 
al., 2015; Hazlett et al., 2012).  EARLI (n=231) and IBIS (n=382) high risk siblings with 
available MSEL data for at least one of 6, 12, 24, or 36 month visits were included in the 
latent class growth analysis (LCGA). EARLI high-risk siblings from the LCGA who had 
available genotype data were included in the genetic association analyses (n=198).   
Latent Trajectory Model and Latent Class Regression Method 
The MSEL (Mullen, 1995) is a clinician-administered standardized (m=50, 
sd=10) assessment which measures five domains of early cognitive (expressive language, 
receptive language, and visual reception) and motor (fine motor and gross motor) 




6, 12, 24, and 36 months of age.  The gross motor scale is not applicable at 36 months.  
Domain scores for each applicable visit were modeled simultaneously in a parallel-
process latent class growth analysis (PP-LCGA) model to obtain latent classes of 
cognitive development trajectory.  A quadratic term was added to the model based on 
lower BIC statistic yielded from a quadratic 1-class model compared to a linear 1-class 
model.   Next, a series of 1- through 5-class PP-LCGA models were estimated with 
variance of intercepts, slopes, and quadratic terms constrained to zero, assuming 
homogeneity of individual growth trajectories within each class.  After considering 
information criteria statistics and theoretical plausibility, a final model was used as the 
dependent variable in latent class regression analyses with various genetic markers as 
independent variables.   
Genotype quality control and imputation 
Genotype quality control procedures were implemented using PLINK version 1.9 
(Chang et al., 2015; Purcell & Chang). DNA samples from EARLI participants were 
genotyped along with 18 HapMap control samples on the Human Omni5 plus Exome 
genotyping array (Illumina, San Diego, CA) at the Center for Inherited Disease Research 
at Johns Hopkins University, generating data on 4,641,218 SNPs. The concordance rate 
between duplicated HapMap samples and five EARLI blind technical duplicates was 
99.72% and 99.9%, respectively.  Samples were filtered out from analysis if missing data 
at >3% of markers, excess heterozygosity/homozygosity (>4 SD).  Markers were 
removed from further analysis if the genotyping facility reported technical problems 
(n=94,712), missing genomic location information (n=8,124), missing rate ≥ 5% for high 




MAF (< 5%) SNPs (n=65,855). SNPs out of Hardy-Weinberg equilibrium (p< 1 x 10
-7
) 
were flagged (n=2,170). Principal components of genetic ancestry were computed using 
the PLINK --pca function in combination with 1000 Genomes Project (1000GP) (Siva, 
2008) samples.  EARLI measured genotype data was phased using Shape-IT (Delaneau, 
Coulonges, & Zagury, 2008) and imputed to the 1000GP data using minimac3 
(Fuchsberger, Abecasis, & Hinds, 2015; Howie, Fuchsberger, Stephens, Marchini, & 
Abecasis, 2012).  SNPs with MAF > 1% were retained, leaving a total of 9,377,008 SNPs 
for analysis.  
ASD polygenic risk score 
ASD polygenic risk scores (PRS) were calculated using results from the 
Psychiatric Genomics Consortium (PGC) mega-analysis (n = 10,610) ("Psychiatric 
Genomics Consortium,").  Score were created using all SNPs achieving specific PGC p-
value thresholds: 1 x 10
-3
, 1 x 10
-4
, 1 x 10
-5
.  Of the 11,660, 1,096, and 135 PGC SNPs 
passing these thresholds respectively, 10,859; 1,027; and 127 were available in the 
EARLI measured and imputed SNP set. These SNPs were further pruned for 
independence (r
2 
< 0.5) within a sliding 500kb window, to leave 6605; 504; and 20 SNPs, 
respectively. Dosages from these remaining independent SNPs were weighted by their 
respective PGC log odds ratios and summed to calculate three PRS values for each 
sample. 
ASD candidate gene selection 
Given that this sample is too small for genetic discovery, we examined a list of 
known ASD candidate genes to identify which may be related to early life trajectories. 




candidate” genes from the Simons Foundation Autism Research Initiative (SFARI) online 
database (accessed June 24, 2016) (Basu, Kollu, & Banerjee-Basu, 2009).  A total of 
64,277 SNPs in our data overlapped with 50 candidate genes.  To reduce computational 
burden, these SNPs were pruned at r
2 
> 0.5 within a 500kb sliding window, yielding 
12,429 SNPs in 48 candidate genes.  Further filtering at MAF > 5% among EARLI high-
risk siblings, yielded 4,257 SNPs in 47 candidate genes to be used in association analyses 
described below.           
Genetic association analyses 
Association between each PRS and ASD status was tested by logistic regression, 
adjusting for sex and ancestral principal components 1 through 5.  Standardized PRS 
odds ratios represent risk of ASD or latent class membership per 1 standard deviation 
increase in PRS.  Quartiled PRS odds ratios represent risk of ASD or class membership 
for those in the top quartile of PRS scores compared to the bottom quartile. 
A 3-step latent class regression approach was used in order to preserve the class 
structure across all PRS and SNP comparisons while  still obtaining appropriate estimates 
and standard errors accounting for uncertainty in class assignment (Asparouhov & 
Muthén, 2013).   We performed multinomial regression models that were adjusted for 
gender and the first 5 principal components of genetic ancestry to reduce potential for 
confounding by population stratification.  For the PRS analyses, each PRS was 
standardized and change in log odds of class membership was calculated based on 1 
standard deviation increase in PRS.  For the candidate gene SNP analyses, an additive 
model was tested, with the minor allele as the risk allele. A Bonferroni significance 
threshold was set at p < 1.2x10
-5 




Suggestive significance was defined as p < 1x10
-3
.   For the two genes with the strongest 
associations to latent class membership,  we repeated the latent class regression approach 
for all SNPs from the EARLI measured or imputed set within those genes  and graphed 
the results using LocusZoom software (Pruim et al., 2010).  Additional loci were mapped 
to these plots based on queries of the NHGRI GWAS catalog (Burdett T; Welter et al., 
2014).  
PP-LCGA and latent class regression analyses were implemented using MPLUS 
version 7 (Muthén & Muthén, 1998-2015).   
 
RESULTS 
Sample characteristics, including study sample sizes, DSM-IV ASD diagnoses, 
sex, and mean MSEL domain T scores for EARLI (n=231) and IBIS (n=382) high-risk 
siblings are reported in Table 4.1. Latent classes of cognitive development trajectory are 
shown in Figure 4.1.   Class proportions and fit statistics for these models are shown in 
Table 4.2. The 3 class model was chosen as the final model for analysis based on 
plateauing of various information criteria statistics and theoretical plausibility.  Figure 4.2 
shows sample MSEL means for each class for 6, 12, 24, and 36 month visits.  The gross 
motor domain is not administered past 33 months of age, so we report only 6, 12, and 24 
month visit means.  Based on general patterns of MSEL domain scores over time, we 
labeled the classes “normative”, “intermediate”, and “declining”; class proportions based 
on the estimated model were 33%, 46%, and 21%, respectively.  Table 4.3 shows the 
distribution of ASD diagnosis and sex by most-likely class assignment based on posterior 




had the highest proportion of ASD cases, followed by the “intermediate” class and the 
“normative” class. The proportion of males in the each class exhibited a similar pattern.  
Table 4.4 shows PRS associations with latent class membership and ASD diagnostic 
status.  PRS was not statistically significantly associated with class membership or ASD 





However, when using liberal thresholds (e.g., p<1x10
-3
), standardized PRS is marginally 
associated with “declining” class (OR = 1.66, p = 0.083) and significantly associated with 
ASD (OR = 1.64, p = 0.032). The most notable association is comparing the top versus 
bottom quartile of PRS by ASD status (OR = 7.72, p = 0.013). 
Figure 4.3 shows latent class association p-values for all SNPs located in one of 
the 47 ASD candidate genes.  For both the intermediate (Panel A) and declining (Panel 
B) classes, no SNPs reached Bonferroni significance.  However, for the “intermediate” 
class, two SNPs reached suggestive significance: chr3:2928197 located in the CNTN4 
gene (OR = 0.23, p=0.001) and rs10265509 in the CNTNAP2 gene on chromosome 7 
(OR = 9.30, p = 0.001).  No SNPs in the “declining” class comparison reached suggestive 
significance.  However, more than twice as many SNPs (n=251) reached nominal 
significance (p<0.05) for the “declining” class (Supplementary Table 4.3) than for the 
“intermediate” class (n=117) (Supplementary Table 4.1).  Table 4.5 and Table 4.6 show 
the SNPs with the 10 smallest p values for the “intermediate” and “declining” class, 
respectively.  There was no overlap of specific SNPs among these tables, although four 
genes (CNTN4, CTNND2, CNTNAP2, and KAT2B) were in both lists.  There was 
moderate correlation of effect sizes between the “intermediate” and “declining” classes 
for all candidate gene SNPs tested (r=0.32, p = 2.2 x 10
-16




chromosome, position, gene, and effect size and p-value for the “intermediate” and 
“declining” groups for the top 10 SNPs based on joint ranking of p-values from both 
comparison groups. Four SNPs in this group harbored in GRIN2B displayed effects of 
similar direction and magnitude in both comparison groups.  
Supplementary Figure 4.1 depicts adjusted odds ratios and 95% confidence 
intervals for these 10 SNPs to show strength of association and direction of effects. The 
direction of effect was consistent for all of these SNPs in the two comparison groups; one 
exception was a SNP harbored in CNTNAP2, which showed a protective effect in the 
“intermediate” class but a risk effect in the “declining” class. Gene-based results are 
ranked by significance of SNPs collapsed by gene and reported in Supplementary Tables 
4.2 (“intermediate” class) and 4.4 (“declining” class).  The number of SNPs tested in 
each gene was modestly correlated with the minimum p-value in that gene for 
“intermediate” (r = -0.42) and “declining” (r = -0.35) comparisons. 
Figures 4.5 and 4.6 show p-values and linkage disequilibrium patterns for 
unpruned SNPs in CNTN4 and CNTNAP2 for the “intermediate” (panel A) and 
“declining” (panel B) class results and PGC ASD case-control results (panel C) 
("Psychiatric Genomics Consortium,"). In CNTN4, the highest peaks, although different 
in location across latent class groups, reach a similar degree of significance to the PGC 
results for this gene. CNTN4 also harbors variants associated with schizophrenia, 
intelligence, and brain connectivity. In CNTNAP2, the “declining” class exhibits a 
suggestive locus near known variants for bipolar disorder and schizophrenia, as well as 




Suggestive PGC results in this gene map to the same location as a previously identified 
variant for Alzheimer’s disease.  
 
DISCUSSION 
In this study, we sought to identify ASD-related genetic variants associated with 
differential trajectories of cognitive and motor development among infant high-risk ASD 
siblings. We used mixture modeling techniques to identify distinct trajectories of 
cognitive development among infant siblings of children with ASD who participated in 
the EARLI and IBIS cohort studies.  We identified three subphenotypes of early 
cognitive and motor development:  “normative”, “intermediate”, and “declining” classes. 
Subsequently, we tested for association of various ASD-related common genetic variants, 
including an ASD PRS and SNPs within 47 ASD candidate genes. Top ranked associated 
SNPs were largely in genes involved in neuronal migration during neurodevelopment and 
showed early trajectory effect sizes similar to those observed in ASD GWAS.  
Three early developmental trajectory classes were identified.  Approximately one 
third (33%) were classified into the “normative” class, where all domains exhibit a slight, 
steady increase in means from 6 to 36 months.  Nearly half (46%) of the sample was 
classified into the “intermediate” class, where the pattern of MSEL mean domain-specific 
scores was similar to that of the “normative” class, but consistently lower by 
approximately 10 points (or 1 SD).  The “declining” class included approximately 21% of 
the sample where mean MSEL scores exhibited a steady decline from 6 to 36 months.   
The “declining” class starts to differentiate from the “intermediate” class at 12 months for 




language skills. The gross motor domain did not appear to differentiate well between 
classes.  Previous work suggests that motor delays at 3 and 6 months precede later 
communication delays and other signs of ASD among high-risk ASD siblings compared 
to low-risk siblings (Bhat, Galloway, & Landa, 2012; Estes et al., 2015).  We did not 
observe an obvious trend of motor deficits preceding communication deficits.  However, 
one reason could be that we did not include low-risk (general population) siblings in our 
model; thus, we may not see an altogether higher functioning group that would otherwise 
be present.  This is supported by the fact that our study means for MSEL domain scores 
are slightly lower (Table 4.1) than would be expected from a general population sample, 
as the MSEL domain t-scores are standardized at a population mean of 50 (Mullen, 
1995).  Additionally, Bhat et al. evaluated 6 month motor delay using a different 
instrument, which may be more sensitive to motor deficits than the MSEL (Bhat et al., 
2012).  
Approximately 22% of the full sample had a DSM-IV ASD diagnosis (Table 4.1).  
This is expected from previous reports of ASD risk among high-risk siblings (Ozonoff et 
al., 2011).  Prevalence of ASD differed between groups, with ASD cases comprising 
approximately half (51.7%) of the “declining” class, 15% of the “intermediate” class, and 
2% of the “normative” class.  These results suggest that while cognitive developmental 
trajectory may be associated with ASD case status, it is not a direct surrogate for ASD, or 
ASD severity (Table 4.3).  This is consistent with previous literature where ASD cases 
were spread among the lower scoring MSEL trajectory classes among high-risk ASD 




ASD-defined polygenic risk scores using relatively stringent thresholds were not 
significantly associated with latent trajectory classes, although PRS based on liberal 
thresholds did associate with ASD and with intermediate class membership.  There are 
several potential reasons for this finding.  The ASD PRS is currently based on PGC 
autism GWAS findings that have very few statistically significant SNPs and wide 
confidence intervals. Therefore, PRS weights developed from those effect sizes may be 
imprecise.  Further, the PRS was informed by ASD-associations, not developmental 
traits.   
We considered specific candidate gene SNPs to examine whether genes with 
known ASD associations also show effects with specific developmental trajectories. Two 
SNPs reached suggestive significance in association with the “intermediate” class 
compared to the “normative” class.  The top hit for the “intermediate” class was located 
in the CNTN4 gene on chromosome 3.  Gene-based results ranked CNTN4 as the top gene 
for the intermediate class (Supplementary Table 4.2) and the second most significant 
gene for the “declining” class (Supplementary Table 4.4), though this may in part be due 
to the modest correlation we observed between the number of SNPs tested in a gene and 
the highest degree of significance reached for that gene.  CNTN4 encodes a member of 
the contactin family of immunoglobulins, which are cell adhesion molecules that mediate 
cell surface interactions during nervous system development (Shimoda & Watanabe, 
2009).  Gene mutations and deletions have been implicated in ASD in both candidate and 
genome-wide studies (Cottrell et al., 2011; Glessner et al., 2009; Guo et al., 2012; Roohi 
et al., 2009).  CNTN4 is also implicated in 3p deletion syndrome, which is associated 




Regional mapping of unpruned SNPs in CNTN4 revealed a peak of suggestive 
significance below rs4075530 (Figure 4.5).  Although this SNP reaches only suggestive 
significance in our modest sample size (n=198), it is interesting to note that for this 
candidate gene, we see significance levels similar to that of the PGC with a much larger 
sample size of 10,610 (5,305 cases and 5,305 pseudocontrols) using ASD diagnostic 
status. This result argues for the utility of these trajectory phenotypes for gene discovery 
of both ASD and neurodevelopment generally; it could be true that the effect sizes for 
these phenotypes are larger and thus more detectible at lower sample sizes. Regardless, 
our result adds to existing evidence for the importance of CNTN4 in neurodevelopment.  
There have been no other associations reported in this linkage disequilibrium block in the 
NHGRI GWAS catalog; however, several genome-wide significant associations for 
intelligence traits in a ADHD sample have been identified in the same gene nearby, 
approximately 50kb downstream (Loo et al., 2012). 
The other SNP reaching suggestive significance was rs10265509 in the CNTNAP2 
gene on chromosome 7 for association with the “intermediate” class.   This gene is highly 
expressed throughout the brain and spinal cord and encodes CASPR2, a protein known to 
have a role in regulating receptor-ligand interactions, cell adhesion, migration and 
differentiation (Rodenas-Cuadrado, Ho, & Vernes, 2014).  In addition to autism (Arking 
et al., 2008), CNTNAP2 has been implicated in many other neurodevelopmental and 
brain-related disorders, intellectual disability (Gregor et al., 2011), schizophrenia 
(Friedman et al., 2008), ADHD (Elia et al., 2010), and epilepsy (Mefford et al., 2010).  
Regional mapping of unpruned SNPs in CNTNAP2 revealed an association peak with 




under previous findings implicating risk for bipolar disorder, schizophrenia (K. S. Wang 
et al., 2010), and Alzheimer’s disease (Hirano et al., 2015). Therefore, our results 
contribute to the large body of evidence linking CNTNAP2 to a broad range of 
neuropsychiatric phenotypes across the life course. This peak was less prominent in the 
“intermediate” class and the PGC case-control results.   
We caution against over-interpretation of protective effects of many odds ratios 
reported among candidate gene SNPs.  Our approach was to test SNPs that overlapped 
the genic boundaries of those reported in the SFARI database, so we did not limit testing 
to only previously associated SNPs, with defined risk alleles.  We coded genotypes 
according to their dosage of the minor allele, as minor alleles confer risk more often than 
protection (Park et al., 2011).  But in this enriched risk sample, it is less likely that the 
reference allele is the same as that in the general population.  This potential for lack of 
concordance would be exacerbated at high MAFs, and we, indeed, used a relatively high 
MAF threshold (> 5%).  Moreover, the propensity for minor alleles to confer risk is 
decreased at higher MAFs (Gorlova et al., 2012).  Still, it could be true that minor alleles 
are less likely to be present in the “intermediate” or “declining” groups than the 
“normative” group.  These SNPs could synonymous and/or located in intronic regions 
and, thus, would not have an effect on the candidate gene function.  Future research with 
larger sample sizes should look to examine the consistency of these protective effects.      
Limitations 
This study is subject to several limitations.   As with any longitudinal study, we 
had missing data across time points.  This was due to an inability to attend an age-




of the MSEL at 24 month visits part way through the data collection phase due to funding 
constraints.  However, we used a full information maximum likelihood (FIML) estimator 
in our PP-LCGA model, which is robust to missing data (Muthen & Shedden, 1999; 
Schafer & Graham, 2002).   Second, the PRS was constructed from SNPs only modestly 
associated with ASD.  Relating an ASD PRS to latent trajectory phenotypes should be 
attempted again once GWAS results from larger studies are available and genome-wide 
significant SNPs have been identified.  Finally, our modest sample size precluded finding 
Bonferroni significant results in the candidate gene analyses.  We plan to add genotype 
data for the IBIS portion of this sample in the near future, which will theoretically 
increase power.     
Conclusion 
Here, we report the first genetic association study with developmental trajectory 
classes among high-risk ASD siblings.  We did not find an association between ASD 
PRS and latent trajectory classes for most PRS SNP association thresholds.  However, 
latent class associations with SNPs in ASD candidate genes show similar magnitude of 
association to ASD-outcome results from much larger sample sizes, suggesting potential 
for further elucidation of mechanism when considering trajectory phenotypes compared 
to diagnostic categories. Genes coding for proteins involved in cell-cell interactions and 
neuronal migration in the developing nervous system may be specifically related to early 
cognitive developmental trajectory.  Larger sample sizes are needed to replicate these 
modest findings.  Future work should look beyond ASD candidate genes and focus on 
genome-wide pathway and gene-set analyses to further explore the genetic basis to 





American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental 
Disorders (5 ed.). Arlington, VA: American Psychiatric Publishing. 
Anney, R., Klei, L., Pinto, D., Almeida, J., Bacchelli, E., Baird, G., . . . Devlin, B. (2012). 
Individual common variants exert weak effects on the risk for autism spectrum 
disorderspi. Human Molecular Genetics, 21(21), 4781-4792. doi: 
10.1093/hmg/dds301 
Anney, R., Klei, L., Pinto, D., Regan, R., Conroy, J., Magalhaes, T. R., . . . Hallmayer, J. 
(2010). A genome-wide scan for common alleles affecting risk for autism. Human 
Molecular Genetics, 19(20), 4072-4082. doi: 10.1093/hmg/ddq307 
Arking, D. E., Cutler, D. J., Brune, C. W., Teslovich, T. M., West, K., Ikeda, M., . . . 
Chakravarti, A. (2008). A common genetic variant in the neurexin superfamily 
member CNTNAP2 increases familial risk of autism. American Journal of 
Human Genetics, 82(1), 160-164. doi: 10.1016/j.ajhg.2007.09.015 
Asparouhov, T., & Muthén, B. (2013). Auxiliary variables in mixture modeling: 3-step 
approaches using Mplus. Mplus web notes, 15, 1-24.  
Basu, S. N., Kollu, R., & Banerjee-Basu, S. (2009). AutDB: a gene reference resource for 
autism research. Nucleic Acids Research, 37(Database issue), D832-836. doi: 
10.1093/nar/gkn835 
Bhat, A. N., Galloway, J. C., & Landa, R. J. (2012). Relation between early motor delay 
and later communication delay in infants at risk for autism. Infant Behavior & 
Development, 35(4), 838-846. doi: 10.1016/j.infbeh.2012.07.019 
Burdett T, H. P., Hastings E, Hindorff LA, Junkins HA, Klemm AK, MacArthur J, 
Manolio TA, Morales J, Parkinson H, Welter D. The NHGRI-EBI Catalog of 
published genome-wide association studies.   Retrieved July 14, 2016, from 
www.ebi.ac.uk/gwas 
Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., & Lee, J. J. (2015). 
Second-generation PLINK: rising to the challenge of larger and richer datasets. 
Gigascience, 4, 7. doi: 10.1186/s13742-015-0047-8 
Chaste, P., Klei, L., Sanders, S. J., Hus, V., Murtha, M. T., Lowe, J. K., . . . Devlin, B. 
(2014). A Genome-wide Association Study of Autism Using the Simons Simplex 
Collection: Does Reducing Phenotypic Heterogeneity in Autism Increase Genetic 
Homogeneity? Biological Psychiatry. doi: 10.1016/j.biopsych.2014.09.017 
Coe, B. P., Girirajan, S., & Eichler, E. E. (2012). The genetic variability and 




Genetics. Part C: Seminars in Medical Genetics, 160C(2), 118-129. doi: 
10.1002/ajmg.c.31327 
Colvert, E., Tick, B., McEwen, F., Stewart, C., Curran, S. R., Woodhouse, E., . . . Bolton, 
P. (2015). Heritability of Autism Spectrum Disorder in a UK Population-Based 
Twin Sample. JAMA Psychiatry. doi: 10.1001/jamapsychiatry.2014.3028 
Cottrell, C. E., Bir, N., Varga, E., Alvarez, C. E., Bouyain, S., Zernzach, R., . . . Herman, 
G. E. (2011). Contactin 4 as an autism susceptibility locus. Autism Res, 4(3), 189-
199. doi: 10.1002/aur.184 
Curran, S., Bolton, P., Rozsnyai, K., Chiocchetti, A., Klauck, S. M., Duketis, E., . . . 
Collier, D. (2011). No association between a common single nucleotide 
polymorphism, rs4141463, in the MACROD2 gene and autism spectrum disorder. 
American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics, 
156b(6), 633-639. doi: 10.1002/ajmg.b.31201 
Delaneau, O., Coulonges, C., & Zagury, J. F. (2008). Shape-IT: new rapid and accurate 
algorithm for haplotype inference. BMC Bioinformatics, 9, 540. doi: 
10.1186/1471-2105-9-540 
Dijkhuizen, T., van Essen, T., van der Vlies, P., Verheij, J. B., Sikkema-Raddatz, B., van 
der Veen, A. Y., . . . Kok, K. (2006). FISH and array-CGH analysis of a complex 
chromosome 3 aberration suggests that loss of CNTN4 and CRBN contributes to 
mental retardation in 3pter deletions. American Journal of Medical Genetics. Part 
A, 140(22), 2482-2487. doi: 10.1002/ajmg.a.31487 
Elia, J., Gai, X., Xie, H. M., Perin, J. C., Geiger, E., Glessner, J. T., . . . White, P. S. 
(2010). Rare structural variants found in attention-deficit hyperactivity disorder 
are preferentially associated with neurodevelopmental genes. Molecular 
Psychiatry, 15(6), 637-646. doi: 10.1038/mp.2009.57 
Estes, A., Zwaigenbaum, L., Gu, H., St John, T., Paterson, S., Elison, J. T., . . . Piven, J. 
(2015). Behavioral, cognitive, and adaptive development in infants with autism 
spectrum disorder in the first 2 years of life. Journal of Neurodevelopmental 
Disorders, 7(1), 24. doi: 10.1186/s11689-015-9117-6 
Fernandez, T., Morgan, T., Davis, N., Klin, A., Morris, A., Farhi, A., . . . State, M. W. 
(2008). Disruption of Contactin 4 (CNTN4) results in developmental delay and 
other features of 3p deletion syndrome. American Journal of Human Genetics, 
82(6), 1385.  
Fountain, C., Winter, A. S., & Bearman, P. S. (2012). Six developmental trajectories 
characterize children with autism. Pediatrics, 129(5), e1112-1120. doi: 
10.1542/peds.2011-1601 
Friedman, J. I., Vrijenhoek, T., Markx, S., Janssen, I. M., van der Vliet, W. A., Faas, B. 




schizophrenia and epilepsy. Molecular Psychiatry, 13(3), 261-266. doi: 
10.1038/sj.mp.4002049 
Fuchsberger, C., Abecasis, G. R., & Hinds, D. A. (2015). minimac2: faster genotype 
imputation. Bioinformatics, 31(5), 782-784. doi: 10.1093/bioinformatics/btu704 
Gaugler, T., Klei, L., Sanders, S. J., Bodea, C. A., Goldberg, A. P., Lee, A. B., . . . 
Buxbaum, J. D. (2014). Most genetic risk for autism resides with common 
variation. Nature Genetics, 46(8), 881-885. doi: 10.1038/ng.3039 
Glessner, J. T., Wang, K., Cai, G., Korvatska, O., Kim, C. E., Wood, S., . . . Hakonarson, 
H. (2009). Autism genome-wide copy number variation reveals ubiquitin and 
neuronal genes. Nature, 459(7246), 569-573. doi: 10.1038/nature07953 
Gorlova, O. Y., Ying, J., Amos, C. I., Spitz, M. R., Peng, B., & Gorlov, I. P. (2012). 
Derived SNP alleles are used more frequently than ancestral alleles as risk-
associated variants in common human diseases. Journal of Bioinformatics and 
Computational Biology, 10(2), 1241008. doi: 10.1142/s0219720012410089 
Gregor, A., Albrecht, B., Bader, I., Bijlsma, E. K., Ekici, A. B., Engels, H., . . . Zweier, 
C. (2011). Expanding the clinical spectrum associated with defects in CNTNAP2 
and NRXN1. BMC Medical Genetics, 12, 106. doi: 10.1186/1471-2350-12-106 
Guo, H., Xun, G., Peng, Y., Xiang, X., Xiong, Z., Zhang, L., . . . Xia, K. (2012). 
Disruption of Contactin 4 in two subjects with autism in Chinese population. 
Gene, 505(2), 201-205. doi: 10.1016/j.gene.2012.06.051 
Hallmayer, J., Cleveland, S., Torres, A., Phillips, J., Cohen, B., Torigoe, T., . . . Risch, N. 
(2011). Genetic heritability and shared environmental factors among twin pairs 
with autism. Archives of General Psychiatry, 68(11), 1095-1102. doi: 
10.1001/archgenpsychiatry.2011.76 
Hazlett, H. C., Gu, H., McKinstry, R. C., Shaw, D. W., Botteron, K. N., Dager, S. R., . . . 
Piven, J. (2012). Brain volume findings in 6-month-old infants at high familial 
risk for autism. American Journal of Psychiatry, 169(6), 601-608. doi: 
10.1176/appi.ajp.2012.11091425 
Hirano, A., Ohara, T., Takahashi, A., Aoki, M., Fuyuno, Y., Ashikawa, K., . . . Kanba, S. 
(2015). A genome-wide association study of late-onset Alzheimer's disease in a 
Japanese population. Psychiatric Genetics, 25(4), 139-146. doi: 
10.1097/ypg.0000000000000090 
Howie, B., Fuchsberger, C., Stephens, M., Marchini, J., & Abecasis, G. R. (2012). Fast 
and accurate genotype imputation in genome-wide association studies through 
pre-phasing. Nature Genetics, 44(8), 955-959. doi: 10.1038/ng.2354 
Jones, E. J., Gliga, T., Bedford, R., Charman, T., & Johnson, M. H. (2014). 




risk. Neuroscience and Biobehavioral Reviews, 39, 1-33. doi: 
10.1016/j.neubiorev.2013.12.001 
Klei, L., Sanders, S. J., Murtha, M. T., Hus, V., Lowe, J. K., Willsey, A. J., . . . Devlin, B. 
(2012). Common genetic variants, acting additively, are a major source of risk for 
autism. Mol Autism, 3(1), 9. doi: 10.1186/2040-2392-3-9 
Landa, R. J., Gross, A. L., Stuart, E. A., & Bauman, M. (2012). Latent class analysis of 
early developmental trajectory in baby siblings of children with autism. Journal of 
Child Psychology and Psychiatry and Allied Disciplines, 53(9), 986-996. doi: 
10.1111/j.1469-7610.2012.02558.x 
Landa, R. J., Gross, A. L., Stuart, E. A., & Faherty, A. (2013). Developmental trajectories 
in children with and without autism spectrum disorders: the first 3 years. Child 
Development, 84(2), 429-442. doi: 10.1111/j.1467-8624.2012.01870.x 
Lichtenstein, P., Carlstrom, E., Rastam, M., Gillberg, C., & Anckarsater, H. (2010). The 
genetics of autism spectrum disorders and related neuropsychiatric disorders in 
childhood. American Journal of Psychiatry, 167(11), 1357-1363. doi: 
10.1176/appi.ajp.2010.10020223 
Liu, X., & Takumi, T. (2014). Genomic and genetic aspects of autism spectrum disorder. 
Biochemical and Biophysical Research Communications, 452(2), 244-253. doi: 
10.1016/j.bbrc.2014.08.108 
Loo, S. K., Shtir, C., Doyle, A. E., Mick, E., McGough, J. J., McCracken, J., . . . Nelson, 
S. F. (2012). Genome-wide association study of intelligence: additive effects of 
novel brain expressed genes. Journal of the American Academy of Child and 
Adolescent Psychiatry, 51(4), 432-440.e432. doi: 10.1016/j.jaac.2012.01.006 
Mefford, H. C., Muhle, H., Ostertag, P., von Spiczak, S., Buysse, K., Baker, C., . . . 
Eichler, E. E. (2010). Genome-wide copy number variation in epilepsy: novel 
susceptibility loci in idiopathic generalized and focal epilepsies. PLoS Genet, 
6(5), e1000962. doi: 10.1371/journal.pgen.1000962 
Mullen, E. M. (1995). Mullen Scales of Early Learning (AGS ed.). Circle Pines, MN: 
American Guidance Service, Inc. 
Muthen, B., & Shedden, K. (1999). Finite mixture modeling with mixture outcomes using 
the EM algorithm. Biometrics, 55(2), 463-469.  
Muthén, L. K., & Muthén, B. O. (1998-2015). MPLUS User's Guide (Seventh ed.). Los 
Angeles, CA: Muthen & Muthen. 
Newschaffer, C. J., Croen, L. A., Fallin, M. D., Hertz-Picciotto, I., Nguyen, D. V., Lee, 
N. L., . . . Shedd-Wise, K. M. (2012). Infant siblings and the investigation of 





Ozonoff, S., Iosif, A. M., Baguio, F., Cook, I. C., Hill, M. M., Hutman, T., . . . Young, G. 
S. (2010). A prospective study of the emergence of early behavioral signs of 
autism. Journal of the American Academy of Child and Adolescent Psychiatry, 
49(3), 256-266 e251-252.  
Ozonoff, S., Young, G. S., Carter, A., Messinger, D., Yirmiya, N., Zwaigenbaum, L., . . . 
Stone, W. L. (2011). Recurrence risk for autism spectrum disorders: a Baby 
Siblings Research Consortium study. Pediatrics, 128(3), e488-495. doi: 
10.1542/peds.2010-2825 
Park, J. H., Gail, M. H., Weinberg, C. R., Carroll, R. J., Chung, C. C., Wang, Z., . . . 
Chatterjee, N. (2011). Distribution of allele frequencies and effect sizes and their 
interrelationships for common genetic susceptibility variants. Proceedings of the 
National Academy of Sciences of the United States of America, 108(44), 18026-
18031. doi: 10.1073/pnas.1114759108 
Pruim, R. J., Welch, R. P., Sanna, S., Teslovich, T. M., Chines, P. S., Gliedt, T. P., . . . 
Willer, C. J. (2010). LocusZoom: regional visualization of genome-wide 
association scan results. Bioinformatics, 26(18), 2336-2337. doi: 
10.1093/bioinformatics/btq419 
Psychiatric Genomics Consortium. 2016, from http://www.med.unc.edu/pgc/results-and-
downloads 
Purcell, S., & Chang, C. PLINK 1.9. from https://www.cog-genomics.org/plink2 
Robinson, E. B., St Pourcain, B., Anttila, V., Kosmicki, J. A., Bulik-Sullivan, B., Grove, 
J., . . . Daly, M. J. (2016). Genetic risk for autism spectrum disorders and 
neuropsychiatric variation in the general population. Nature Genetics, 48(5), 552-
555. doi: 10.1038/ng.3529 
Rodenas-Cuadrado, P., Ho, J., & Vernes, S. C. (2014). Shining a light on CNTNAP2: 
complex functions to complex disorders. European Journal of Human Genetics, 
22(2), 171-178. doi: 10.1038/ejhg.2013.100 
Roohi, J., Montagna, C., Tegay, D. H., Palmer, L. E., DeVincent, C., Pomeroy, J. C., . . . 
Hatchwell, E. (2009). Disruption of contactin 4 in three subjects with autism 
spectrum disorder. Journal of Medical Genetics, 46(3), 176-182. doi: 
10.1136/jmg.2008.057505 
Rozga, A., Hutman, T., Young, G. S., Rogers, S. J., Ozonoff, S., Dapretto, M., & Sigman, 
M. (2011). Behavioral profiles of affected and unaffected siblings of children with 
autism: contribution of measures of mother-infant interaction and nonverbal 





Sandin, S., Lichtenstein, P., Kuja-Halkola, R., Larsson, H., Hultman, C. M., & 
Reichenberg, A. (2014). The familial risk of autism. JAMA, 311(17), 1770-1777. 
doi: 10.1001/jama.2014.4144 
Schafer, J. L., & Graham, J. W. (2002). Missing data: our view of the state of the art. 
Psychological Methods, 7(2), 147-177.  
Shimoda, Y., & Watanabe, K. (2009). Contactins: emerging key roles in the development 
and function of the nervous system. Cell Adh Migr, 3(1), 64-70.  
Siva, N. (2008). 1000 Genomes project. Nature Biotechnology, 26(3), 256. doi: 
10.1038/nbt0308-256b 
Szatmari, P., Georgiades, S., Duku, E., Bennett, T. A., Bryson, S., Fombonne, E., . . . 
Thompson, A. (2015). Developmental trajectories of symptom severity and 
adaptive functioning in an inception cohort of preschool children with autism 
spectrum disorder. JAMA Psychiatry, 72(3), 276-283. doi: 
10.1001/jamapsychiatry.2014.2463 
Wang, K., Zhang, H., Ma, D., Bucan, M., Glessner, J. T., Abrahams, B. S., . . . 
Hakonarson, H. (2009). Common genetic variants on 5p14.1 associate with 
autism spectrum disorders. Nature, 459(7246), 528-533. doi: 
10.1038/nature07999 
Wang, K. S., Liu, X. F., & Aragam, N. (2010). A genome-wide meta-analysis identifies 
novel loci associated with schizophrenia and bipolar disorder. Schizophrenia 
Research, 124(1-3), 192-199. doi: 10.1016/j.schres.2010.09.002 
Weiss, L. A., Arking, D. E., Daly, M. J., & Chakravarti, A. (2009). A genome-wide 
linkage and association scan reveals novel loci for autism. Nature, 461(7265), 
802-808. doi: 10.1038/nature08490 
Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., . . . Parkinson, 
H. (2014). The NHGRI GWAS Catalog, a curated resource of SNP-trait 











Table 4.1. EARLI-IBIS collaborative cohort sample counts, descriptive statistics, and 
overall scores for Mullen Scales of Early Learning domains.  
Study  n % 
     EARLI 231 37.7 
     IBIS 382 62.3 
DSM-IV ASD Diagnosis  109 22.4 
Sex  n % 
     Male 362 59.1 
     Female 251 40.9 
Gross Motor mean sd 
     6 months 47.7 8.9 
     12 months 47.4 12.0 
     24 months 47.9 9.9 
Fine Motor mean sd 
     6 months 48.8 9.6 
     12 months 56.2 9.5 
     24 months 47.9 10.7 
     36 months 44.4 13.8 
Visual Reception mean sd 
     6 months 50.8 9.3 
     12 months 53.3 9.9 
     24 months 51.2 11.7 
     36 months 55.6 15.7 
Receptive Language mean sd 
     6 months 50.0 9.6 
     12 months 42.7 9.1 
     24 months 48.1 13.5 
     36 months 46.7 11.2 
Expressive Language mean sd 
     6 months 44.1 7.6 
     12 months 46.2 11.9 
     24 months 46.5 12.7 








Figure 4.1. Parallel process LCGA model.  Latent variable intercepts (i), slopes (s), and 
quadratic (q) terms are used to construct latent classes.  The boxed G represents genetic 
predictors (ASD polygenic risk score, and ASD candidate gene SNPs) tested using latent 
class regression.  Boxed numbers represent Mullen Scales of Early Learning domain-









Class proportions Fit Statistics  











1 20 1 NA NA NA NA 64796 64884 64821 NA NA NA 
2 36 0.67 0.33 NA NA NA 63425 63584 63469 <0.001 <0.001 0.79 
3 52 0.46 0.21 0.33 NA NA 63116 63345 63180 0.092 <0.001 0.73 
4 68 0.47 0.26 0.12 0.15 NA 62998 63299 63083 0.188 <0.001 0.74 
5 84 0.24 0.11 0.26 0.25 0.14 62877 63248 62982 0.246 <0.001 0.70 
a
Akaike information criterion 
b
Bayesian information criterion 
c
Sample size adjusted Bayesian information criterion 
d
Vuong-Lo-Mendell-Rubin likelihood ratio test 
e







Figure 4.2.  Estimated mean MSEL domain scores by class for 3-class LCGA 
solution.  The classes are named “normative”, “intermediate”, and “declining” based on 
general patterns of MSEL subscale scores over time.  Class proportions based on the 












Table 4.3.  Distribution of autism spectrum disorder diagnostic status and sex by most-







 n % n % N % 
DSM-IV Diagnosis       
    ASD a 46 15.4 60 51.7 3 1.5 
    Non-ASD b 185 61.9 39 33.6 154 77.8 
    Missing diagnosis 68 22.7 17 14.7 41 20.7 
Sex       
    Male 184 61.5 86 74.1 92 46.5 
    Female 115 38.5 30 25.9 106 53.5 
a
 ASD = Autism spectrum disorders (autism, Asperger syndrome, or PDD-NOS) 
b 





















Table 4.4. Standardized and quartiled PRS associations with class membership and ASD 
diagnosis.   
 








 PRS p-value threshold PRS p-value threshold 
 1 x 10
-3
 1 x 10
-4
 1 x 10
-5
 1 x 10
-3
 1 x 10
-4
 1 x 10
-5
 
Latent class       
  Intermediate  1.06 (0.822) 1.25  (0.443) 0.92 (0.553) 0.68 (0.654) 1.38 (0.765) 0.31 (0.253) 
  Declining 1.66 (0.083) 1.12  (0.626) 0.99 (0.895) 1.98 (0.450) 1.76 (0.699) 0.50 (0.349) 
Diagnosis       
  ASD 
b 
1.64 (0.032) 1.09 (0.706) 1.45 (0.096) 7.72 (0.013) 1.24 (0.744) 1.91 (0.328) 
a Odds ratios are adjusted for sex and ancestral principal components 1 through 5. 
b














Figure 4.3. Manhattan plots of association p-values for 4,257 SNPs located in 47 
candidate genes under an additive genetic model.   P-values were obtained using a 3-
step latent class multinomial logistic regression with the “normative” class as the 
reference category and adjusted for ancestry principal components 1 through 5 and 
gender.  The horizontal blue line represents a threshold for suggestive significance 
defined at 1 x 10
-3
.  The horizontal red line represents a Bonferroni significant threshold 
at 1.2 x 10
-5
.  Panel s A and B show -log10 p-values by genomic position for the 








“Intermediate” v. “Normative” 




Table 4.5. Top 10 significant SNPs associated with the “intermediate” class relative to 
the “normative” class. 
Chr. Position rsID Gene SFARI Gene Class OR p 
3 2928197 NA CNTN4 Strong Candidate 0.23 0.001 
7 147815663 rs10265509 CNTNAP2 Strong Candidate 9.3 0.001 
3 20173805 rs11705766 KAT2B Strong Candidate 0.25 0.003 
4 114001887 rs2135354 ANK2 High Confidence 0.14 0.004 
5 11128927 rs67775011 CTNND2 Strong Candidate 0.15 0.004 
3 2163838 NA CNTN4 Strong Candidate 0.12 0.008 
3 2425824 rs9830036 CNTN4 Strong Candidate 4.79 0.009 
3 3014060 rs340804 CNTN4 Strong Candidate 0.21 0.009 
10 28886626 rs332160 WAC Strong Candidate 0.29 0.009 




















Table 4.6. Top 10 significant SNPs associated with the “declining” class relative to the 
“normative” class. 
Chr. Position rsID Gene SFARI Gene Class OR p 
2 1859595 NA MYT1L Strong Candidate 4.01 0.002 
2 60757467 rs202108972 BCL11A Strong Candidate 0.27 0.002 
3 2145996 rs2727926 CNTN4 Strong Candidate 0.32 0.002 
3 20108644 rs1610186 KAT2B Strong Candidate 4.68 0.002 
7 145921523 rs201323315 CNTNAP2 Strong Candidate 4.07 0.002 
5 11585335 rs2429307 CTNND2 Strong Candidate 0.29 0.003 
3 2596520 rs79864813 CNTN4 Strong Candidate 4.53 0.004 
7 145934145 rs17579058 CNTNAP2 Strong Candidate 0.31 0.004 
3 2280429 NA CNTN4 Strong Candidate 3.24 0.005 




















Table 4.7. Top 10 jointly ranked SNPs associated with both the “intermediate” and 
“declining” classes.   
CHR Position rsID Gene 
SFARI 
Gene Class 
OR1a p1a OR2b p2b 
7 145934145 rs17579058 CNTNAP2 
Strong 
Candidate 
0.36 0.027 0.31 0.004 
2 51201137 NA NRXN1 
Strong 
Candidate 
0.35 0.033 0.46 0.014 
15 93501165 rs62023142 CHD2 
Strong 
Candidate 
2.88 0.047 3.5 0.005 
3 2928197 NA CNTN4 
Strong 
Candidate 
0.23 0.001 0.39 0.029 
12 13744039 rs34942586 GRIN2B 
High 
Confidence 
0.25 0.019 0.45 0.032 
3 2425824 rs9830036 CNTN4 
Strong 
Candidate 
4.79 0.009 2.37 0.039 
12 13740803 rs918092 GRIN2B 
High 
Confidence 
2.42 0.058 2.58 0.019 
7 147980396 NA CNTNAP2 
Strong 
Candidate 
0.42 0.069 4.41 0.015 
12 13752832 rs2268097 GRIN2B 
High 
Confidence 
0.18 0.01 0.42 0.045 
12 13753829 rs1805518 GRIN2B 
High 
Confidence 
0.18 0.01 0.42 0.045 
a
Intermediate class vs. normative class 
b






Figure 4.4. Correlation of effect sizes (log odds ratios) between the “intermediate” 
class and “declining” class for all candidate gene SNPs tested.  Effect sizes were 












r = 0.32 





Figure 4.5. Regional 
plots for unpruned 
SNPs in CNTN4. Left y-
axis indicates degree of 
significance (-log10p-
value) for association 
tests of unpruned SNPs 
tested in CNTN4. Right y-
axis depicts 
recombination rates. X-
axis depicts genomic 
position. Points are 
shaped in accordance 
with whether they were 
tested for association in 
EARLI (for panels A and 
B) (n=198) or the ASD 
PGC study (Panel C) 
(n=10,610) or are SNPs 
that have been previously 
demonstrated to be 
associated with another 
neuropsychiatric 
phenotype. Points are 
colored according the 
extent to which that SNP 




with the most statistically 
significant SNP in the 
gene. A) Results for 
association testing 
comparing “intermediate” class to “normative” class. B) Results for association testing 








Figure 4.6. Regional 
plots for unpruned 
SNPs in CNTNAP2. 
Left y-axis indicates 
degree of significance (-
log10p-value) for 
association tests of 
unpruned SNPs tested in 
CNTNAP2. Right y-axis 
depicts recombination 
rates. X-axis depicts 
genomic position. Points 
are shaped in 
accordance with whether 
they were tested for 
association in EARLI 
(for panels A and B) 
(n=198) or the ASD 
PGC study (n=10,610) 
(Panel C) or are SNPs 
that have been 
previously demonstrated 
to be associated with 
another neuropsychiatric 
phenotype. Points are 
colored according the 
extent to which that SNP 




with the most 
statistically significant SNP in the gene. A) Results for association testing comparing 
“intermediate” class to “normative” class. B) Results for association testing comparing 









Supplementary Figure 4.1. Odds ratios and 95% confidence intervals for the top 10 jointly 
ranked SNPs in candidate genes tested under an additive model.  ORs and CIs were obtained 
using a 3-step latent class multinomial logistic regression with the “normative” class as the 
reference category and adjusted for ancestry principal components 1 through 5 and gender.  Red 





























Supplementary Table 4.1. 117 Nominally significant (p < 0.05) SNPs associated with 
the “intermediate” class compared to the “normative” class. 
Chr. Position rsID Gene SFARI Gene Class OR p 
3 2928197 NA CNTN4 Strong Candidate 0.23 0.001 
7 147815663 rs10265509 CNTNAP2 Strong Candidate 9.3 0.001 
3 20173805 rs11705766 KAT2B Strong Candidate 0.25 0.003 
4 114001887 rs2135354 ANK2 High Confidence 0.14 0.004 
5 11128927 rs67775011 CTNND2 Strong Candidate 0.15 0.004 
3 2163838 NA CNTN4 Strong Candidate 0.12 0.008 
3 2425824 rs9830036 CNTN4 Strong Candidate 4.79 0.009 
3 3014060 rs340804 CNTN4 Strong Candidate 0.21 0.009 
10 28886626 rs332160 WAC Strong Candidate 0.29 0.009 
12 13753091 rs1805479 GRIN2B High Confidence 0.15 0.009 
12 13752832 rs2268097 GRIN2B High Confidence 0.18 0.01 
12 13753829 rs1805518 GRIN2B High Confidence 0.18 0.01 
12 13753852 rs1805519 GRIN2B High Confidence 0.18 0.01 
3 2420429 rs9826250 CNTN4 Strong Candidate 0.26 0.011 
3 2811719 rs60667714 CNTN4 Strong Candidate 5.64 0.011 
7 147617447 NA CNTNAP2 Strong Candidate 3.45 0.011 
7 147905708 rs11975702 CNTNAP2 Strong Candidate 0.19 0.011 
7 147649402 rs79028592 CNTNAP2 Strong Candidate 3.32 0.012 
10 28841769 rs332122 WAC Strong Candidate 0.26 0.012 
10 28869729 rs332147 WAC Strong Candidate 0.26 0.012 
11 70813928 rs11823567 SHANK2 Strong Candidate 0.26 0.012 
11 70421468 rs11236691 SHANK2 Strong Candidate 0.18 0.013 
2 51003771 NA NRXN1 Strong Candidate 0.29 0.014 
7 147991580 rs10155900 CNTNAP2 Strong Candidate 0.29 0.014 
10 28832820 rs61848477 WAC Strong Candidate 0.3 0.014 
10 28843854 rs332125 WAC Strong Candidate 0.3 0.014 
10 28862152 rs332141 WAC Strong Candidate 0.3 0.014 
3 2926235 rs17646423 CNTN4 Strong Candidate 0.25 0.015 
3 71462441 rs73119151 FOXP1 Strong Candidate 0.32 0.016 
16 9036281 rs2447931 USP7 Strong Candidate 0.16 0.016 
6 157213008 NA ARID1B High Confidence 3.39 0.017 
3 71374638 rs201114438 FOXP1 Strong Candidate 0.09 0.019 
12 13744039 rs34942586 GRIN2B High Confidence 0.25 0.019 
4 114167779 rs362497 ANK2 High Confidence 3.17 0.02 
12 13743245 rs2041889 GRIN2B High Confidence 0.28 0.02 
12 13812566 rs35222999 GRIN2B High Confidence 3.87 0.02 
12 13957091 rs202127623 GRIN2B High Confidence 3.66 0.02 




7 146179491 NA CNTNAP2 Strong Candidate 3.67 0.021 
7 146194998 NA CNTNAP2 Strong Candidate 4.33 0.021 
7 146422410 rs344461 CNTNAP2 Strong Candidate 4.88 0.021 
12 13804359 rs2284404 GRIN2B High Confidence 0.2 0.021 
3 2884787 rs67182448 CNTN4 Strong Candidate 0.46 0.022 
3 71434958 rs13070452 FOXP1 Strong Candidate 0.2 0.022 
3 2198047 rs57594411 CNTN4 Strong Candidate 0.44 0.023 
6 157432660 rs4869907 ARID1B High Confidence 0.31 0.023 
7 147923566 rs12532590 CNTNAP2 Strong Candidate 0.35 0.023 
16 1249494 rs12918213 CACNA1H Strong Candidate 2.36 0.023 
16 1249495 rs12922159 CACNA1H Strong Candidate 2.36 0.023 
3 2413302 rs6795931 CNTN4 Strong Candidate 0.38 0.024 
3 20162216 rs7617840 KAT2B Strong Candidate 0.36 0.024 
12 13739350 rs10772694 GRIN2B High Confidence 0.23 0.024 
12 66994814 rs7131878 GRIP1 Strong Candidate 0.4 0.024 
16 1236190 rs58094843 CACNA1H Strong Candidate 0.33 0.025 
7 147960601 rs12704004 CNTNAP2 Strong Candidate 0.37 0.026 
2 50476423 rs1712914 NRXN1 Strong Candidate 2.41 0.027 
3 54327590 NA CACNA2D3 Strong Candidate 0.4 0.027 
6 157266505 rs4870499 ARID1B High Confidence 2.6 0.027 
7 103400437 NA RELN Strong Candidate 0.3 0.027 
7 145934145 rs17579058 CNTNAP2 Strong Candidate 0.36 0.027 
16 8995927 rs2304466 USP7 Strong Candidate 2.95 0.027 
3 3043267 rs163353 CNTN4 Strong Candidate 0.41 0.028 
7 147854500 rs10256938 CNTNAP2 Strong Candidate 0.35 0.029 
12 14079894 rs200556225 GRIN2B High Confidence 0.36 0.029 
1 202695165 rs4950740 KDM5B Strong Candidate 0.27 0.031 
1 202718588 rs7519619 KDM5B Strong Candidate 0.27 0.031 
1 202730535 rs7551390 KDM5B Strong Candidate 0.27 0.031 
2 166238034 rs7581427 SCN2A High Confidence 0.31 0.031 
3 20112234 rs73179773 KAT2B Strong Candidate 4.62 0.031 
3 54896405 NA CACNA2D3 Strong Candidate 2.44 0.031 
7 147808629 NA CNTNAP2 Strong Candidate 0.34 0.031 
16 89507995 rs2911268 ANKRD11 Strong Candidate 3.02 0.031 
3 54660737 rs74500931 CACNA2D3 Strong Candidate 2.93 0.032 
3 54958762 rs201096330 CACNA2D3 Strong Candidate 0.2 0.032 
2 51201137 NA NRXN1 Strong Candidate 0.35 0.033 
12 13805633 rs10845819 GRIN2B High Confidence 0.2 0.033 
3 2195692 rs55883839 CNTN4 Strong Candidate 0.24 0.034 
11 70418346 rs10899191 SHANK2 Strong Candidate 3.01 0.034 




3 20117417 rs76536306 KAT2B Strong Candidate 2.43 0.035 
6 157250189 rs284430 ARID1B High Confidence 3.46 0.035 
6 157404463 rs12197388 ARID1B High Confidence 2.48 0.035 
7 103153373 rs3808036 RELN Strong Candidate 5.03 0.035 
12 13762597 rs2268098 GRIN2B High Confidence 0.29 0.035 
12 13763455 rs1805481 GRIN2B High Confidence 0.29 0.035 
16 9035781 rs56410892 USP7 Strong Candidate 0.17 0.035 
3 71164888 NA FOXP1 Strong Candidate 3.05 0.037 
3 71210210 rs34347778 FOXP1 Strong Candidate 0.35 0.037 
6 157227472 rs479079 ARID1B High Confidence 0.28 0.037 
2 50600432 rs3081368 NRXN1 Strong Candidate 0.37 0.038 
3 71065947 rs3846030 FOXP1 Strong Candidate 3 0.038 
12 66982974 rs76650031 GRIP1 Strong Candidate 0.34 0.038 
7 147993238 rs4726946 CNTNAP2 Strong Candidate 2.4 0.039 
12 67028845 rs7311299 GRIP1 Strong Candidate 0.4 0.04 
16 8996636 rs4985062 USP7 Strong Candidate 3.29 0.04 
3 2391613 rs1720194 CNTN4 Strong Candidate 3.39 0.041 
3 20179892 rs201896750 KAT2B Strong Candidate 2.62 0.041 
11 70470633 rs4980629 SHANK2 Strong Candidate 0.42 0.041 
2 50817470 rs6733430 NRXN1 Strong Candidate 0.37 0.042 
4 114005198 rs7676179 ANK2 High Confidence 3.25 0.043 
7 103417134 rs262338 RELN Strong Candidate 0.45 0.043 
2 2223972 rs11127372 MYT1L Strong Candidate 0.32 0.044 
7 103397953 rs1476446 RELN Strong Candidate 0.38 0.044 
2 2289761 NA MYT1L Strong Candidate 3.31 0.045 
1 155398245 rs9787192 ASH1L High Confidence 2.69 0.046 
2 50334395 NA NRXN1 Strong Candidate 2.75 0.047 
2 50804847 rs113038770 NRXN1 Strong Candidate 2.39 0.047 
4 113745292 NA ANK2 High Confidence 0.43 0.047 
15 93501165 rs62023142 CHD2 Strong Candidate 2.88 0.047 
16 9035124 rs1471435 USP7 Strong Candidate 2.32 0.047 
2 2240556 rs150627539 MYT1L Strong Candidate 2.27 0.048 
11 70492808 rs11237057 SHANK2 Strong Candidate 3.58 0.048 
21 41800106 rs2837623 DSCAM Strong Candidate 2.45 0.048 
2 2288632 rs4998343 MYT1L Strong Candidate 0.16 0.049 
3 2819988 rs112758727 CNTN4 Strong Candidate 2.46 0.049 
7 103259560 rs201553109 RELN Strong Candidate 2.35 0.049 






Supplementary Table 4.2.  All candidate genes ranked by association with the 
“intermediate” class compared the “normative” class, based on SNP-level results 
collapsed by gene.  
CHR Gene SFARI Gene Class SNP Count p 
3 CNTN4 Strong Candidate 432 0.001 
7 CNTNAP2 Strong Candidate 446 0.001 
3 KAT2B Strong Candidate 48 0.003 
4 ANK2 High Confidence 130 0.004 
5 CTNND2 Strong Candidate 188 0.004 
10 WAC Strong Candidate 92 0.009 
12 GRIN2B High Confidence 584 0.009 
11 SHANK2 Strong Candidate 146 0.012 
2 NRXN1 Strong Candidate 177 0.014 
3 FOXP1 Strong Candidate 150 0.016 
16 USP7 Strong Candidate 15 0.016 
6 ARID1B High Confidence 64 0.017 
12 MED13L Strong Candidate 9 0.02 
16 CACNA1H Strong Candidate 16 0.023 
12 GRIP1 Strong Candidate 213 0.024 
3 CACNA2D3 Strong Candidate 244 0.027 
7 RELN Strong Candidate 147 0.027 
1 KDM5B Strong Candidate 39 0.031 
2 SCN2A High Confidence 27 0.031 
16 ANKRD11 Strong Candidate 59 0.031 
21 DSCAM Strong Candidate 255 0.034 
2 MYT1L Strong Candidate 98 0.044 
1 ASH1L High Confidence 20 0.046 
15 CHD2 Strong Candidate 95 0.047 
15 GABRB3 Strong Candidate 162 0.059 
1 ILF2 Strong Candidate 4 0.076 
2 BCL11A Strong Candidate 20 0.102 
18 ASXL3 High Confidence 99 0.102 
3 SETD5 High Confidence 12 0.103 
3 SLC6A1 Strong Candidate 21 0.103 
2 SPAST Strong Candidate 8 0.105 
10 PTEN High Confidence 24 0.107 
21 DYRK1A High Confidence 16 0.126 
7 KMT2C Strong Candidate 15 0.152 
13 INTS6 Strong Candidate 13 0.157 
11 DEAF1 Strong Candidate 25 0.159 




22 SHANK3 High Confidence 17 0.183 
1 POGZ High Confidence 3 0.184 
14 IRF2BPL Strong Candidate 2 0.216 
18 KATNAL2 Strong Candidate 53 0.229 
20 ADNP High Confidence 4 0.233 
2 TBR1 High Confidence 2 0.309 
11 KMT2A Strong Candidate 8 0.334 
2 CUL3 Strong Candidate 11 0.393 
7 MET Strong Candidate 18 0.426 























Supplementary Table 4.3.  251 Nominally significant (p < 0.05) SNPs associated with 
the “declining” class compared to the “normative” class.  
CHR Position rsID Gene SFARI Gene Class OR p 
2 1859595 NA MYT1L Strong Candidate 4.01 0.002 
2 60757467 rs202108972 BCL11A Strong Candidate 0.27 0.002 
3 2145996 rs2727926 CNTN4 Strong Candidate 0.32 0.002 
3 20108644 rs1610186 KAT2B Strong Candidate 4.68 0.002 
7 145921523 rs201323315 CNTNAP2 Strong Candidate 4.07 0.002 
5 11585335 rs2429307 CTNND2 Strong Candidate 0.29 0.003 
3 2596520 rs79864813 CNTN4 Strong Candidate 4.53 0.004 
7 145934145 rs17579058 CNTNAP2 Strong Candidate 0.31 0.004 
3 2280429 NA CNTN4 Strong Candidate 3.24 0.005 
15 93501165 rs62023142 CHD2 Strong Candidate 3.5 0.005 
5 11555821 NA CTNND2 Strong Candidate 0.39 0.006 
21 38744586 rs2409894 DYRK1A High Confidence 0.38 0.006 
3 2846838 rs12633320 CNTN4 Strong Candidate 3.34 0.007 
5 170704942 NA RANBP17 Strong Candidate 2.65 0.007 
7 147258631 rs6960319 CNTNAP2 Strong Candidate 2.82 0.007 
2 51089340 NA NRXN1 Strong Candidate 3.97 0.008 
3 20103476 NA KAT2B Strong Candidate 4.95 0.008 
21 41997529 rs9974484 DSCAM Strong Candidate 2.52 0.008 
3 2617954 rs2728056 CNTN4 Strong Candidate 0.33 0.01 
7 147121340 rs7794718 CNTNAP2 Strong Candidate 0.33 0.01 
12 14024769 rs10845851 GRIN2B High Confidence 0.21 0.01 
11 70692076 rs7941869 SHANK2 Strong Candidate 0.29 0.011 
21 38817390 rs9982990 DYRK1A High Confidence 0.4 0.011 
3 3080200 rs7617493 CNTN4 Strong Candidate 0.42 0.012 
6 157216039 rs184074 ARID1B High Confidence 2.63 0.012 
11 686127 NA DEAF1 Strong Candidate 2.45 0.012 
12 13803051 rs2300234 GRIN2B High Confidence 2.53 0.012 
21 42024988 rs78896678 DSCAM Strong Candidate 0.3 0.012 
2 1858603 rs6709806 MYT1L Strong Candidate 3.59 0.013 
2 1874731 rs11675862 MYT1L Strong Candidate 0.25 0.013 
2 51257248 NA NRXN1 Strong Candidate 0.43 0.013 
3 20183278 rs75731241 KAT2B Strong Candidate 0.34 0.013 
5 11354932 rs1363940 CTNND2 Strong Candidate 2.63 0.013 
7 103411103 NA RELN Strong Candidate 2.34 0.013 
12 13948309 NA GRIN2B High Confidence 0.39 0.013 
2 51201137 NA NRXN1 Strong Candidate 0.46 0.014 
12 13813330 rs2300238 GRIN2B High Confidence 2.53 0.014 




2 51257062 rs34300360 NRXN1 Strong Candidate 0.31 0.015 
3 2187631 NA CNTN4 Strong Candidate 0.29 0.015 
3 2206373 rs2727927 CNTN4 Strong Candidate 0.36 0.015 
3 2209756 rs2727930 CNTN4 Strong Candidate 0.29 0.015 
3 2746456 rs13080275 CNTN4 Strong Candidate 3 0.015 
7 147980396 NA CNTNAP2 Strong Candidate 4.41 0.015 
5 11538818 rs60883018 CTNND2 Strong Candidate 0.41 0.016 
15 26876249 rs751994 GABRB3 Strong Candidate 2.83 0.016 
5 11316583 rs113400641 CTNND2 Strong Candidate 2.45 0.017 
12 13939697 rs78812890 GRIN2B High Confidence 3.32 0.017 
12 14068789 rs6488624 GRIN2B High Confidence 2.22 0.017 
12 14070156 rs2216344 GRIN2B High Confidence 2.22 0.017 
12 14083859 rs219885 GRIN2B High Confidence 0.26 0.017 
12 14084808 rs219887 GRIN2B High Confidence 0.29 0.017 
12 14085176 rs219888 GRIN2B High Confidence 0.29 0.017 
12 14091037 rs219902 GRIN2B High Confidence 0.29 0.017 
15 26981846 rs7179279 GABRB3 Strong Candidate 0.33 0.017 
15 93520108 rs34026217 CHD2 Strong Candidate 0.33 0.017 
3 2465934 rs76882636 CNTN4 Strong Candidate 2.78 0.018 
12 13950074 rs11055623 GRIN2B High Confidence 2.91 0.018 
12 13950577 rs7974275 GRIN2B High Confidence 2.91 0.018 
12 14075430 rs219872 GRIN2B High Confidence 0.3 0.018 
12 14076446 rs219873 GRIN2B High Confidence 0.3 0.018 
12 14085886 NA GRIN2B High Confidence 2.33 0.018 
12 14085920 rs28695969 GRIN2B High Confidence 2.33 0.018 
12 14087599 rs219892 GRIN2B High Confidence 0.3 0.018 
18 44557886 rs138970065 KATNAL2 Strong Candidate 2.6 0.018 
21 42026025 NA DSCAM Strong Candidate 0.29 0.018 
3 2194392 rs2729017 CNTN4 Strong Candidate 0.24 0.019 
3 2588293 rs35787589 CNTN4 Strong Candidate 3.13 0.019 
3 2616751 rs734246 CNTN4 Strong Candidate 0.4 0.019 
7 146747059 rs11983645 CNTNAP2 Strong Candidate 2.26 0.019 
12 13740803 rs918092 GRIN2B High Confidence 2.58 0.019 
15 93523632 rs2033844 CHD2 Strong Candidate 0.34 0.019 
3 3057903 rs3907591 CNTN4 Strong Candidate 0.3 0.02 
4 114154261 NA ANK2 High Confidence 0.41 0.02 
7 145943555 rs148812117 CNTNAP2 Strong Candidate 2.55 0.02 
12 14082733 rs219879 GRIN2B High Confidence 0.31 0.02 
12 14083520 rs219882 GRIN2B High Confidence 0.31 0.02 
7 145831671 rs62504792 CNTNAP2 Strong Candidate 0.38 0.021 




12 13948580 rs220561 GRIN2B High Confidence 0.43 0.021 
12 14088861 rs219894 GRIN2B High Confidence 0.28 0.021 
12 14092888 rs219904 GRIN2B High Confidence 2.2 0.021 
15 26834590 rs11161319 GABRB3 Strong Candidate 2.7 0.021 
15 93498105 rs3817597 CHD2 Strong Candidate 0.35 0.021 
15 93537958 rs17525800 CHD2 Strong Candidate 0.34 0.021 
2 51186984 rs10197386 NRXN1 Strong Candidate 0.35 0.022 
12 13734420 rs12308472 GRIN2B High Confidence 2.33 0.022 
12 13734426 NA GRIN2B High Confidence 2.33 0.022 
12 13912776 rs7296762 GRIN2B High Confidence 2.38 0.022 
12 13954403 rs220567 GRIN2B High Confidence 2.4 0.022 
15 93536804 rs62023149 CHD2 Strong Candidate 3.11 0.022 
15 93536811 rs58966536 CHD2 Strong Candidate 3.01 0.022 
18 44556883 NA KATNAL2 Strong Candidate 0.37 0.022 
3 2575184 NA CNTN4 Strong Candidate 0.39 0.023 
5 11520099 NA CTNND2 Strong Candidate 3.4 0.023 
11 70488398 rs7946437 SHANK2 Strong Candidate 2.28 0.023 
12 13959245 rs220581 GRIN2B High Confidence 2.44 0.023 
12 14083631 rs219884 GRIN2B High Confidence 2.19 0.023 
12 14090624 rs219900 GRIN2B High Confidence 2.19 0.023 
15 93526003 rs11634207 CHD2 Strong Candidate 0.36 0.023 
21 42130162 rs734571 DSCAM Strong Candidate 0.42 0.023 
12 13953118 rs2058878 GRIN2B High Confidence 2.49 0.024 
15 93473624 rs961233 CHD2 Strong Candidate 0.4 0.024 
4 114155056 rs362462 ANK2 High Confidence 0.31 0.025 
5 11578574 rs7737639 CTNND2 Strong Candidate 0.43 0.025 
12 13749831 rs1805508 GRIN2B High Confidence 2.49 0.025 
12 14096444 rs219915 GRIN2B High Confidence 2.17 0.025 
15 93540089 rs11630582 CHD2 Strong Candidate 0.37 0.025 
3 2576262 rs35501813 CNTN4 Strong Candidate 2.91 0.026 
12 13901815 rs1005549 GRIN2B High Confidence 3.71 0.026 
12 14004787 rs2193511 GRIN2B High Confidence 2.37 0.026 
12 14095457 rs11055693 GRIN2B High Confidence 0.31 0.026 
15 93531312 NA CHD2 Strong Candidate 0.36 0.026 
15 93546474 rs12906132 CHD2 Strong Candidate 0.35 0.026 
3 54280586 NA CACNA2D3 Strong Candidate 2.6 0.027 
7 103397082 rs3819479 RELN Strong Candidate 2.6 0.027 
7 146291525 rs368392827 CNTNAP2 Strong Candidate 0.42 0.027 
7 147692624 rs5003321 CNTNAP2 Strong Candidate 2.15 0.027 
12 13734261 rs1806197 GRIN2B High Confidence 2.09 0.027 




15 93473251 rs201925722 CHD2 Strong Candidate 0.41 0.027 
15 93473752 rs1318689 CHD2 Strong Candidate 0.41 0.027 
21 38817699 rs9974713 DYRK1A High Confidence 0.3 0.027 
21 41631588 rs372505754 DSCAM Strong Candidate 0.4 0.027 
12 13975298 rs220599 GRIN2B High Confidence 0.42 0.028 
12 13975719 NA GRIN2B High Confidence 0.42 0.028 
12 14109687 rs219931 GRIN2B High Confidence 0.33 0.028 
12 14117136 rs219936 GRIN2B High Confidence 0.37 0.028 
15 93464509 rs28573213 CHD2 Strong Candidate 0.42 0.028 
22 51146740 rs9628239 SHANK3 High Confidence 0.46 0.028 
2 1865275 NA MYT1L Strong Candidate 0.35 0.029 
3 2423855 NA CNTN4 Strong Candidate 0.28 0.029 
3 2581603 rs9878895 CNTN4 Strong Candidate 2.62 0.029 
3 2636695 rs2616597 CNTN4 Strong Candidate 2.23 0.029 
3 2928197 NA CNTN4 Strong Candidate 0.39 0.029 
3 54297185 rs7614823 CACNA2D3 Strong Candidate 2.9 0.029 
12 13956734 rs220573 GRIN2B High Confidence 0.43 0.029 
12 13957286 rs220575 GRIN2B High Confidence 0.43 0.029 
12 14082188 rs219878 GRIN2B High Confidence 2.14 0.029 
10 89626375 NA PTEN High Confidence 0.41 0.03 
12 13886268 rs10492135 GRIN2B High Confidence 3.21 0.03 
12 13886646 rs11055606 GRIN2B High Confidence 3.21 0.03 
12 13887243 rs73051594 GRIN2B High Confidence 3.21 0.03 
12 13893865 rs17833849 GRIN2B High Confidence 3.21 0.03 
12 13898935 rs73053620 GRIN2B High Confidence 3.21 0.03 
12 13898968 rs77252419 GRIN2B High Confidence 3.21 0.03 
12 13899012 NA GRIN2B High Confidence 3.21 0.03 
15 26838405 rs12437672 GABRB3 Strong Candidate 2.53 0.03 
2 60777498 rs6747099 BCL11A Strong Candidate 0.46 0.031 
3 54894545 rs1526596 CACNA2D3 Strong Candidate 0.45 0.031 
7 103624813 rs12667675 RELN Strong Candidate 2.58 0.031 
12 14007590 NA GRIN2B High Confidence 0.44 0.031 
12 14093981 rs219906 GRIN2B High Confidence 2.12 0.031 
2 225399718 NA CUL3 Strong Candidate 2.18 0.032 
3 2725785 rs1878181 CNTN4 Strong Candidate 2.12 0.032 
7 147244724 rs2190008 CNTNAP2 Strong Candidate 0.44 0.032 
12 13744039 rs34942586 GRIN2B High Confidence 0.45 0.032 
3 54308840 rs11130410 CACNA2D3 Strong Candidate 2.3 0.033 
12 13734262 rs2058771 GRIN2B High Confidence 2.05 0.033 
12 13967591 rs220595 GRIN2B High Confidence 0.39 0.033 




12 14089032 rs1421104 GRIN2B High Confidence 0.28 0.033 
15 26852038 rs12904322 GABRB3 Strong Candidate 2.52 0.033 
21 42162117 rs28663497 DSCAM Strong Candidate 0.36 0.033 
22 51126128 rs9616937 SHANK3 High Confidence 0.47 0.033 
2 1890939 NA MYT1L Strong Candidate 0.32 0.034 
2 2223972 rs11127372 MYT1L Strong Candidate 0.38 0.034 
6 157437279 rs12212699 ARID1B High Confidence 2.6 0.034 
7 146467409 rs199643489 CNTNAP2 Strong Candidate 2.21 0.034 
12 13762597 rs2268098 GRIN2B High Confidence 0.43 0.034 
12 13763455 rs1805481 GRIN2B High Confidence 0.43 0.034 
12 13810877 rs11055566 GRIN2B High Confidence 2.5 0.034 
22 51151724 rs6010061 SHANK3 High Confidence 0.43 0.034 
3 2152889 rs4300993 CNTN4 Strong Candidate 2.36 0.035 
4 113914277 rs6849022 ANK2 High Confidence 2.25 0.035 
5 11386206 rs1479617 CTNND2 Strong Candidate 2.11 0.035 
2 51173811 rs7584445 NRXN1 Strong Candidate 0.46 0.036 
5 11538379 rs6893111 CTNND2 Strong Candidate 2.2 0.036 
12 14001257 rs67376488 GRIN2B High Confidence 2.26 0.036 
3 54283689 NA CACNA2D3 Strong Candidate 0.4 0.037 
6 157442069 rs17088149 ARID1B High Confidence 2.59 0.037 
12 13891551 rs2300261 GRIN2B High Confidence 0.42 0.037 
12 14077636 rs10845862 GRIN2B High Confidence 0.3 0.037 
12 14125564 rs10505778 GRIN2B High Confidence 2.34 0.037 
15 26872003 rs12907740 GABRB3 Strong Candidate 2.45 0.037 
15 93559387 rs11074126 CHD2 Strong Candidate 0.43 0.037 
3 2195692 rs55883839 CNTN4 Strong Candidate 0.4 0.038 
7 103402243 rs10487172 RELN Strong Candidate 0.37 0.038 
12 13880012 rs12317264 GRIN2B High Confidence 3.13 0.038 
12 13960034 rs4764034 GRIN2B High Confidence 2.65 0.038 
21 38740824 rs12483205 DYRK1A High Confidence 0.34 0.038 
3 2425824 rs9830036 CNTN4 Strong Candidate 2.37 0.039 
12 13972323 NA GRIN2B High Confidence 0.46 0.039 
3 2280464 rs1178531 CNTN4 Strong Candidate 0.43 0.04 
12 13948065 rs220558 GRIN2B High Confidence 0.45 0.04 
15 26865933 NA GABRB3 Strong Candidate 2.35 0.04 
18 44540376 rs12386118 KATNAL2 Strong Candidate 1.89 0.04 
2 50207044 rs7608575 NRXN1 Strong Candidate 2.22 0.041 
3 2498369 rs67890258 CNTN4 Strong Candidate 0.41 0.041 
7 116317877 rs40239 MET Strong Candidate 2.2 0.041 
7 147205780 rs1881443 CNTNAP2 Strong Candidate 2.3 0.041 




15 26832891 rs11633705 GABRB3 Strong Candidate 2.7 0.041 
15 26833912 rs7166689 GABRB3 Strong Candidate 2.7 0.041 
7 145928134 rs28610113 CNTNAP2 Strong Candidate 2.45 0.042 
12 13810845 rs2300235 GRIN2B High Confidence 2.16 0.042 
12 13909056 rs58125071 GRIN2B High Confidence 3.08 0.042 
15 26840998 rs1426210 GABRB3 Strong Candidate 2.38 0.042 
15 26870064 rs12595837 GABRB3 Strong Candidate 2.38 0.042 
15 93539390 rs144685798 CHD2 Strong Candidate 2.38 0.042 
21 42158664 rs56106057 DSCAM Strong Candidate 0.33 0.042 
22 51138535 rs13054536 SHANK3 High Confidence 0.54 0.042 
3 2145937 NA CNTN4 Strong Candidate 0.27 0.043 
3 2857557 NA CNTN4 Strong Candidate 0.45 0.043 
7 103521249 rs4729935 RELN Strong Candidate 0.46 0.043 
7 147630586 NA CNTNAP2 Strong Candidate 2.06 0.043 
12 13953703 rs2300270 GRIN2B High Confidence 2.54 0.043 
12 13955362 rs2300271 GRIN2B High Confidence 2.48 0.043 
12 13948760 rs220562 GRIN2B High Confidence 0.46 0.044 
12 13957167 NA GRIN2B High Confidence 0.46 0.044 
3 20084079 rs1915922 KAT2B Strong Candidate 2.75 0.045 
11 70469410 rs4980545 SHANK2 Strong Candidate 0.37 0.045 
11 70481872 rs76804246 SHANK2 Strong Candidate 0.39 0.045 
12 13752832 rs2268097 GRIN2B High Confidence 0.42 0.045 
12 13753829 rs1805518 GRIN2B High Confidence 0.42 0.045 
12 13753852 rs1805519 GRIN2B High Confidence 0.42 0.045 
15 26843901 rs7178850 GABRB3 Strong Candidate 2.53 0.045 
15 26846584 rs1834533 GABRB3 Strong Candidate 2.53 0.045 
15 26849185 rs7172598 GABRB3 Strong Candidate 2.53 0.045 
15 26849884 NA GABRB3 Strong Candidate 2.53 0.045 
2 50244128 rs10181439 NRXN1 Strong Candidate 2.04 0.046 
12 14001534 rs2417306 GRIN2B High Confidence 0.46 0.046 
12 14037970 rs2041986 GRIN2B High Confidence 2.21 0.046 
21 42166769 rs2210272 DSCAM Strong Candidate 0.5 0.046 
3 20091691 NA KAT2B Strong Candidate 2.05 0.047 
7 103468842 NA RELN Strong Candidate 2.02 0.047 
12 13743245 rs2041889 GRIN2B High Confidence 0.48 0.047 
15 93536197 rs2272457 CHD2 Strong Candidate 0.43 0.047 
3 2576058 rs11719503 CNTN4 Strong Candidate 2.33 0.048 
3 2726271 rs199966573 CNTN4 Strong Candidate 0.21 0.048 
4 114068306 rs6854397 ANK2 High Confidence 2.07 0.048 
12 13913509 rs73053644 GRIN2B High Confidence 2.55 0.048 




12 13954737 rs220568 GRIN2B High Confidence 0.46 0.048 
12 13981051 rs7956383 GRIN2B High Confidence 2.21 0.048 
15 93484106 rs11632302 CHD2 Strong Candidate 0.43 0.048 
15 93488094 NA CHD2 Strong Candidate 0.43 0.048 
3 2148393 rs2729003 CNTN4 Strong Candidate 0.49 0.049 
12 13797570 rs2216215 GRIN2B High Confidence 2.19 0.049 
12 13897461 rs2268122 GRIN2B High Confidence 0.37 0.049 
























Supplementary Table 4.4.  All candidate genes ranked by association with the 
“declining” class compared to the “normative” class, based on SNP-level results 
collapsed by gene.  
CHR Gene SFARI Gene Class SNP Count p 
2 BCL11A Strong Candidate 20 0.002 
3 CNTN4 Strong Candidate 432 0.002 
3 KAT2B Strong Candidate 48 0.002 
7 CNTNAP2 Strong Candidate 446 0.002 
5 CTNND2 Strong Candidate 188 0.003 
15 CHD2 Strong Candidate 95 0.005 
21 DYRK1A High Confidence 16 0.006 
5 RANBP17 Strong Candidate 23 0.007 
2 NRXN1 Strong Candidate 177 0.008 
21 DSCAM Strong Candidate 255 0.008 
12 GRIN2B High Confidence 584 0.01 
11 SHANK2 Strong Candidate 146 0.011 
6 ARID1B High Confidence 64 0.012 
11 DEAF1 Strong Candidate 25 0.012 
7 RELN Strong Candidate 147 0.013 
15 GABRB3 Strong Candidate 162 0.016 
18 KATNAL2 Strong Candidate 53 0.018 
4 ANK2 High Confidence 130 0.02 
3 CACNA2D3 Strong Candidate 244 0.027 
22 SHANK3 High Confidence 17 0.028 
10 PTEN High Confidence 24 0.03 
2 CUL3 Strong Candidate 11 0.032 
7 MET Strong Candidate 18 0.041 
7 KMT2C Strong Candidate 15 0.055 
3 FOXP1 Strong Candidate 150 0.056 
6 SYNGAP1 High Confidence 3 0.062 
12 GRIP1 Strong Candidate 213 0.071 
2 SCN2A High Confidence 27 0.077 
3 SLC6A1 Strong Candidate 21 0.077 
18 ASXL3 High Confidence 99 0.08 
13 INTS6 Strong Candidate 13 0.081 
14 IRF2BPL Strong Candidate 2 0.083 
16 ANKRD11 Strong Candidate 59 0.094 
16 CACNA1H Strong Candidate 16 0.132 
1 ASH1L High Confidence 20 0.15 
16 USP7 Strong Candidate 15 0.17 




2 SPAST Strong Candidate 8 0.231 
1 POGZ High Confidence 3 0.24 
3 SETD5 High Confidence 12 0.282 
12 MED13L Strong Candidate 9 0.286 
2 TBR1 High Confidence 2 0.318 
1 KDM5B Strong Candidate 39 0.349 
11 KMT2A Strong Candidate 8 0.418 
20 ADNP High Confidence 4 0.655 


























































5.1. Summary of findings 
 ASD is a neurodevelopmental disorder that is heterogeneous in presentation and 
etiology.  Comorbid conditions, symptom profiles, and variable onset trajectories 
contribute to phenotypic heterogeneity, while genetic and early-life environmental risk 
factors contribute to etiologic heterogeneity (Gardener, Spiegelman, & Buka, 2009; 
Landa, Gross, Stuart, & Faherty, 2013; Landa, Holman, & Garrett-Mayer, 2007; Sandin 
et al., 2014; Schieve et al., 2012; Veatch, Veenstra-Vanderweele, Potter, Pericak-Vance, 
& Haines, 2014).   The goal of this dissertation was to examine comorbidity, 
environmental, and genetic risk factors associated with ASD in the context of other 
neurodevelopmental disorders and general early neurodevelopment.   
 Results from this dissertation add to the evidence for increased risk of other 
neurodevelopmental disorders and physical comorbidity among ASD (Bauman, 2010; 
Gurney, McPheeters, & Davis, 2006; Matson & Goldin, 2013; Schieve et al., 2012).  
Using data from a nationally representative population-based survey (NCS-A), we found 
that 70% of adolescents with parent reported ASD had concurrent LD and 42% had 
concurrent ADHD.  Additionally, we found that ASD adolescents were at increased risk 
for gastrointestinal problems (OR = 5.60, p = 0.004), epilepsy and seizures (OR = 9.97, p 
< 0.001), allergies (OR = 3.48, p = 0.004), acne (OR = 3.25, p=0.020), heart problems 
(OR= 4.08, p = 0.020), and early morning awakening (OR = 2.44, p = 0.04).  Of note, we 
see that adolescents with LD were also at increased risk for ADHD (OR = 6.13, p < 
0.001), gastrointestinal problems (OR = 1.70, p = 0.030), and epilepsy/seizure (OR = 
2.82, p = 0.001), suggesting an association with neurodevelopmental disorders in general. 




across ID and other types of developmental delay, where effect sizes are larger with more 
severe neurodevelopmental disorders (Schieve et al., 2012).  
However, as the first population-based based study to evaluate mental health 
conditions among ASD by direct evaluation with the subject, we do not confirm previous 
findings of increased risk for depression and anxiety among individuals with ASD from 
clinical studies and parent report surveys (Gurney et al., 2006; Joshi et al., 2013; 
McPheeters, Davis, Navarre, & Scott, 2011).  One potential reason for this could be that 
previous studies ascertained clinically could be biased toward a more severely affected 
treatment-seeking population of individuals with ASD.  Further, other population based 
studies assessing mental disorders among ASD have relied on parent report, which may 
not be accurate for assessing the presence of internalizing disorders such as depression 
and anxiety (De Los Reyes et al., 2015).  However, another explanation for this could be 
that we evaluated mental disorders using the CIDI (Robins et al.), which is not validated 
for use among individuals with ASD.  Therefore, it might not be the appropriate 
measurement tool for these disorders, as the sensitivity for evaluation of these disorders 
in ASD is unknown. 
 Results from this dissertation also provide further support for the hypothesis that 
the pre/perinatal period is a critical window of risk for non-genetic factors that may 
impact development of ASD (Gardener et al., 2009; Gardener, Spiegelman, & Buka, 
2011; Schieve, Clayton, Durkin, Wingate, & Drews-Botsch, 2015).  Using nationally 
representative survey data (NCS-A), we found prenatal exposure to alcohol (ASD: OR = 
2.43, p = 0.017, LD: OR = 1.42, p = 0.039), maternal urinary tract infection during 




(ASD: OR=6.27, p=0.028; LD: OR=1.86, p=0.031), respiratory distress at birth (ASD: 
OR=5.85, p=0.020; LD: OR=2.28, p=0.003, and preterm birth (ASD; OR=3.57, p=0.018; 
LD: OR=2.33, p=0.001) to be associated with both ASD and LD.  This is in support of 
other research suggesting that prenatal risk factors contribute to multiple 
neurodevelopmental outcomes (Krakowiak et al., 2012; Schieve et al., 2010; Schieve et 
al., 2015; Schieve et al., 2016; Tamaru et al., 2011).  However, after controlling for 
preterm birth, associations between neonatal conditions and LD dissipated while 
remaining significant for ASD (convulsions: OR=9.23, p=0.008); jaundice: OR=3.21, 
p=0.028; requirement of oxygen: OR=2.26, p=0.048; blood transfusion: OR=7.04, 
p=0.018).  Of note, persistent proteinuria was associated with ASD (OR = 13.13, p = 
0.005), but not LD and was the only obstetric complication examined in our sample, 
including gestational diabetes, that was associated with either neurodevelopmental 
disorder.  Previous research has been inconsistent in results linking gestational diabetes to 
ASD (Gardener et al., 2009; Guinchat et al., 2012; Krakowiak et al., 2012); however, 
preeclampsia and related symptoms, such as proteinuria, have been far more consistently 
linked to ASD (Gardener et al., 2009; Polo-Kantola et al., 2014; Walker et al., 2015; 
Wallace, Anderson, & Dubrow, 2008).  As gestational diabetes increases the mother’s 
risk for developing preeclampsia, it is possible that the consequences of preeclampsia, 
such as increased inflammation, vascular damage, decreased placental perfusion, and 
decreased blood flow and oxygen to the fetus, are more closely involved in the 
mechanisms contributing to ASD risk rather than those specifically related to gestational 
diabetes.  Further work is needed to understand the possible mechanisms liking this 




 There may be clinical implications of these findings regarding comorbid 
conditions and prenatal risk factors for ASD and LD.  First, treating sleep and physical 
health problem in kids with ASD could improve not only quality of life, but also 
behavioral symptoms associated with ASD (Bauman, 2010).  Therefore, greater 
awareness of comorbid conditions affecting adolescents with ASD and LD could improve 
quality of life and school performance, especially for those with LD, where services 
provided are primarily through the educational system, rather than clinical care. Several 
perinatal risk factors associated with ASD, such as proteinuria, birth outcomes, and 
neonatal complications may warrant timely developmental surveillance which could lead 
to earlier intervention, and therefore, better prognosis.  However, further work should be 
done in appropriate samples to try to disentangle the pathways leading to compilations in 
neurodevelopment to know when and how to intervene. 
 In our examination of early cognitive development among infants at elevated risk 
for developing ASD, we found three distinct subpopulations of early cognitive and motor 
development trajectories which we named “normative”, “intermediate”, and “declining” 
based on patterns of MSEL domain scores over time.   Nearly half of the “declining” 
class consisted of ASD cases, compared to 15% of the intermediate class, and 2% of the 
normative class.  While cognitive developmental trajectory was associated with ASD, it 
is not a direct surrogate of ASD.   
  The declining class was marginally associated with a liberally defined burden score 
of common genetic variation associated with ASD (OR = 1.66, p = 0.083).  A candidate 
gene approach assessing independent SNPs from 47 ASD-implicated genes yielded 




membership. The two top ranked genes associated with the trajectory classes were 
CNTN4 and CNTNAP2.   These genes both code for proteins involved neuronal cell 
adhesion and migration (Rodenas-Cuadrado, Ho, & Vernes, 2014; Shimoda & Watanabe, 
2009).  Further assessment of unpruned SNPs in CNTN4 on chromosome 3 revealed an 
association peak of suggestive significance below rs4075530 for the “intermediate” class 
compared to the “normative” class.  There have been no other associations reported in 
this linkage disequilibrium block in the NHGRI GWAS catalog; however, several 
genome-wide significant associations for intelligence traits in a ADHD sample have been 
identified in the same gene nearby approximately 50kb downstream (Loo et al., 2012).   
Regional mapping of unpruned SNPs in CNTNAP2 revealed an association peak for the 
“declining” class at the 5’ end of the gene.  This peak lies under previous findings 
implicating risk for bipolar disorder, schizophrenia, and late-onset Alzheimer’s disease 
(Hirano et al., 2015; Wang, Liu, & Aragam, 2010).  Association peaks from our results in 
either gene generally did not align with association peaks from the Psychiatric Genomics 
Consortium (PGC). 
 The use of a phenotype associated with underlying ASD traits, rather than diagnostic 
criteria gives some additional insight into potential underlying biology.  Interestingly, 
previous findings ASD case-control studies reporting on CNTN4 largely implicate the 
role of rare CNVs, rather than common SNPs (Cottrell et al., 2011).  Here, we see SNP 
associations using a phenotype that is associated with ASD, rather than diagnostic 
criteria.  It could be that common variants of CNTN4 affect neurodevelopment, but to a 
lesser extent than gene disrupting structural variants that have been so strongly implicated 




associations in these genes similar in magnitude to results from PGC (n=10,610) where 
the sample size was over 50 times the size of ours (n=198).  Further investigation into 
other candidate genes should be done to investigate this pattern. 
 
5.2. Summary of strengths and challenges 
 The two study designs used in this dissertation offered both strengths and 
challenges.  The NCS-A, a nationally representative population-based sample offers 
representativeness not typical in a clinically selected sample.  The estimates we report 
accurately represent that of the target population – US adolescents attending school 
during the time of data collection (2001-2004).  However, we face a tradeoff between 
representativeness and rigorous phenotyping.  While the NCS-A is the only US 
representative sample that has collected face-to-face diagnostic interviews on a range of 
mental disorders affecting adolescents (i.e. depression, bipolar disorder, anxiety, eating 
disorders, ADHD, etc.), specific diagnoses including ASD, LD, physical health 
conditions, and prenatal and perinatal factors were collected via parent report.  Therefore, 
we are less confident in the accuracy of these variables due to the potential for recall bias 
for health conditions and prenatal/perinatal factors and unconfirmed diagnoses for ASD 
and LD.   
Furthermore, while the overall NCS-A sample size used in this dissertation was 
quite large (n=6,296), the number of adolescents in the ASD-affected analytic group was 
small (n=51) due to the low prevalence of ASD at the time of data collection (~ 0.08%) 
(CDC, 2007).  This resulted in large standard errors in prevalence and association 




group, it is likely that our prevalence estimates of comorbid conditions would have been 
elevated due to ascertainment bias.      
Similarly, we dealt with relatively small sample sizes in EARLI/IBIS, enriched 
risk cohorts, compared to what is typically attainable through case-control designs.  
However, the use of enriched risk longitudinal design allows for prospective data 
collection, in-depth phenotyping, and biomarker collection.  Due to the careful 
phenotypic, biologic, and risk factor characterization of these participants, obtaining large 
sample sizes on the order of case-control designs is cost prohibitive.   While not 
representative of the general population, an enriched risk sample yields a higher 
proportion of ASD affected individuals compared to sampling from the general 
population, making outcome numbers feasible for association analyses while preserving 
the benefits of a prospective design.    
Additionally, the work on genetic association with developmental trajectory is 
limited by a small sample size to date, so it is unclear whether this phenotyping approach 
will yield more insights than traditional case-control designs until it can be compared 
with comparable sample sizes.  However, given the magnitude of statistical significance 
achieved in our modest sample size (n=198) for the genetic association analyses 
compared to the largest known ASD case-control GWAS to date (n=10,610), this 
approach seems promising.  For this project our sample also consists of individuals from 
a variety of ethnicities.  The modest sample size precluded us from stratifying analyses 
by ancestral background.  While we did adjust analyses for principal components of 





5.3. Future directions 
 The work presented in this dissertation can be expanded upon to gain additional 
insight into comorbidity, environmental, and genetic risk associated with ASD and other 
neurodevelopmental disorders.  First, to assess true specificity for comorbid conditions 
and early life risk factors associated with ASD compared to other neurodevelopmental 
disorders, such as LD, it would be advantageous to directly calculate change in risk for 
ASD compared to LD instead of a typically developing group.   
Second, prevalence and association estimates of individual comorbid conditions 
do not reveal the extent to which the same cases may have multiple comorbid conditions.  
While many conditions are associated, it would be informative to know if particular 
comorbid conditions tend to occur together in the same individuals, while other sets of 
conditions co-occur in other individuals with neurodevelopmental disorders. To do this, 
one could use latent class analysis, or other cluster analysis methods that recognize 
patterns among variables. Others have taken a similar approach mining electronic health 
record data (Doshi-Velez, Ge, & Kohane, 2014), but this could be informative among a 
representative sample such as the NCS-A.  Given the strong overlap between many of the 
common comorbid conditions across neurodevelopmental disorders, this would better 
direct us toward etiologic subtypes of disease. A similar clustering approach should be 
used for assessing prenatal and perinatal risk factors associated with ASD.  A review of 
over 85 studies examining prenatal and perinatal risk factors for ASD concluded that, in 
light of so many implicated risk factors and inconsistency among findings, future work 




pathways and mechanisms by which these early-life factors are associated (Guinchat et 
al., 2012).  
 The polygenic risk score (PRS) analyses may be limited by lack of ASD-
associated SNPs that inform the score calculation.  Increasing sample size of the PGC 
discovery sample could improve ability to identify common variants associated with 
ASD, as was achieved in their schizophrenia case-control GWAS (Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014).  As these analyses are 
currently underway by the PGC, we plan to re-calculate risk scores in our sample when 
they become publically available.  Additionally, PRS and candidate gene analyses 
presented in this dissertation will benefit from obtaining genotype data for the IBIS 
participants included in the latent trajectory model.  Genotyping for these participants is 
currently underway, which will approximately double the sample size for the genetic 
association portion of this project.   
The combination of EARLI and IBIS will still leave us with a small sample size 
by traditional genome-wide association standards, and thus, still lack power to reach 
genome-wide significant SNP associations.  Future extensions of this work in larger 
cohorts would benefit from an agnostic genome-wide investigation of early cognitive and 
motor development.  With power for genome-wide discovery, one could evaluate the 
overlap between pathways and gene-sets associated with ASD diagnostic category and 
developmental trajectory prior to diagnosis to assess whether these phenotypic 
manifestations are operating similarly on a molecular level.  If new gene-sets are 




ASD by identifying loci affecting general neurodevelopmental traits rather than ASD 
specifically.   
 
5.4. Public health significance 
Population-based studies suggest the incidence of ASD is on the rise (Boyle et al., 
2011).   As such, it is important to understand the constellation of physical and mental 
health problems that will affect an aging population with ASD that is also increasing in 
size.  This dissertation used nationally representative data to support previous work 
indicating that children with ASD and other neurodevelopmental disorders are at 
increased risk for developing a number of physical health problems. These conditions 
may significantly decrease quality of life if not properly identified and treated.  
Awareness of these conditions by clinicians treating individuals with neurodevelopmental 
disorders could aid in earlier recognition of potential physical and mental health problems 
that may be contributing to behavioral symptoms, or decreased performance in school or 
work (Bauman, 2010).   
There is substantial evidence for contribution of both genetic and environmental 
elements to ASD risk (Hallmayer et al., 2011; Sandin et al., 2014) and that the critical 
window of risk for exposure to non-genetic risk factors lies in the pre-conception to 
neonatal period of life (Bauman & Kemper, 2005; Newschaffer, Fallin, & Lee, 2002). 
Therefore, depending on the child’s genetic liability for ASD, identification of malleable 
non-genetic risk factors could potentially prevent or decrease severity of some cases.  
While more work is needed to understand exact combinations, timing, and mechanisms 




dissertation substantiate previous implications of several factors, including those 
associated with preeclampsia, from a representative non-clinical sample. 
Although more work is needed to characterize the genetic underpinnings of ASD, 
understanding the genetic architecture can lead to better risk prediction, which can lead to 
earlier intervention and better prognosis.   Additionally, knowledge of genes involved 
will give insight into biological pathways involved in disease, which can potentially lead 
to development of new treatments.  Similarly, increased knowledge of genetic 
underpinnings of a child’s developmental trajectory may allow us to eventually screen 
children who are more susceptible to decline and target them for early intervention, 
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